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ABSTRACT
The tylophorine analogue, DCB-3503 (1-62b, NSC-716802), has been found to exhibit
broad spectrum activity in vitro in the National Cancer Institute’s (NCI) panel of 60
human-derived cell lines. Recent studies involving HepG2, a human hepatocellular
carcinoma cell line, and two pancreatic ductal carcinoma cell lines (PANC-1 and
HPAC), have suggested that DCB-3503 (1-62b) exerts its unique growth inhibition
properties by modulating nuclear factor kappa B activity as well as through the
inhibition of nuclear protein synthesis. However, the physiologically relevant protein
binding partner(s) of DCB-3503 (1-62b) have not been identified. Herein, the design
and synthesis of two biotin conjugates of DCB-3503 are described.

In both cases,

attachment of the biotin moiety to the active core was achieved through a Cu(I)catalyzed 1,3-dipolar Huisgen cycloaddition (“click”) coupling reaction. Additionally,
3D QSAR studies were performed using comparative molecular field analysis (CoMFA)
on a set of phenanthrolizidine alkaloids with inhibitory activities against the HepG2 cell
line. A satisfactory CoMFA model was obtained with LOO cross-validation q2 and noncross-validated r2 values of 0.567 and 0.935, respectively.

The developed model

demonstrated promising predictive abilities as discerned by the results of the external
test set.
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CHAPTER 1
INTRODUCTION
1. INTRODUCTION
1.1

Natural Products as Anti-tumor Agents
Throughout history, the natural world has continued to furnish man with an

effective arsenal of compounds that have served as antitumor, antibacterial, and
antifungal agents. It is the lush tropical rainforests and vibrant coral reefs of the planet
that have yielded these numerous natural products. However, passage from nature to
the world of human therapeutics has been simpler for plants than it has been for
invertebrates. To date, over 60% of clinically useful antitumor agents are natural, plant–
derived products. In fact, a milestone took place in 2006 when after several trials, the
Food and Drug Administration (FDA) approved the drug ziconotide1 for the treatment
of intractable severe chronic pain. Derived from a toxin of the cone snail Conus magus,2
ziconotide (Prialt®) became the first licensed pharmaceutical to make the transition from
invertebrate to man.3
More importantly though, within the sphere of cancer therapeutics, natural
products have served as sources of lead molecules for the development of new drugs.
Due to their immense structural diversities and high bioactivity potentials, natural
products have continuously provided new avenues for the treatment of cancers that
have resisted conventional antitumor therapies. In fact there are currently 30 naturally

1

derived compounds in different phases of clinical trials targeted at several types of
cancer.4

Of note are ixabepilone (epothilone B from Soragium cellulosum) and the

dibenzodiazepine ECO-4601 (Micromonospora) (Figure 1.1).
Considering the fact that over 60% of the current anticancer drugs are from
natural sources5 or are “natural product mimics”, natural products seem poised to play
an important role in the fight against cancer.

The cancer problem though is

multifaceted and, accordingly, warrants the deployment of compounds with unique
modes of action if they are to play any role in the field of oncology. An example of such
a compound is romidespin (Figure 1.2), which has recently emerged as a novel
antitumor agent. Belonging to new class of anticancer drugs known as histone

Figure 1.1. Naturally derived antitumor agents ixabepilone and ECO-4601

2

Figure 1.2. Romidepsin

deacetylase (HDAC) inhibitors,6 romidespin’s mode of action involves the induction of
chromatin

remodeling,

growth

inhibition

apoptosis,

tumor

suppressor

gene

transcription and tumor suppression.7

1.2

The Phenanthroindolizidine Alkaloids

Hallucinogenic alkaloids from plants of the Convolvulaceae family (Argyreia, Ipomoea,
Rivea, Turbina) have been known to be used for divinatory means in Mexico,
particularly by the Aztecs.8 Several of these alkaloids were isolated by Gourley et al.
from Ipomoea albla which, after characterization, revealed a family of heterocycles9
(Figure 1.3). Each member bore a bicyclic skeleton consisting of a six-membered ring
fused to a five membered one, with nitrogen as one of the bridging atoms. These
compounds and their derivatives would later be known as the indolizidine alkaloids.
Then, in 1891, Hooper noted the presence of two alkaloids10 isolated from Tylophora

3

Figure 1.3. Simple indolizidine alkaloids from Ipomoea alba.

indica of the plant family Asclepiadaceae.

Plants of the genus Tylophora are found

throughout Africa, Asia, Australia and the Pacific islands; of its 50 or so species, 23 have
been reported to possess alkaloids.11,12

Due to limitations in methods of

characterization at the time, the structures of Hooper’s isolations were never properly
determined. However, Ratnagiriswaran and Venkatachalam managed to re-isolate and
characterize them in 1935, naming them “tylophorine” (1-1) and “tylophorinine” (1-2)
(Figure 1.4).13 Featuring conjoined phenanthrene and indolizidine moieties, tylophorine
(1-1), tylophorinine (1-2) and all other compounds bearing this unique architecture
would become known as the phenanthroindolizidine alkaloids. These alkaloids were
found to exhibit interesting cytotoxicities, and this prompted a re-investigation by
Govindachari et al. who aside from reaffirming Ratnagiriswaran and Venkatachalam’s
discovery,14 isolated numerous more alkaloids from T.crebiflora15,16 (Figure 1.5) and the
genus Pergularia17,18 (Figure 1.6).

4

Figure 1.4. Alkaloids 1-1 and 1-2 from Tylophora indica.

Figure 1.5. Alkaloids from T. crebiflora.

5

Figure 1.6. Alkaloids from the genus Pergularia.

1.3

The Phenanthroindolizidine Alkaloids and Cancer
Following early but promising pharmacological studies as described in the 1935

isolation by Ratnagirisvaran and Venkatachalam,13 tylophorine (1-1) and its analogues
warranted further biological evaluation.

The 1960’s saw studies focused on the

inhibitory properties of these alkaloids on nucleic acid and protein synthesis,19,20 as well
as an evaluation by the National Cancer Institute (NCI) of tylophorine (1-1) in its
antitumor screen. Tylophorine (1-1) and its related analogues demonstrated a potent
growth inhibitory effect (average GI50 ≈10-8 M) against all 60 human–derived cell lines
in the screen.21 Selectivity was directed towards several refractory cell lines notably
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melanoma, and the lymphocytic L1210 leukemia cell lines.22
A few years later, Gellert and Rudzats reported their findings on the effect of the
administration of tylocrebrine (1-3), a positional isomer of tylophorine (1-1), to L1210
leukemia bearing mice.23 Encouragingly, the results of this study showed that 1-3
caused the leukemia-bearing mice to gain a 50% increase in life span (ILS). However,
tylocrebrine (1-3) showed no activity against the sarcoma 180, B16 melanoma,
adenosarcinoma 755, P1534 carcinosarcoma tumor cell lines. Tylophorine (1-1) and
tylophorinine (1-2) were also shown to be active against the L1210 leukemia cell line but
with diminished ILS values of about ca. 30% and ca. 20%, respectively. Accordingly,
based on its superior antitumor activity, tylocrebrine (1-3) was selected as a drug
candidate and progressed through to phase I clinical trials. Unfortunately, tylocrebrine
(1-3) induced negative central nervous system (CNS) effects which manifested as ataxia
and disorientation.24 In addition to prematurely terminating clinical trials in 1966, this
unfortunate

development

also

disseminated

any

further

interest

in

the

phenanthroindolizidine alkaloids as antitumor agents for many years to come.
As 1989 dawned, Bhutani and Ali isolated a set of seven additional alkaloids
from Tylophora indica, some of which bore novel structural features.25 Of particular
interest, was the presence of an angular methyl in the indolizidine periphery and
varying patterns of substitution in the phenanthrene framework. A subset of these rare
phenanthroindolizidine alkaloids would be known as the tyloindicines A–E (Figure
1.7). In a follow-up study in 1991, Ali et al. isolated yet another set of tyloindicines
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Figure 1.7. Tyloindicines A–I
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(Figure 1.7, F–I) from T. indica with even more intriguing structural features.26 Of this
set, tyloindicines F (1-15) and G (1-16) each featuring a unique tertiary hydroxy group at
the 12a position, were screened for anti-tumor potential by the NCI and found to be
extremely potent. Tyloindicines F (1-15, NSC-650393) and G (1-16, NSC-650394)
displayed GI50’s in the 10-10 M range with pronounced activities against certain lung and
melanoma cell lines,27 for which there are few effective agents. Furthermore, of the
33,744 compounds screened at the time, 1-15 and 1-16 were ranked as the two most
potent antitumor agents in the 60–cell NCI screen. The results of this screen proved to
be instrumental in the renewed vigor toward developing the phenanthroindolizidine
alkaloids into a new class of antitumor agents.

1.4

Biosynthesis of Tylophorine
Interest in the biogenesis of these phenanthroindolizidine alkaloids was first

investigated by Herbert and co-workers28 and Bhakuni and Mangala29 utilizing an
isotope-labeling technique. Herbert and co-workers30 then published a report in 1978
prompting the first biomimetic total synthesis (Figure 1.8) of tylophorine (1-1).31,32 This
was accomplished by the condensation of 3,4-dimethoxybenzoylacetic acid (1-19) with
1-pyrroline (1-20) affording the amino ketone 1-21. Further condensation of the amine
ketone 1-21 with 3,4-dimethoxyphenylacetaldehyde (1-22) occurred, and the reaction
was then followed up with a series of NaBH4 reductions/rearrangements to yield

9

Figure 1.8. Biosynthesis of tylophorine (1-1).
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septicine (1-25). A final oxidation of 1-25 ultimately furnished racemic tylophorine (11).
Since its isolation and purification, tylophorine (1-1) was well characterized33 by
1H

and 13C- NMR spectroscopy and by mass spectrometry; however its absolute three-

dimensional structure remained largely unknown. Wang et al. were finally able to solve
the crystal structure of tylophorine B,34 a close analogue of 1-1, in the year 2000. The
ORTEP (Oak Ridge Thermal Ellipsoid Plot) representation revealed that these alkaloids’
phenanthrene skeleton was almost planar, and that their indolizidine moieties were
somewhat puckered.

1.5

Total Syntheses of Tylophorine
Featuring a chiral center at C-13, tylophorine is optically active. These isomers

are shown in Figure 1.9; the 13-S-isomer [(S)-1-1] was confirmed to be dextrarotatory,35
while its 13-R-enantiomer [(R)-1-1]) was determined to be levrorotatory.
The impressive antitumor potential of this class of compounds mandated a total
synthesis.

Accordingly, tylophorine (1-1) was synthesized both in racemic36-38 and

optically active forms.35,39 Highlights of some of these synthetic accomplishments are
discussed in the following sections.
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Figure 1.9. The two enantiomers of tylophorine (1-1).

1.5.1

Synthesis of Tylophorine (1-1) by Ihara et al.
In 1985, Ihara et al.40 utilized an intramolecular double Michael reaction in their

short synthesis of racemic tylophorine [(±)-1-1]. This highly effective annelation was
accomplished by reaction of enamide ester 1-30 (derived from Wittig reaction of 1-29)
with tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf), followed by an
oxidative ring closure to give the indolizidine derivative 1-32. Saponification and
decarboxylation of 1-32 followed by the reduction of 1-33 finally afforded tylophorine
[(±)-1-1] in 29.7% yield (Figure 1.10).
Ihara et al. later revised their original synthetic approach by employing two
chiral

auxiliaries;

(-)-phenylmenthol41-42

and

(2R,4S,5R)-(–)-4-(tert-butyl-

dimethylsiloxymethyl)-5-hydroxy-2-phenyl-1,3-dioxane (BDH).42-43

This modification

resulted in a highly enantioselective synthesis of (R)-(-)-tylophorine [(R)-1-1] and in the
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Figure 1.10. Synthetic approach adopted by Ihara et al.40
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process confirmed the absolute configuration of naturally occurring tylophorine as
being [(R)-1-1].

1.5.2

Synthesis of Tylophorine (1-1) by Nordlander and Njoroje
In 1987, Nordlander and Njoroje’s short but enantioselective synthesis39 (Figure

1.11) employed a Friedel–Crafts acylation as the key step and a Pictet–Spengler
cyclomethylation as the final step.

The five-step synthesis commenced with the

decarboxylation of 2,3,6,7-tetramethoxyphenanthrene-9-carboxylic acid (1-34) to the
substituted phenanthrene 1-35 which was then acylated with (S)-N-(trifluoroacetyl)prolyl chloride (1-36) to give ketone 1-37. Deketonization of 1-37 with Et3SiH and
BF3Et2O afforded 1-38, which underwent deacylation in methanolic ammonia to yield
amine 1-39. (S)-(+)-Tylophorine [(S)-1-1] was then obtained in 53% yield upon Pictet–
Spengler cyclomethylenation of amine 1-39.

1.5.3

Synthesis of Tylophorine (1-1) by Buckley and Rapoport

Buckley and Rapoport’s 1983 effort35 (Figure 1.12) would feature the use of (S)(+)-glutamic acid as a chiral educt and an intramolecular Friedel–Crafts acylation. The
successful implementation of these key steps would prove to be pivotal in their
asymmetric

synthesis

of

(S)-(+)-tylophorine

[(S)-1-1].

Accordingly,

dimethoxybenzylcyanide (1-40) was reduced to the aldehyde 1-41, which upon
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3,4-

Figure 1.11. Nordlander and Njoroje’s concise enantiospecific synthesis.39
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Figure 1.12. Buckley and Rapoport’s total synthesis of (S)-(+)-tylophorine [(S)-1-1].35
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treatment with the diisopropyl ester of (S)-(+)-glutamic acid (1-42a) yielded amine 1-43.
Reduction of 1-43 with NaCNBH3 and cyclization with AcOH afforded 1-44, which was
then hydrolyzed, converted into its corresponding acid chloride and then reacted with
SnCl4 to furnish ketone 1-45. Deketonization of 1-45, followed by reduction of 1-46 with
LiAlH4, secured (S)-(+)-tylophorine [(S)-1-1].

1.5.4

Jin’s Approach

The ten-step synthesis by Jin and co-workers44 (Figure 1.13) would employ the
Lewis acid-catalyzed ring closure that Buckley and Rapoport used in their earlier
synthesis.35 Additionally, Jin et al.’s total synthesis would also feature an N-alkylation
of the heterocyclic moiety 1-49 by the halomethylphenanthrene derivative 1-48.

1.6

The Phenanthroquinolizidine Alkaloid Cryptopleurine
Cryptopleurine (1-51, Figure 1.14), is a representative phenanthroquinolizidine

alkaloid. This highly toxic skin irritant and vesicant was isolated by Saifah et al. from
Cissus rheifolia Planch.45 It is structurally similar to tylophorine (1-1), but in place of the
pyrrolizidine ring, there exists a quinolizidine moiety. An asymmetric synthesis of (S)(+)- cryptopleurine [(+)-1-51] was reported by Buckley and Rapoport in their series

17

Figure 1.13. Jin et al.’s total synthesis of (S)-(+)-tylophorine [(S)-1-1].44
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devoted to amino acids as chiral educts.35 Of note, Grieco and Parker were able to effect
an intramolecular Diels–Alder reaction using an immonium ion in their synthetic
approach to 1-51.46 A study by Dolz et al. using the 40S, 60S, 70S and 80S ribosomal
units of the yeast Sacchromyces cerevisiae found that low concentrations of
cryptopleurine (1-51) resulted in the blockage of pepitidyl–tRNA translocation from the
40S ribosomal subunit.47 On the other hand, higher concentrations of cryptopleurine (151) inhibited peptide bond formation.

The latter was attributed to non-specific

interactions of 1-51 with the 60S subunit.
Although the phenanthroquinolizidine alkaloids have not garnered as much
interest

as

their

phenathroindolizidine

counterparts,

their

equally

profound

cytotoxicities and unique modes of action may provide yet another avenue in the
continued development of effective antitumor agents.

Figure 1.14. (S)-(+)-Cryptopleurine [(S)-1-51]
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1.7

The Tylophorine Analogues

1.7.1

Background

The impressive antitumor potential of tyloindicines G (1-16) and F (1-15) as
revealed by the NCI 60-cell screen would soon prompt efforts towards their total
synthesis. The indolizidine moiety of these two alkaloids is adorned with a tertiary
hydroxy group at the 12a position and a double bond between C13 and C14. Their
phenanthrene skeletons, however, differ slightly; tyloindicine F (1-15) has an unbridged trimethoxy skeleton, while tyloindicine G (1-16) has a bridged tetramethoxy
one. With only two chiral centers, the seemingly simple indolizidine periphery would
conceal the difficulty that lay in the installation of the allylic tertiary hydroxy group.
In their synthetic efforts towards tyloindicine G (1-16), Baker and co-workers48
elected to install the signature tertiary hydroxy during the final stages of the synthetic
pathway (Figure 1.15) via an allylic oxidation. This operation, however, yielded only
minute amounts of the synthetic target, 1-16, but also afforded a sparing amount of two
epimeric alcohols, 1-62a and 1-62b. Separation of the two epimers resulted in the
discovery of two new tylophorine analogues; identified as DCB-3501 (1-62a) and DCB3503 (1-62b). Furthermore, the reduction of 1-60 was attempted using LiAlH4 but failed
to furnish 1-61 instead giving rise to DCB-3500 or (S)-(+)-tylophorine [(S)-1-1], by the
way of a double bond rearrangement.
Although novel, this new class of tylophorine analogues bore structural features
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that were similar to previously isolated alkaloids. For instance, the indolizidine moiety
of DCB-3501 (1-62a) was identical to that of pergularinine (1-7) and tylophorinicine (1-9)
whilst DCB-3503 and tylophorinidine (1-2, Figure 1.16) shared an identical indolizidine
periphery as well. The more distinct structural differences arose from the substitution
patterns on their phenanthrene skeletons.

1.7.2

Biological Profile of the Tylophorine Analogues
In 2000, Rao and Ventachalam evaluated both pergularinine (1-7) and

tylophorinidine

(1-2)

in

their

in-vitro

assessment49

phenanthrolizidine alkaloids on cell growth.

of

the

effect

of

these

The study did unveil several new

pharmacological properties such as anti-amoebic and anti-inflammatory effects, but it
was the antitumor potential of these alkaloids that remained the focal point.
Additionally, based in part on their previous work,50 Rao and Venkachalam were able
to allude to the participation of the indolizidine moiety of these alkaloids in pocket
binding possibly via hydrogen bonding. As such, Rao and Venkachalam were able to
conclude that these alkaloids possessed a “high order of potency as anticancer agents”.
These and similar findings implicating phenanthroindolizidine alkaloids as a new class
of antitumor agents therefore warranted further evaluation of analogues DCB-3500 [(S)1-1], DCB-3501 (1-62a), DCB-3502 (1-61) and DCB-3503 (1-62b) by the NCI.
Of the evaluated congeners, DCB-3500 [NSC-717335, (S)-1-1] and DCB-3503

21

Figure 1.15. Synthesis of tyloindicine G (1-16) by Baker et al.48
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Figure 1.16. Novel tylophorine analogues.

(NSC-716802, 1-62b) exhibited impressive, broad–based potencies with an average GI50
~10-8 M (concentration of drug that causes 50% growth inhibition) for most tumors in
the 60–cell in vitro NCI screen of human–derived tumors. Notably, selectivity was
directed at several refractory cell lines including melanoma and lung tumor cell lines.
The NCI’s COMPARE algorithm analyzes every compound’s in vitro growth pattern for
similarity to other compounds in its class. Results from this analysis revealed their
activity to be unique among known antitumor compounds, suggesting that these
compounds operate via a novel mode of action. The results of the screen also identified
the S-enantiomer of tylophorine [(S)-1-1] as being the more potent in the series.
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1.8

Biological Evaluation of the Tylophorine Analogues
In light of the results of the 60–cell NCI screen, the antitumor potential of these

tylophorine analogues was further investigated in collaboration with Dr. Yung-Chi
Cheng’s group (Department of Pharmacology, Yale University School of Medicine)
against several cell lines.

Highlights of these studies will be summarized in the

following sections.

1.8.1

Hepatocellular Carcinoma (HCC) Studies
Hepatocellular carcinoma (HCC) is a primary cancer of the liver. It is a secondary

occurrence to either a viral heptatide infection (hepatitis B or C) or cirrhosis. Due to its
resistance to most chemotherapeutic agents, surgery remains the most effective cure.51
Even so, the five year survival rate is less than 5%. Although HCC is one of the most
common tumors worldwide, the NCI screen does not include hepatoma cell lines,
perhaps due to the non-endemic nature of hepatitis in the North America. There is,
however, a rising incidence of HCC in the United States.52
A major obstacle to successful cancer treatment is resistance to chemotherapy. Of
the various mechanisms employed by cancer cells to overcome conventional treatment,
over-expression of the multidrug resistance gene (mdr) product, P-glycoprotein,53-54 is
one of the best characterized. Using this 170-kDa P-glycoprotein, the cancer cell is able
to channel the drug out of the cell, thereby rendering the treatment ineffective.
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In a 2004 study, Cheng and co-workers investigated the antitumor potential of
the tylophorine analogues DCB-3500 [(S)-1-1] and DCB-3503 (1-62b) against the human
hepatocellular carcinoma cell line (Figure 1.17), HepG2, both in vitro and in vivo.55 Both
[(S)-1-1] and 1-62b were able to markedly suppress HepG2 tumor growth and were
concluded to be potent HepG2 inhibitors (Figure 1.18). However, unlike conventional
antitumor drugs, the tylophorine analogues DCB-3500 [(S)-1-1] and DCB-3503 (1-62b)
were not found to exert their antitumor abilities by targeting DNA synthesis or by
inducing DNA damage. This discovery confirmed that these alkaloids operated via a
unique mode of action that was different from other antitumor compounds.
Intriguingly, it was also discovered that even though [(S)-1-1] was more potent than 162b in vitro, 1-62b was much more potent in vivo. This discrepancy was attributed to a

Figure 1.17. Untreated HepG2 cells as viewed by an inverted phase–contrast
microscope
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Figure 1.18. Morphology of HepG2 cells after treatment with DCB-3500 [(S)-1-1].
The HepG2 cells were checked with actin (shown as red fluorescence) and the
liver cell differentiation marker, albumin (green fluorescence). The HepG2 cells
lost proliferative abilities and appeared to be well differentiated after exposure to
DCB-3500 [(S)-1-1]. Adapted from the 2004 study by Cheng and co-workers.55
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difference in pharmacokinetics between DCB-3503 (1-62b) and DCB-3500 [(S)-1-1] in
vivo.

1.8.2

DCB-3503 (1-62b), Cancer and the NF-κ
κB Pathway
The nuclear factor kappa B (NF-κB) complex of proteins is a set of closely related

transcription factors that, amongst other things, regulates immune responses to
infection and is a factor in the inflammatory response.56 In mammalian cells, it consists
of five members (Table 1.1): Rel (also known as c-Rel), RelA (also known as p65 and NFκB3), RelB, NF-κB1 (also known as p50) and NF-κB2 (also known as p52).57 Since first
being discovered by Sen and Baltimore in 1986,58 activation of the NF-κB group of
proteins has since been found to mediate the expression of tumor promotion genes.59
Significantly, the NF-κB groups of proteins have also been found to regulate the
production of prostaglandins via the proinflammatory gene cyclooxygenase-2 (COX2),
which has been shown to be overexpressed in several cancers.60-62 The link between
cancer and inflammation was first hypothesized by the German physician, Rudolf
Virchow, in 1863 who alleged that “chronic inflammation caused by certain irritants can
lead to cancer”.63 This hypothesis was then validated by the work of Yamagiwa and
Ichikawa in 1915.64 By repeatedly painting the ears of rabbits with coal tar, Yamagiwa
and Ichikawa were able to demonstrate that the animals developed tumors as a result.
The NF-κB transcription factors are usually sequestered in an inactive state in the
cytoplasm by the inhibitory protein IκBα.65 Upon receipt of an appropriate signal, the
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Table 1.1. The names and aliases of the nuclear factor B (NF-κB) group of proteins.

Protein
Rel
RelA
RelB

Aliases
c-Rel
p65 or NF-κB3
p50
p52

NF-κB1
NF-κB2
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enzyme IκB kinase (IKK) becomes activated and in turn, phosphorylates the IκBα
protein, resulting in its dissociation from the NF-κB complex (Figure 1.19, shown using
only RelA and p65). This “activated” NF-κB complex then translocates to the nucleus
where it binds to specific sequences of DNA (Figures 1.20 and 1.21) and upregulates the
transcription of specific genes. The phosphorylated IκBα protein is left in the cytoplasm
to undergo eventual degradation by the proteasome 66
Although the NF-κB group of proteins play an important role in the inducible
expression of many proteins, including cytokines, acute–phase response proteins, and
cell–adhesion molecules;67-68 incorrect regulation of this signaling pathway has been
linked to a host of problems including viral infection, autoimmune diseases, improper
immune development, inflammation and cancer.56 With regards to the progression of
oncogenesis, a study by Baldwin and Mayo found that activation of NF-κB resulted in
the promotion of cell proliferation and suppression of apoptosis in tumor cells.69
Furthermore, aberrant NF-κB activation has been implicated as one of the contributing
factors involved in the resistance to chemotherapy.70 Conversely, interruption of the
NF-κB cascade has been found to limit the proliferative activities of cancer cells.71 The
mediation by NF-κB of genes involved in the promotion of tumor growth,59 makes any
drug that interrupts NF-κB an ideal target for development as an anticancer agent.
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In a 2004 study, Cheng and co-workers found that even at a concentration of 100
nM, DCB-3503 (1-62b) exerted a 50% inhibition on NF-κB-mediated transcription in
chemoresistant HepG2 cells.55

While this finding confirmed DCB-3503’s (1-62b)

profound cytotoxity, it provided the definitive link between the growth inhibitory
properties of the phenanthrolizidine alkaloids and the NF-κB group of proteins. A
subsequent study by Cheng and co-workers revealed that the inhibition of NF-κB
activity was mainly due to the down-regulation of nuclear phosphorylated RelA (also
known as p65) by DCB-3503 (1-62b).74 Intriguingly, the decrease in RelA (or p65) levels
was presumed to arise from 1-62b’s ability to suppress IKK activity via degradation of
the IKK subunit, IKK-α (Figure 1.19). The IKK complex consists of catalytic kinase
subunits, IKK-α and IKK-β; however, only IKK-α has been identified to play an
auxiliary role in the activation of an alternative pathway.75 This unique role makes IKKα a prime target for therapeutic intervention by anticancer compounds such as 1-62b.76
To date there are no potent IKK-α-specific inhibitors, but other compounds capable of
suppressing IKK activity by targeting IKK-α are under development. Some examples
include a quinazoline analogue (SPC-839),77 a β-carbolin analogue (PS-1145)78 and
several others.79

1.8.3

Additional Evaluations

In addition to its antitumor properties, DCB-3503 (1-62b) has been shown to
suppress collagen-induced arthritis80 and lupus-associated skin lesions as well.81
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STATEMENT OF THE PROBLEM I
1.9

STATEMENT OF THE PROBLEM I

The original synthesis of DCB-3503 (1-62b) was accomplished by Baker and co-workers
in 2003.48,82-84 Inspired, in part, by Buckley and Rapoport’s synthesis of tylophorine (11),35 its synthetic blueprint was later modified by Kaczmarek, resulting in improved
product yields.83 Even though recent biological studies have offered some insight into
the mechanism of action of DCB-3503 (1-62b),85-86 there still exists the need to synthesize
additional quantities of DCB-3503 (1-62b), of sufficient purity, for the continued in vitro
and in vivo evaluations. In order to accomplish this, improvements (mostly technical)
would have to be made to the synthetic approach devised by Kaczmarek, in order to
facilitate a “scaled-up” synthesis of DCB-3503 (1-62b).
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1.10 Synthesis and Purification of DCB-3503 (1-62b)
The scheme for the synthesis of DCB-3503 (1-62b) employed by Kaczmarek, is
presented in Figures 1.22 and 1.23.

The stilbene 1-27 was afforded in high yield

commencing with the Perkin condensation of 3,4-dimethoxyphenylacetic acid and 3,4dimethoxybenzaldehyde. Esterification of 1-27 using H2SO4 and MeOH furnished 1-47,
an intermediate suitable for the Fe(III)-mediated ring closure. Accordingly, treatment
of 1-47 with Fe(III) chloride yielded the phenanthrene 1-52, whose formation was
confirmed by the presence of only five characteristic, aromatic proton peaks at 8.63,
8.41, 7.78, 7.74 and 7.24 ppm in its 1H NMR spectrum (Figure 1.24).
Reduction of the ester present within the stilbene 1-52 with lithium aluminum
hydride yielded the alcohol 1-53. Conversion of 1-53
1-63 was then accomplished
using phosphorous tribromide. The resulting benzylic bromide 1-63 was immediately
coupled to the chiral auxiliary 1-42b in the presence of K2CO3 and DMF to afford the
aminal 1-64. Treatment of the aminal 1-64 with MeOH–AcOH induced lactamization
and secured the tetracylic derivative 1-65. The 1H NMR spectrum of the intermediate 165 confirms the compound’s intriguing structural features, particularly the doublet of
doublets between 3.80–3.84 ppm and the set of multiplets between 1.90–2.54 ppm
(Figure 1.25). Hydrolysis of 1-65 was conducted using 2 N KOH in a system of MeOH–
1,4-dioxane to give the acid 1-50 which, upon treatment with oxalyl chloride and a
Lewis acid, underwent intramolecular cyclization to give the pentacylic ketone 1-45.
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Figure 1.22. Scheme for the synthesis of DCB-3503 (1-62b).
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Figure 1.23. Continued scheme for the synthesis of DCB-3503 (1-62b).
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1-47

Figure 1.24.

1H

1-52

NMR spectra of the characteristic changes that take place in the
conversion of 1-47
1-52.
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Figure 1.25.

1H

NMR spectra of the intriguing structural features of intermediate 1-65.

They key to securing pure samples of DCB-3503 (1-62b) suitable for biological
39

evaluation is mainly dependent on the purity of intermediates 1-45 and 1-66.
1
Therefore,
both of these intermediates must be purified exhaustively in order to exclude any
contaminants that may otherwise impact overall product yield and/or purity.
Accordingly, the pentacylic ketone 1-45 was purified using silica gel chromatography
(0.1:2 MeOH–CHCl3) and its purity confirmed by the HPLC trace shown in Figure 1.26.
This purified ketone 1--45 was then reduced by the bulky hydride,
e, potassium trisec-butylborohydride (K-selectride
selectride®), to furnish intermediate 1-66
66.

Extensive

purification of 1-66 was also accomplished using silica gel chromatography (0.1:2
MeOH–CHCl3) and its purity is illustrated by the HPLC trace shown in Figure 1.27.

Figure 1.26. HPLC trace and chromophore (inset) illustrating the purity of
intermediate 1-45.
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Figure 1.27. HPLC trace and chromophore (inset) illustrating the purity of
intermediate 1-66.

The installation of intermediate 1-66’s
’s hydroxy is evident by the change in retention
times between 1-45 and 1--66, reflecting a change in polarity between the two
intermediates. Furthermore, there is a subtle change in the chromophores of these two
intermediates and these are illustrated by the insets in Figures 1.26 and 1.27.
Reduction of the amide within 1-66 was accomplished using lithium aluminum
hydride and this secured sufficient quantities of the target, 1-62b. A sampling of the
reaction mixture, taken after two hours, in the reduction of 1-66 with lithium aluminum
hydride is presented in Figure 1.
1.28. The simultaneous formation of the target 1-62b and
depletion of the starting material 1-66 can be observed. The disappearance of the peak
at 3.9 min verifies that intermediate 1-66 has been completely consumed (Figure 1.29).
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Figure 1.28. HPLC trace of the reaction of 1-66 with LiAlH4 taken after 2 h.
The simultaneous formation of the target 1-62b and depletion of the starting
material 1-66 can be observed.

Figure 1.29. HPLC trace of the reaction of 1-66 with LiAlH4 taken after 10 h.
The absence of the peak at at 3.9 min verifies that intermediate 1-66
66 has been
completely consumed.
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The formation of the target, DCB
DCB-3503 (1-62b),
), was also confirmed by HRDARTMS as
shown in Figure 1.30. There is a characteristic peak at m/z 392.18819 that corresponds
cor
to the loss of a hydroxy group.

Figure 1.30. HRDART MS of DCB-3503 (1-62b).
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STATEMENT OF THE PROBLEM II
1.11 STATEMENT OF THE PROBLEM II
Tylophorine and other phenanthrolizidine alkaloids are a group of compounds
that have been shown to have potent growth inhibitory properties.

Recently the

tylophorine analogue, DCB-3503 (1-62b, NSC-716802), has been found to exhibit
antitumor activity both in vitro and in vivo against a hepatoma cell line, HepG2.55 A
study by Cheng and co-workers suggested that DCB-3503 (1-62b) exerts its unique
growth inhibition properties by modulating nuclear factor kappa B (NF-κB) activity
through the suppression of IκB kinase (IKK). However, no direct target was identified.
The study also revealed that DCB-3503 (1-62b) interfered with cell-cycle progression by
the down-regulation of several cell-cycle regulatory proteins including cyclin D1. To
date, DCB-3503’s (1-62b) target protein(s) and underlying mechanism of action remain
largely unknown.
Affinity-based methods employing biologically active biotin-conjugates of DCB3503 (1-62b) have the potential, to identify specific DCB-3503 (1-62b) binding proteins.
Previous attempts aimed at synthesizing functional biotinylated probes of DCB-3503 (162b) have been unsuccessful. Given the structural and biological similarities between
DCB-3503 (1-62b) and other phenanthrolizidine alkaloids, the elucidation of the cellular
targets of DCB-3503 (1-62b) may also shed light on the biological mechanism of this
interesting class of natural products.
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OBJECTIVES
The project described in this dissertation was primarily focused on the design
and synthesis of biotinylated molecular probes incorporating all of the necessary
features of DCB-3503 (1-62b) required for in-vitro binding and activity. Access to these
probes involved the development of several strategies ranging from the classical
protective group approach to the late-stage, Cu(I)-mediated union (“click”) of suitable
alkyne-azide pairs:

•

In the first approach, several protective group strategies were utilized in the
construction of a tethered form of 1-62b which, upon conjugation with biotin,
would provide access to a functional biotin conjugate.

•

The second approach sought to synthesize a propargylated derivative of 1-62b
for later coupling to an azide-bearing biotin moiety using the Cu(I)-catalyzed
variant of the Huisgen 1,3-dipolar cycloaddition.

•

A third approach would seek to synthesize a biotin-conjugate of 1-62b bearing a
super-long polyethylene glycol (PEG) based linker. Access to this probe would
involve the incorporation of functionalized PEG spacer units on both 1-62b and
biotin for later coupling using the Cu(I)-catalyzed variant of the Huisgen 1,3dipolar cycloaddition.
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Finally, using a computational model, more potent analogues of the lead compound,
1-62b, would undergo in silico screening. New analogues that are found to be more
active than 1-62b would be placed in a virtual library and prioritized as future synthetic
targets.
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CHAPTER 2
PROTECTIVE GROUP STRATEGIES TOWARD
BIOCONJUGATION: A CLASSICAL APPROACH
2.

2.1

PROTECTIVE GROUP STRATEGIES TOWARD
BIOCONJUGATION: A CLASSICAL APPROACH
Introduction

Molecules that are able to modulate cellular functions are often identified
through the phenotypic changes that result from their administration to cell or
organism-based models. Antitumor drugs, in particular, are commonly discovered
using this methodology. In fact, the in vivo antitumor potential of DCB-3503 (1-62b) and
several other tylophorine analogues was realized by the phenotypic observation of
tumor-bearing mice after undergoing treatment with doses of DCB-3503 (1-62b)86-87
(Figure 2.1).

Despite the fact that a large percentage of drugs in use today were

discovered in this manner, their specific mechanisms of action of were not known until
several years after their approval by the FDA.

2.2

Target Identification
A promising new strategy for the development of efficacious disease therapies

relies on the discovery and validation of novel drug targets.

Of the 1,357 FDA-

approved drugs on the market today, about 50% of them target only four of the ca.
16,000 protein families in the genome.88

Current approaches toward target

identification employ either genomic or affinity-based proteomic methods.
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Figure 2.1. The phenotype-based approach to drug discovery.
In this study, a tumor-bearing animal model is injected with a
dose of the bioactive drug of interest and the resulting
phenotypic changes are noted.

2.2.1

The Genomic Approach

In the genomic approach, mutants that are missing specific functions are
engineered from genetic model organisms (e.g., S.cerevisae, C. elegans, D. melangonaster
or mammalian cells).89 Upon exposure to the bioactive molecule of interest, only the
mutants that demonstrate sensitivity or resistance are investigated further. Although
this approach is useful in the indirect determination of molecular targets, it is
particularly suited to molecules whose targets are already known but whose cellular
48

impact is not completely understood.
Utilizing the genomic approach to target identification, Davis et al. were able to
successfully identify the drug target of tunicamycin90 using deletion strains of S.
cerevisae.

2.2.2

The Affinity-Based Approach

Affinity based approaches, on the other hand, are based on the assumption that
the lead compound will bind strongly (covalently or non-covalently) to its target and
that this binding event is responsible for the observed change(s) in phenotype. This
approach often entails the addition of an affinity tag to the lead compound prior to its
immobilization on resin. The resulting affinity matrix is then incubated with a lysate of
a cell line of interest, followed by chromatographic purification. Typically, the bound
protein(s) is (are) separated from other cellular proteins by simple filtration, washing
and elution.91

In most cases, the bound protein(s) can be identified by modern

degradative mass spectrometric (MS) methods or with a combination of enzyme
degradation and MS techniques (Figure 2.2).92
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Figure 2.2. The affinity-based approach to target identification.
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2.3

Successful Target Identification Studies Employing AffinityBased Approaches
The power of natural products as discovery tools in chemical biology was well

demonstrated by Schreiber and co-workers in their studies of trapoxin (Figure 2.2) and
histone deacetylases (HDACs).93-94 Since being discovered in 1964 by Allfrey et al.,95 the
enzymatic activity of histone deacetylase remained relatively uncharacterized until 1993
when Kijima et al. demonstrated that the natural product trapoxin96 was found to inhibit
histone deacetylation in vivo.97 However, trapoxin, also induced phenotypic changes in
cells in addition to its inhibition of histone deacetylation. Although the changes in cell
morphology were thought to arise from cell-cycle arrest, the correlation between
histone deacetylation and cell-cycle arrest was not completely understood.

Figure 2.3. The natural product, trapoxin, which inhibits histone deacetylation.
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To further investigate this issue, Schreiber and co-workers synthesized an
analogue of trapoxin called K-trap93 (Figure 2.3) that was able to be covalently
immobilized on resin. Following incubation with a mammalian cell extract, K-trap
revealed that one of the molecular targets of trapoxin was a protein (HD1) whose amino
acid sequence was 60% identical to that of the yeast protein Rpd3p.94 Although the
function of this protein was unknown at the time, the RPD3 gene had already been
shown to be essential for the transcriptional regulation of a subset of inducible genes in
yeast.98
Ultimately, Schreiber and co-workers were able to clone the human ortholog of
the yeast gene RPD3, and its recombinant protein was found to exhibit histone
deacetylase activity. This exclusive finding was instrumental in the identification of a
histone deacetylase gene.94 Additionally, the changes in cell morphology were found

Figure 2.4. Structure of the tethered trapoxin derivative, K-trap.
52

to be an indirect consequence of trapoxin’s interaction with actin filaments. Although
trapoxin was never developed into a drug, the work by Taunton and others established
a precedent for the development of vorinostat99 (Zolinza®, Merck), a potent histone
deacetylase inhibitor, which was approved by the FDA in 2006 for the treatment of
cutaneous T-cell leukemia.

In another example, in which affinity chromatography

played a key role, Schreiber and co-workers utilized an agarose-supported derivative of
the immunosuppressant FK-506, which after incubation with the cellular lysate of
bovine thymus, revealed that FK-506 bound to the protein FKBP12, a cis-trans prolyl
isomerase.100

2.4

Biotinylated Probes in Target Identification
A commonly used technique in target identification is the synthesis of

biotinylated versions of the lead compound for immobilization on avidin/streptavidin
beads. Biotin binds to the proteins avidin and streptavidin with dissociation constants
of 10-15 M, making it one of the strongest non-covalent proteins known.101-102 As a
result, streptavidin-based resins, when incubated with a biotinylated probe of interest,
will give rise to a stable non-covalent affinity matrix. The resulting affinity matrix can
then be treated with a lysate of a cell line of interest to identify any target protein(s)
(Figure 2.3). This method is directly analogous to the affinity-based approach described
in Section 2.2.2.
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Figure 2.5. The use of biotinylated probes in target identification studies.
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2.4.1

Probing the NF-κB Pathway With Biotinylated Probes

The sesquiterpene lactone parthenolide (Figure 2.6) is an anti-inflammatory
agent from the medicinal herb Feverfew (Tanacetum parthenium). It was demonstrated
to be a potent inhibitor of the transcription factor NF-κB (see Section 1.8.2) by Bork et
al.103-104 In a subsequent study, Hehner et al. found that parthenolide inhibited NF-κB
activity by interfering with the phosphorylation of the IκB kinase complex; however, it
was not known whether parthenolide directly targeted the catalytic subunits IKK-α and
IKK-β.105 In a study aimed at identifying the specific target of parthenolide, Crews and
co-workers synthesized a parthenolide-biotin conjugate (Figure 2.6), which upon
incubation with lystates from human cervical carcinoma (HeLa) cells, revealed that
parthenolide’s direct molecular target was in fact IKK-β.106 Thus, the anti-inflammatory
properties of parthenolide were found to arise from its direct binding to IKK-β, which
resulted in the loss of NF-κB activity.
In another example, Crews and co-workers synthesized a biotinylated
isopanepoxydone derivative (Figure 2.7) in order to determine the cellular target(s) of
isopanepoxydone, a potent NF-κB signaling inhibitor.107

After treatment of the

biotinylated isopanepoxydone derivative with HeLa cells, a protein species ca. 50 kDa
was confirmed to be isopanepoxydone’s target. This 50 kDa protein, however, has not
yet been characterized.
The examples described above illustrate the power of biotinylated probes in
ascertaining the specific mechanisms by which the compounds of interest operate. To
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date, all that is known is DCB-3503 (1-62b) exerts its unique growth inhibition
properties by modulating nuclear factor kappa B (NF-κB) activity.

Although this

inhibition was suggested by Cheng and co-workers to occur through the suppression of
IκB kinase (IKK),85 the protein/cellular targets of DCB-3503 (1-62b) remain unidentified.
Therefore, a biotin-based affinity agent has the potential to isolate and identify the
binding protein(s) of DCB-3503 (1-62b).

Figure 2.6. The structure of pathenolide and the pathenolide–biotin conjugate.
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Figure 2.7. The structure of isopanepoxydone and its biotin conjugate.

2.5

Synthesis of Biotin-Based Affinity Reagents
In all target identification strategies, the molecular probe plays a central role in

identifying the molecular target(s) of a compound of interest. In most cases, the probe
arises from the attachment of an affinity tag such as biotin, to the bioactive compound
using a suitable linker. Classical approaches to the biotinylation of bioactive molecules
often involve the formation of peptide and ester bonds.108 In a generic approach (Figure
2.8), the molecule of interest is appended with a functional linker arm for subsequent
coupling to a biotin moiety through the formation of either an ester or amide bond.
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Figure 2.8. The generic approach to classical biotinylation.
The small molecule of interest is typically appended with a
functional linker arm bearing either a terminal hydroxy or
amino function. Conjugation with biotin occurs through the
formation of either an ester or amide linkage.

2.5.1

The Use of Protective Groups in the Synthesis of Biotinylated Probes

Because the conjugation of a bioactive compound with biotin often takes place in
the end stages of a synthetic strategy, protective groups are commonly utilized to
preserve the integrity of the appropriate amine or hydroxy motif. For example, Abrams
and co-workers synthesized a biotinylated derivative of the plant hormone abscisic acid
S-(+)-ABA using tert-butyldimethylsilyl (TBDMS) as their hydroxy protecting
function.109 Towards the end of their synthesis, Abrams and co-workers first cleaved
the silyl ether using TBAF before coupling the deprotected hydroxyl group to the biotin
moiety (Figure 2.9).

In another example, Kobayashi and co-workers were able to

synthesize a biotinylated derivative of neoechinulin A by using a methoxymethyl ether
to protect the phenolic position of neoechinulin A, which would later serve as the site of
biotinylation (Figure 2.10).110
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Figure 2.9. Abrams and co-workers’ protective group approach to the synthesis of a
biotinylated derivative of abscisic acid.109

Figure 2.10. Kobayashi and co-workers’ protective group approach to the synthesis of
a biotinylated derivative of neoechinulin A.110
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2.6

Target Validation
Once a molecule’s potential target protein has been identified, it has to undergo

validation to confirm that it is indeed the relevant binding partner of the molecule in
vivo.

Several experimental strategies exist to accomplish this,111 including gene

expression profiling and yeast three hybrid studies. One of the simplest validation
strategies involves the in vitro analysis of the bioactive compound with its presumed
target. Using either fluorescence anisotropy, isothermal titration calorimetry or surface
plasmon resonance, the direct binding of the affinity-purified protein to the compound
can be experimentally observed.
Cell-culture experiments have also been developed to assist in target validation.
Of the cell-culture validation experiments available, the modulation of the expression
level of the putative target protein using RNAi techniques is the most common. Cells
that lack the putative target protein should exhibit no changes in phenotype upon
exposure to the compound of interest. Conversely, cells that are overly abundant in the
putative target protein through overexpression should diminish the potency of the
molecule of interest.

2.7

Limitations of Target Identification Strategies
The successful target identification strategies discussed so far have demonstrated

the ability of natural products (or their mimics) to serve as powerful discovery tools in
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the fields of chemistry and biology. However, the determination of the protein target(s)
of bioactive molecules remains a significant challenge in modern drug discovery. A
common issue seems to be an attenuation of activity of the bioactive compound upon
biotinylation;107,112 however, biotinylated derivatives with diminished activities have
been successfully employed in past studies.106,113-114

Furthermore, the aqueous

solubility of biotin conjugates can be rather poor especially if an aliphatic variant such
as biotinyl-6-aminohexanoic is used.115-116 This induced hydrophibicity can result in the
retention of many proteins from an extract in addition to the physiologically relevant
target(s).

Additionally, the compound of interest also has the potential to behave

“promiscuously” by binding to numerous targets and forming aggregates as
demonstrated by Shoichet and co-workers.117
Typically, in an affinity chromatography experiment, an extract is passed over
the immobilized compound of interest, requiring extensive washing (using denaturing
buffers) to remove non-specific binding partners. In this case, if the molecule–protein
interaction has a low kinetic half-life, then the likelihood exists that the target may not
survive washing. Therefore, the degree of affinity that a compound has for its target is
a key determinant of the success or failure of an affinity chromatography experiment.
Another obvious factor in all target identification strategies is the abundance of the
target protein(s). If the abundance of this protein is low, then it becomes exceedingly
difficult to detect it above background noise.
Clearly, the success of a target identification experiment depends on many
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factors, and there are a considerable number of challenges that need to be overcome.
However, the discovery of the targets of bioactive compounds can reveal new proteins
and revolutionize targeted-based drug discovery efforts.

2.8

Research Plan: Retrosynthetic Analysis
A DCB-3503-biotin conjugate (2-19) suitable for the investigation of DCB-3503 (1-

62b) binding partners is presented in Figure 2.11.

As demonstrated by the

retrosynthetic transform, the ester linkage is expected to arise from the late stage
esterification between 2-18’s primary hydroxy and commercially available D-(+)- biotin.
In designing the affinity agent, 2-19, the length of the carbon chain between the active
head unit and the biotin moiety was anticipated to comprise six carbon atoms. A linker
of this length would ensure that any potentially unfavorable interactions between the
functional tag (biotin) and the active head unit of 2-19 would be kept to a minimum.
Additional

retrosynthetic

transformations

are

detailed

in

Figure

2.12.

Intermediate 2-17, the protected derivative of 2-18, is presumed to arise from ketone 215 by means of a selective hydride delivery procedure. The formation of 2-15 can be
anticipated from the intramolecular cyclization of an appropriate form of intermediate
2-13. Retrosynthetic cleavage at 2-13’s benzylic position identifies the chiral adduct 142b and the benzylic bromide, 2-10, as being the suitable coupling partners. It is likely
that the bromo derivative 2-10 could be accessed from 2-5c via a series of functional
group transformations.
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In his attempted synthesis of a DCB-3503–biotin conjugate, Kaczmarek elected to
attach a functional linker in the final stages of his synthetic route (Figure 2.13) using a
free hydroxy intermeidate of DCB-3503. 83 However, this strategy was unsuccessful due
in part, to the poor solubility of the phenolic derivative. Therefore, to circumvent this
issue, attachment of the six-carbon linker is expected to occur in the early stages 2-19’s
synthesis. Continued cleavage at the phenolic and equatorial positions of 2-5c (Figure
2.14) reveals the commercially available building blocks as being 4-hydroxy-3methoxybenzaldehyde, 2-(3,4-dimethoxyphenyl)acetic acid and 6-chlorohexanol.

esterification

Figure 2.11. Initial retrosynthetic transforms of the molecular probe 2-19.
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Figure 2.12. Retrosynthetic scheme for the construction of the subtarget, 2-18.
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Figure 2.13. Kaczmarek’s attempted alkylation of a free hydroxy intermediate.83

alkylation

Perkin condensation
+
oxidative ring closure

Figure 2.14. Retrosynthetic scheme of intermediate 2-5c.
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2.9

Synthesis of the O-linked DCB-3503 Subtarget, 2-18

2.9.1

Attachment of the Linker Arm

Construction of the desired stilbene core, 2-2, was accomplished in two steps
commencing with the Perkin condensation118 of 3,4-dimethoxyphenylacetic acid and
vanillin, followed by the Fisher esterification119 of 2-1 to afford the stilbene 2-2 (Figure
2.15).86 Based in part on Kaczmarek’s earlier work,83 early attempts focused on the
derivation of a functional linker from the ammonolysis of γ-butyrocaprolactone to give
6-hydroxyhexanamide. Attachment of this linker to the stilbene core 2-2 was attempted
using a phenolic Mitsunobu procedure,120 which, despite its ability to couple a wide
range of phenol and alcohol substrates, proved unsuccessful (Figure 2.16). In a revised
approach, alkylation of the stilbene 2-2 was attempted using a sodium hydride/DMF
system and the bromo and chloro derivatives 6-hydroxyhexanamide (Figure 2.17). This
approach, however, did not yield any trace of the product 2-2a.
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Figure 2.15. Construction of the stilbene core 2-2.
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Figure 2.16. Attempted Mitsunobu coupling to the stilbene 2-2.
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Figure 2.17. Derivatization of 6-hydroxyhexanamide and attempted alkylation of the
stilbene 2-2.

A more exotic approach employed the triflate 2-5a (Figure 2.18) and two linkers,
2-6 and 2-7, derived from 1-bromo-6-chlorohexane and 6-chlorohexanol, respectively,
(Figure 2.19). It was hoped that a Stille coupling121 reaction would enable attachment of
the linkers to the stilbene core (Figure 2.20).122 Although this approach went against the
plan set forth in the retrosynthesis (Figure 2.12), it was interesting for one particular
reason, the elimination of the polar phenolic ether linkage could conceivably alter the
overall pharmacokinetics of the resulting probe. Disappointingly, attempts to effect this
Stille coupling123 using several palladium catalysts such as Pd(dppf)2Cl2 and
Pd(PPh3)2Cl2 were unsuccessful.
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Figure 2.18. Synthesis of the Stille coupling partner 2-5a.

Figure 2.19. Synthesis of the Stille-compatible linker arms 2-6 and 2-7 .
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Figure 2.20. Mechanism of the attempted Stille coupling of the triflate 2-5a with
partners 2-6 and 2-7.
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Corona co-workers were able to accomplish the late-stage biotinylation of a
phenylalanine derivative using an alkyne functionalized biotin moiety124 and this
inspired the attempted Suzuki–Miyaura coupling125 shown in Figure 2.21. Moreover,
biotinylation was envisaged to occur via a similar palladium-mediated coupling during
the end stages of the synthesis (Figure 2.22).

Unfortunately, repeated attempts at

coupling 2-5a with a potassium alkyltrifluoroborate linker, 2-8, using PdCl2(dppf)
failed.

After a personal discussion with Akira Suzuki, it was postulated that the

electron-rich nature of the phenanthrene core of triflate 2-5a may be a factor in the
attempted couplings of 2-5a and 2-8.126 This unfortunate revelation prompted a return
to the original synthetic plan.

Figure 2.21. Attempted Suzuki–Miyaura coupling of 2-5a with a potassium
alkyltrifluoroborate linker, 2-8.
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Figure 2.22. The envisaged late-stage biotinylation via a Pd-mediated coupling.

Pioneering efforts by a fellow group member, Julio Gutierrez, successfully
established K2CO3 and refluxing acetone as being the optimal conditions for the
monoalkylation of the stilbene 2-2 with 1-bromo-6-chlorohexane (Figure 2.23) to give 22c.127 Employing similar conditions, the O-linked stilbene 2-2d was afforded in good
yield from 2-2 and 6-chlorohexanol (Figure 2.24).

It is important to note that the

reaction required 48 h of continuous refluxing in order to furnish 2-2d in good yield.
The addition of sodium iodide dramatically shortened reaction times, presumably
through halide exchange (Finkelstein reaction).128
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Figure 2.23. Gutierrez’s successful alkylation of the stilbene 2-2.127

Figure 2.24. Alkylation of the stilbene 2-2 using the Finklestein modification.
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2.9.2

Protection with TBDPS

With the desired O-linked stilbene 2-2d now in hand, efforts would now be
directed toward the installation of a suitable protecting group at 2-2d’s hydroxy
position. Given the spate of functional group transformations needed to go from 22d2-10, the appropriate protecting function would not only have to withstand all of
these operations, but also be able to continually mask the primary hydroxyl group for
the remainder of the synthesis.
Silyl ethers are commonly used in organic synthesis for the protection of
alcohols, and depending on steric bulk, are known to be stable under a wide range of
conditions. As such, silylation of 2-2d with tert-butyldiphenylsilyl chloride (TBDMSCl)
yielded the silyl-protected derivative 2-2e (Figure 2.25), which was then subjected to a
FeCl3-mediated ring closure procedure (Figure 2.26). This mild, yet effective oxidative
ring closure was able to yield the O-linked phenanthrene 2-5, but the Lewis acidity of
FeCl3 also caused simultaneous cleavage of the silyl ether.

This problem was

immediately addressed by attaching the linker to the bridged-phenanthrene 2-5 instead
of the stilbene 2-2 (Figure 2.27).
The ester 2-5d was then treated with a suspension of LiAlH4 in THF to effect its
conversion to 2-9 (Figure 2.28). Initially, this reduction resulted in the unexpected and
unusual cleavage of the silyl ether,129-130 prompting a switch to lithium borohydride; a
milder reducing agent (Figure 2.28).131

However, in doing so, 2-9’s yield was

compromised considerably probably as a consequence of the acidic work-up conditions.
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Figure 2.25. Silylation of the O-linked stilbene derivative 2-2d with TBDMSCl.

Figure 2.26. Cleavage of the silyl ether by FeCl3 during the oxidative ring closure of 22e.
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Figure 2.27. Alkylation of the bridged phenanthrene core 2-5 with 6-chlorohexanol.

Figure 2.28. Cleavage of 2-9’s silyl ether by LiAlH4 and reduction of 2-5d with LiBH4.
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Ultimately, changes were made to the lithium aluminum hydride procedure,
which included shortening the reaction time from the original 4 h to 2 h and keeping the
reaction temperature at 0 °C.

These modifications then resulted in the smooth

conversion of 2-5d2-9.
The resulting benzylic alcohol 2-9 would first have to be converted to the bromo
derivative 2-10 before coupling to the chiral auxiliary 1-42b can take place. All attempts
to effect this conversion with phosphorous tribromide (Figure 2.29) resulted in complex
reaction mixtures with no isolatable product. Investigations into the failure of this
seemingly straightforward operation revealed that the silicon and oxygen atoms of 2-9
could be complexing to the phosphorous and bromine atoms of PBr3 (Figure 2.29).132
The inevitable decomposition of the unstable four center adduct likely resulted in
cleavage of the Si–O bond.

Figure 2.29. Interaction of PBr3 with 2-9’s silyl ether.

77

With the incompatibility of 2-9 with PBr3 noted, conversion of 2-92-10 was
attempted using other reagents but was met with little success (Figure 2.30), probably
due to the interaction of triphenylphosphine (PPh3) with the silyl ether.133
Conversion of 2-9 to its benzylic chloride form 2-10a was achieved using Nchlorosuccinimide,134 but this intermediate proved to be extremely unstable,
decomposing readily in the presence of light.35 Conversion of 2-9 into the tosylate (210b),135 acetimidate (2-10c)136 and triflate (2-10d)137 forms was also not effective (Figure
2.30). It was postulated that the reactive nature of the 2-9’s benzylic position was
affecting the stability of intermediates 2-10b, 2-10c and 2-10d through a probable SN1
decomposition process.138
At this juncture, with all attempts at converting the hydroxy group in 2-9 into a
stable leaving group exhausted, the synthetic strategy was redesigned so that coupling
of the chiral auxiliary 1-42b could occur via a “reductive lactamization” procedure.139
Accordingly, 2-9 was first converted to the aldehyde 2-11 via a Swern oxidation
protocol140 and aminated using the chiral auxiliary 1-42b. The resulting imine 2-12 was
then treated with sodium triacetoxyborohydride in hopes that the tandem reduction–
lactamization sequence would be able to afford 2-13 (Figure 2.20). Discouragingly, even
though Abdel–Magid and co-workers were able to complete a similar operation using
benzaldehyde and methyl 4-aminobutyrateHCl,139 the attempted conversion of 2112-13 proved to be unsuccessful. Other attempts at reducing the imine 2-12 using
either Pd/C or NaBH4 also did not succeed. The main obstacle to this conversion
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Figure 2.30. Failed attempts at accessing the bromo derivative 2-10.
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Figure 2.31. Attempted conversions of 2-9 to other derivatives.

80

O
OCH3
TBDPSO

OCH3

HN

O

CO2Bn
H

O
O

H2, Pd

O

H3CO

TBDPSO

N
CO2H

H3CO

OCH3

OCH3

2-11

2-14

Figure 2.32. Reductive–lactamization strategies in the TBDPS-protective group approach.
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seemed to lie with the instability of the imine 2-12 which, upon formation, was
presumed to dissociate back to 2-11 and 1-42b.

2.9.3

MOM Protection Route

In light of the challenges presented in the TBDPS strategy, the protecting group
was switched to a methoxymethyl (MOM) ether. As a result, the MOM-protected
derivative 2-5e was obtained in good yield from 2-5c using MOM-Cl and DIPEA.
Reduction of 2-5e using LiAlH4 proved successful and furnished 2-9b without incident
(Figure 2.33). Unfortunately, this initially promising approach was again thwarted by
the failed conversion of 2-9b2-10e using phosphorous tribromide (Figure 2.34). At
this stage, the practicality of using MOM as a protecting group for the remainder of the
synthesis was re-examined. Assuming that intermediate 2-9b could be advanced past
the bromination step, the MOM group would certainly undergo cleavage in the
upcoming acid-catalyzed lactamization, necessitating the need to re-protect the hydroxy
motif.

2.9.4

Trityl Protecting Route

Although a myriad of hydroxy protecting groups are available as alternatives to
TBDPS and MOM, it became apparent at this point in 2-18’s synthesis that a more
resilient protecting function was needed. More importantly, this protecting function
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Figure 2.33. MOM protection of 2-5c and conversion to 2-9b.

Figure 2.34. Attempted conversion of 2-9b using PBr3.
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would have to completely suppress the hydroxy group’s reactivity within the protected
moiety. To this end, it was envisioned that conversion of 2-5c to its triphenylmethyl
ether form 2-5f would minimize or block interactions at the protected hydroxy’s
oxygen.

In fact, the steric bulk of this protecting function has been utilized in

nucleoside synthesis to intentionally block access to certain portions of the substrate.141
As such, introduction of the trityl group was first attempted by reaction of 2-5c with
trityl chloride (TrCl) in a mixture of DMAP, TEA and DMF (Figure 2.35).142-143
While this method provided only tangible amounts of 2-5f, it marked a turning
point in the synthetic strategy as 2-18 would no longer be pursued as the subtarget. As

Figure 2.35. Protection of 2-5c using trityl chloride.
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exemplified in the redesigned retrosynthesis (Figure 2.36), 2-34 was selected as the new
probe and would seem to be attainable from the conjugation of 2-31 and the
commercially available biotin–maleimide derivative, 2-33. In contrast to the original
probe 2-18, the new probe 2-34 was redesigned to preclude ester linkages as these could
be subject to cleavage by nonspecific esterases144 in the ensuing affinity studies (see
Section 3.7).
In this revised approach, a shorter linker arm would be incorporated in the early
stages of 2-31’s synthesis, and access to the primary hydroxyl would be blocked by
installation of a trityl ether.

In accordance with this strategy, alkylation of the

phenanthrene 2-5 with 1,3-dibromopropane in a refluxing mixture of acetone and
K2CO3 afforded 2-20 in excellent yield (Figure 2.37).
Etherification of 2-20 was accomplished using carbinol and NaH (Figure 2.37) to
furnish the protected derivative 2-21, which was then reduced to the alcohol 2-22 using
lithium aluminum hydride. Intriguingly, during a routine conversion of 2-212-22, an
additional product was isolated and was subsequently identified as 2-36 (Figure 2.38).
The alkene 2-36 was postulated to arise from the ethoxide-induced elimination of 2-22’s
triphenylmethoxy motif (Figure 2.38). Generation of the ethoxide was attributable to
the action of excess hydride on EtOAc during workup.

The 1H NMR spectrum

confirmed that elimination of the triphenyl methoxy product had in fact taken place
and this event had triggered the formation of the alkene 2-36. The characteristic allylic
peaks are highlighted in Figure 2.39.
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1,4-conjugate
addition

Figure 2.36. Retrosynthetic analysis of the new molecular probe 2-34.
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Figure 2.37. Etherification of 2-20 with carbinol.

Figure 2.38. Elimination of 2-22’s triphenylmethoxy motif.
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Figure 2.39. Intriguing structural features of intermediate 2-36 and their corresponding
1H NMR patterns.
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Intermediate 2-22 was advanced to the bromo-derivative 2-23 with phosphorous
tribromide without complication. Bromine displacement of 2-23 (Figure 2.40) using the
chiral auxiliary 1-42b, established access to the aminal 2-24, which upon treatment with
0.5% acetic acid, underwent lactamization to give minute amounts of 2-25 (Figure 2.41).
The inherent sensitivity of trityl groups to acid was hypothesized to be the main factor
that was impacting 2-15’s yield. Other, attempts to obtain 2-25 from 2-24 using a
thermal cyclization procedure145 failed as did refluxing 2-24 in toluene146 (Figure 2.42).
Selective hydrolysis of 2-24 (LiOH, dioxane–H2O),147 followed by tosylation with TsCl
in pyridine, also did not result in the formation of 2-25 (Figure 2.42).

Figure 2.40. Coupling of the chiral auxiliary 1-42b to the bromo derivative 2-23.
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Figure 2.41. Acid catalyzed lactamization of 2-24.

Then, the diester 2-24 was hydrolyzed to the diacid (LiOH, MeOH–H2O),148
which, upon workup with acid, resulted in cleavage of the trityl group to give the
intermediate 2-27. With the subtarget 2-31 still a few steps away, the unprotected state
of 2-27 would appear to present a tactical disadvantage. However, it was projected that
the remaining conversions could be effected in the presence of 2-27’s free hydroxy
group. As such, the cyclization of the diacid 2-27 was completed by activation of the
diacid using N,N’-carbonyldiimidazole149 in refluxing THF to yield the bisimidazole
derivative, which then immediately cyclized, affording 2-28 (Figure 2.43).

The

pentacyclic ketone 2-29 was then accessed via the intramolecular acylation of 2-28 using
TFAA and BF3Et2O, which also resulted in “reprotection” of the free hydroxy as the
trifluoroacetate.

Selective hydride delivery using K-Selectride®, accomplished the

conversion of 2-292-30. Finally, reduction of 2-30 with LiAlH4 (Figure 2.43) secured
access to usable amounts of the subtarget 2-31.
90

OCH3
TrO

O

toluene

H3CO2C
H
N

2-25
reflux

140 °C
2-25

H3CO2C H

H3CO

OCH3
2-24

OCH3
TrO

O
HO2C
H
N

LiOH
2-24
dioxane-H2O

TsCl
2-25
pyridine

H3CO2C H

H3CO

OCH3

Figure 2.42. Attempted lactamization of 2-24 using non-acidic means.
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Figure 2.43. Scheme for the synthesis of 2-31.
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Conjugation of 2-31 to the maleimide–biotin derivative 2-33 was anticipated to
occur via the 1,4-conjugate addition of 2-31’s hydroxy motif with 2-33’s maleimide
moiety.

To probe the viability of this approach, 2-31 was allowed to react with

cyclohex-2-enone under mild conditions150 (K2CO3/acetone) giving rise to 2-32 (Figure
2.44). Despite the success of this model study, it was deemed that 2-31’s overall yield
and purity were not adequate for coupling to the maleimide biotin derivative 2-33.

Figure 2.44. Model study for the 1,4-conjugate addition of 2-31 to cyclohex-2-enone.
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2.9.5

Synthesis of the Allylated Derivative 2-44

The unexpected formation of intermediate 2-36 during the conversion of 2-21222 (Figure 2.38) inspired an overhaul of the problematic, protective group-based
approach toward the subtarget 2-31. As demonstrated by the retrosynthetic transform
in Figure 2.45, the use of an allylic linker would obviate the need for protective groups
and allow the subtarget 2-31 to be accessed from 2-44 through a hydroboration or
epoxidation procedure. Of note, allyl ethers are stable to moderately acidic conditions
and are commonly employed in carbohydrate research as stable protective groups.

hydroboration
or
epoxidation

Figure 2.45. Retrosynthetic transform of 2-31 leading to the allylated precursor 2-44.
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Construction of the new subtarget 2-44 began with allylation of 2-5’s phenolic
handle to furnish the intermediate 2-35, which then underwent smooth conversion to
the alcohol 2-36 using lithium aluminium hydride. Conversion of 2-36 to the bromo
derivative, 2-37, was again accomplished with the use of phosphorous tribromide. The
coupling of 2-37 with the chiral auxiliary 1-42b was conducted using K2CO3 and DMF
to yield the aminal 2-38 (Figure 2.46). Lactamization was attempted by heating 2-38 at
30 °C in a mixture of AcOH–MeOH but yielded only detectable amounts of 2-40.
Attempts to secure higher yields of 2-40 using a NaH-mediated cyclization procedure151
were also unsuccessful.

However, hydrolysis of 2-382-39 with LiOH–MeOH,

followed by activation of the resulting diacid 2-39 with N,N’-carbonyldiimidazole,149
provided only moderate amounts of 2-41 (Figure 2.47). Amazingly, ample quantities of
2-40 were finally accessed by first passing the aminal 2-38 through a plug of silica gel
(hexanes–EtOAc) and then allowing the evaporated crude product to self-condense at
ambient temperature for 48 h (Figure 2.48). The formation of the intermediate 2-40 was
confirmed by its 1H NMR spectrum which reflected a lot of its intriguing structural
figures (Figure 2.49).
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Figure 2.46. Allylation of the phenanthrene core 2-5 and advancement to the aminal 238.

Figure 2.47. Lactamization of the diacid 2-38 using N,N’-carbonyldiimidazole.
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Figure 2.48. Self-condensation of the aminal 2-38 at ambient temperature.
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Figure 2.49. Intriguing structural features of intermediate 2-40 and their corresponding
1H NMR patterns.
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With adequate quantities of 2-40 in hand, rapid hydrolysis of its methyl ester was
achieved using 2 N KOH to furnish the carboxylic acid intermediate 2-41 in good yield.
The usual protocol of effecting the intramolecular Friedel–Crafts acylation via Lewis
acid activation (BF3Et2O or SnCl4) failed in going from 2-412-42 (Figure 2.50). It was
later discovered that allyl ethers have the potential to interact strongly with Lewis
acids.152 To overcome this eventuality, the intramolecular cyclization of 2-412-42 was
accomplished by reaction of the carboxylic acid 2-41 with triflic anhydride.

The

mechanism of this transformation is thought to involve formation of the
trifloxycarbenium

cation,

which

upon

loss

of

triflic

trifluoromethanesulfonic carboxylic anhydride153 (Figure 2.50).

acid

forms

the

This was then

proceeded by acylation of the phenanthrene furnishing the aryl ketone 2-42. Reduction
of 2-42 with K-Selectride® cleanly afforded 2-43, which upon further treatment with
LiAlH4, was able to furnish 2-44 (Figure 2.51).
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Figure 2.50. Intramolecular acylation of 2-412-42 via treatment with triflic anhydride.
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Figure 2.51. Final stages in the synthesis of the allylated derivative 2-44.

The attempted epoxidation of 2-44 with m-CPBA resulted in the unanticipated
formation of 2-45, the N-oxide derivative of 2-44 (Figure 2.52). In their synthesis of
potent enediynes, Nicolaou et al. also noted the formation of a similar adduct and were
able to effect its deoxygenation by refluxing in Ac2O.154

However, efforts to

deoxygenate 2-45 in the same manner did not succeed. Hydroboration of 2-44 also
resulted in the over-oxygenated derivative 2-46, probably due to exposure to hydrogen
peroxide (Figure 2.52).
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Figure 2.52. Formation of N-oxides of 2-44 during hydroboration and epoxidation

2.10 Conclusions
The synthetic sequences to prepare the targeted affinity probes, 2-19 and 2-34
were based, in part, on the methodology by Buckley and Rapoport35 and Kaczmarek83
but included several new and notable modifications.

Among the most interesting

features of the synthetic strategy were the following:
1. The efficient lactamization of the aminal 2-38 to give 2-40 through selfcondensation.
2. The utilization of trifluoromethanesulfonic anhydride in the conversion of 2-
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41 to 2-42 provided a means of effecting intramolecular acylation without the
need for a Friedel–Crafts type catalyst.
Efforts to secure biotin-conjugated derivatives of DCB-3503 (1-62b) via protective
group approaches proved to be unsuccessful. Because the synthesis employed some
harsh transformations, the protecting functions were often prematurely cleaved or
involved in complex side reactions.
Most significantly, the unanticipated formation of the alkene intermediate 2-36
was instrumental in the development of a strategy that utilized no protecting functions
(Section 2.9.5). While only partially successful, the use of an allylic linker as a masked
tether could be poosibly expanded upon in future syntheses by attachment of a dithiol
linker155 instead of relying on oxidation of the alkene (Figure 2.51).

Figure 2.51. Possible attachment of a dithiol linker to 2-44 in lieu of alkene oxidation.
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CHAPTER 3
BIOCONJUGATION VIA CLICK CHEMISTRY: A
NONCLASSICAL APPROACH.
3.
3.1

BIOCONJUGATION VIA CLICK CHEMISTRY: A
NONCLASSICAL APPROACH

Background and Significance
Classical approaches to the synthesis of probes for the elucidation of protein

binding targets have often relied on the formation of peptide and ester bonds.108 More
recently, the Cu(I)-catalyzed variant of the Huisgen 1,3-dipolar cycloaddition (“click”
chemistry) has emerged as a powerful technique for chemoselective ligation.156-158
In a generic approach, the synthesized probe is chemically tagged with a
propargyl marker and coupled with a biotinylated azide under standard “click”
coupling conditions to give rise to the biotinylated probe (Figure 3.1). The use of
kinetically stable entities such as azides and alkynes, which in addition to being tolerant
to a wide range of synthetic conditions,159 have allowed this particular type of click
chemistry to have broad utility in organic synthesis.

Additionally, azides160 and

alkynes possess a relatively narrow window of reactivity allowing them to be
incorporated in the early stages of a synthetic strategy, providing the ability to “click” at
any stage. Furthermore, the relative inertness of these functional groups161 allows them
to remain virtually “invisible” throughout the synthesis, thereby minimizing the need
for protective groups. Another advantage offered by this approach arises from the
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rigidity of the 1,2,3-triazole moiety, which ensures that the two linked substances are
not intruding into each other’s structural space.
This highly modular approach to bioconjugation has simplified syntheses and
allowed for the rapid and high-yielding synthesis of several molecular probes.
For example:
1. Uemura and co-workers recently synthesized and evaluated biotin-labeled (-)ternatin,162 a potent fat-accumulation inhibitor against 3T3-L1 adipocytes.
Biotinylation was accomplished using a strategically installed propargyl marker
and click chemistry (Figure 3.2)
2. Hulme and co-workers utilized the Cu(I)-catalyzed 1,3-DCR to couple an Nlinked propargyl ansiomyic derivative to an azido functionalized biotin fragment
affording the corresponding biotinyated probe in 73% yield (Figure 3.2).163

3.1.1

Click Chemistry: A Background

The exergonic fusion of 1,3-dipoles to dipolarophiles (i.e., acetylenes or alkenes)
via the 1,3-dipolar cycloaddition reaction (1,3-DCR) to afford five-membered
heterocycles is a ubiquitous transformation in synthetic organic chemistry.

Of the

various five-membered heterocycles that are accessed using this reaction, the
cycloaddition of azides and alkynes to give triazoles is arguably the most utilized. The
classical Huisgen 1,3-DCR between an azide and an alkyne proceeds under thermal
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Figure 3.1. A generic approach to biotinylation via click chemistry.
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conditions affording a mixture of 1,4- and 1,5-disubstituted 1,2,3-triazoles (Figure 3.3).
Although the relative proportion of these regioisomers is dictated by electronic and
steric factors, 1,4-regioselectivity can be increased by reacting an electron deficient
acetylene with an azide that is electron rich.164-165
In 1999, Sharpless and co-workers introduced a Cu(I)-catalyzed variant of the
Huisgen 1,3-dipolar cycloaddition

which in addition to featuring a dramatically

enhanced rate (up to 107 times),166 also offered improved regioselectivity.167 Recent
thermal and kinetic studies have shown that compared to the non-catalyzed, concerted
process, this Cu(I)-catalyzed (“click”) variant occurs via a stepwise process whose
activation barrier is lowered by as much as 11.8 kcal mol-1.166 The proposed catalytic
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Figure 3.3. The thermal and Cu(I)-catalyzed 1,3-DCR reactions.
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cycle (Figure 3.4)166 is postulated to involve several transient Cu(I)-acetylide complexes
that originate from complexation of the terminal alkyne to the Cu(I) metal center
(Sonogashira coupling168) resulting in a Cu(I)–alkyne ̟-complex (A, Figure 3.4).
Deprotonation results in the dimeric copper species (B, Figure 3.4) then complexes with
the azido group to set up nucleophilic attack at the N-3 center of the azide by the
acetylide C-4 affording (C, Figure 3.4). Facile ring contraction of the metallocycle C via
a transannular association of the N-1 lone pair with the C5–Cu ̟* orbital results in a
copper–triazole complex (D, Figure 3.4). Subsequent protonation of complex D results
in dissociation of the labile copper complex securing the 1,4-disubstituted 1,2,3-triazole
(E, Figure 3.4).
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Figure 3.4. Mechanism of the Cu(I)-catalyzed 1,3-DCR.166
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3.1.2

The 1,2,3-Triazole

1,2,3-Triazoles share similar structural and electronic features to amide bonds
with a few exceptions; the extra atom in the triazole backbone causes a 1.1 Å increase in
the R1–R2 distance over the amide bond (Figure 3.5).169 Also, ab initio calculations have
revealed that triazoles possess a larger dipole character than ordinary amide bonds,170
and this may possibly enhance their amide mimicry by increasing the hydrogen
bonding and acceptor abilities.169 Additionally, this larger dipole may polarize the C-5
proton of the triazole to the extent that it may function as a hydrogen-bond donor
similar to that of the amide proton.171 Because of these properties, many 1,2,3-triazoles
exhibit biological activities including anti-HIV activity,172-173 potent anti-histamine
activity,174 anti-bacterial activity175 and more.176-177 Unlike their amide counterparts,
however, these heterocycles do not share the same susceptibility to hydrolytic
cleavage.178-179 These and other features of the 1,2,3-triazole moiety establish it as being
more than just a rigid linking unit; its mimicry of the conventional amide bond and
enhanced characteristics highlight its pharmacological potential.

3.2

Retrosynthetic Analysis and Strategy
Azides and alkynes have been noted for their tolerance to a wide range of

synthetic conditions; however, as with all unsaturated functionalities, they are
vulnerable under reducing conditions.

In fact, azides are often utilized in organic
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synthesis as “masked” forms of the amino group;180 they are reliably introduced via
nucleophilic displacement and are usually a single reduction away from the
corresponding amine. Likewise, upon exposure to hydride-rich reagents, alkynes are
often reduced to their appropriate alkene or alkane forms. Therefore, incorporation of
either of these functionalities into a synthetic strategy employing hydride-rich reagents
must be done so with careful planning.
Access to the biotinylated probe 3-17 is envisioned to involve a chemoselective
ligation procedure that gives rise to its 1,4-disubstituted 1,2,3-triazole. Accordingly,
initial operations of the retrosynthetic analysis logically excised both the azide 3-14 and
the alkyne 3-9 from 3-17 as two separate fragments (Figure 3.6). Fragment 3-14 would
bear the azide handle as it can be prepared by a literature procedure.156

Further

cleavage across 3-14’s amide bond reveals its building blocks as being D-(+)-biotin and
the bifunctionalized polyethylene glycol (PEG) derivative, 3-12.

Figure 3.5. Comparison of bond distances in the 1,2,3 triazole and amide motifs.
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[3+2] cycloaddition

Figure 3.6. Retrosynthetic cleavage of the triazole within the affinity probe 3-17.
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peptide formation

azidization

Figure 3.6. Retrosynthetic analysis of the azide-functionalized biotin derivative 3-14.
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Upon initial retrosynthetic examination, 3-9 is revealed to be a propargyl
“tagged” derivative of the previously synthesized tylophorine analogue DCB-3506;86
thus 3-9 can potentially be accessed from the phenolic alkylation of DCB-3506 with
propargyl bromide (Figure 3.7). Considering that the preparation of DCB-3506 entails a
sequence of reductions,86 this would seem like the logical approach as it would ensure
the integrity of the propargyl tag.

While attractive, this approach has a few

shortcomings; there are additional sites on DCB-3506 that could also undergo alkylation
(Figure 3.8). Even with the careful regulation of reagents, alkylation at the tertiary
amine center could still pose a problem.

propargylation

Figure 3.7. Access to 3-9 via the late-stage propargylation of the tylophorine analogue
DCB-3506.
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Figure 3.8. Possible sites of propargylation on DCB-3506.

Another avenue of possibility for introducing the propargyl tag could occur as
shown in Figure 3.9 using an intermediate in the synthesis of DCB-3506, whose only
viable site of alkylation is at the phenolic position. Previous studies,83 however, have
shown that this intermediate has poor solubility in conventional organic solvents thus
making this approach less likely.
With the various options surveyed and scrutinized, installation of the propargyl
handle was envisoned to occur in the early steps of the synthetic strategy, with several
goals in mind:
1. By masking the naked phenolic handle, its participation during the synthesis
would be kept to a minimum and this might limit any unfavorable
interactions that may otherwise impact product yield.
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2. It is postulated that the solubilities of the intermediates resulting from
alkylation at the phenolic position maybe enhanced over their free hydroxy
counterparts.

Phenolic compounds are generally known to have good

solubilities in aqueous media,181 but this solubility is diminished in organic
solvents.182
3. Installation of the chemical tag in the infancy of the synthesis ensures that an
intermediate can be readily “clicked” at any stage of the synthesis, in one
step, should the need arise.

Figure 3.9. Possible propargylation of an intermediate from DCB-3506’s synthesis.
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The appropriate retrosynthetic transforms resulting from this approach are
presented in Figure 3.10. A critical feature of the synthetic strategy is the installation of
the hydroxy function at 3-9’s benzylic position, possibly by the asymmetric reduction of
3-7.

Early isolation and characterization studies revealed the labile nature of this

functionality, particularly to sodium borohydride;17 therefore, its incorporation is
reserved until the later stages of the synthesis. Intermediate 3-7 is envisioned to arise
from the intramolecular acylation of the saponified form of 3-5.

Intermediate 3-5

possesses a lone stereogenic center, whose formation can be anticipated from the
coupling of the halo form of 3-2 with an appropriate auxiliary from the chiral pool.
Attachment of the functional chemical handle would have to occur prior the formation
of 3-2, possibly via the alkylation of 3-1 with propargyl bromide. Finally, disassembly
of 3-1 exposes 3,4-dimethoxyphenyl acetic acid and vanillin as being the commercially
available building blocks responsible for construction of the phenanthrene skeleton.

3.3

Synthesis of the Propargyl Tagged Analogue 3-9

3.3.1

Overview of the Target

The pentacylic architecture of 3-9 consists of a planar, functionalized
phenanthrene backbone (rings A,B,C) and the conjoined indolizidine portion (rings D,
E) which houses the molecule’s two stereogenic centers at C-13a and C-14. Other
structural highlights include the hydroxy function at C-14 and several methoxy groups
distributed throughout the phenanthrene framework.
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Figure 3.11. Overview of the propargyl tagged subtarget, 3-9.

119

N-alkylation

intramolecular
acylation
asymmetric
reduction
Perkin condensation
+
oxidative ring-closure
reduction

propargylation
Figure 3.10. Retrosynthetic analysis of the propargyl-tagged subtarget 3-9.
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3.3.2

Synthesis of 3-9’s Phenanthrene Core

As with most endeavors in natural product total synthesis, preliminary efforts
towards the synthesis 3-9 begin with construction of a suitable scaffold. Intended to set
the foundation for construction of the indolizidine motif, the desired scaffold was
accessed with the Perkin condensation183-184 of 3,4-dimethoxyphenyl acetic acid and
vanillin to give the carboxylic acid 2-1 in excellent yield (Figure 3.11).

Such

condensations have been known to invariably give a mixture of E and Z isomers with
the Z-isomer being the minor product.35 Transformation of 2-12-2 proceeded via a
Fisher esterification procedure in a straightforward fashion to yield the deacetylated
stilbene derivative. With the A and B rings of the scaffold now complete, access to ring
C commences with the re-acetylation at the phenolic position of 2-2 to furnish the
oxygenated stilbene 2-3 in good yield. Oxidative ring closure is then effected using a
facile FeCl3-mediated procedure, bridging the stilbene and affording the phenanthrene
derivative 2-4 (Figure 3.11).185-187

The first synthesis of a phenanthrene core was

established using an arenediazonium salt by Pschorr in 1896 as a means to conduct the
intramolecular coupling.188 Through the years, the Pschorr reaction has become the
standard for phenanthrene formation; however, it generally features long steps and
only modest yields that restrict its implementation in this synthesis. Alternatively, the
oxidative aryl–aryl coupling could be accomplished using a transition metal oxide such
as vanadium(V) trifluoride oxide,189 which has been known to effectively cyclize
polymethoxy stilbenes. While an attractive possibility, the transition metal oxide is
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prohibitively expensive, highly toxic and often leads to numerous side products.
Fortunately, the FeCl3 procedure is devoid of all these shortcomings and has become
the new method of choice for oxidative ring closures leading to phenanthrene
formation.190-191 The proposed mechanism associated with this Fe(III)-mediated ring
closure is presented in Figure 3.12.191 The initial step in this sequence is presumed to
involve a single-electron oxidation of the stilbene unit to generate an aryl radical cation.
The electrophilic center is then subsequently attacked by the opposing aromatic ring
bridging the stilbene in the process. A series of deprotonations then restores aromaticity
to give the phenanthrene 2-4.
In the advancement of intermediate 2-1 to intermediate 2-4, there was a sequence
of acetylation/reacetylation steps that must be addressed. One could theoretically go

Figure 3.11. Construction of the stilbene 2-1 and advancement to the phenanthrene 2-4.
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Figure 3.12. Mechanism for the FeCl3-mediated ring closure191 of stilbene 2-3.

from 2-22-5 directly, but this proved difficult under experimental conditions as more
molar equivalents of the catalyst are required and overall product yields poor. This
compromise in product yields maybe caused by the generation of a radical species
through the reaction of the phenolic hydroxy group with the catalyst (Figure 3.12). The
oxygenated phenanthrene 2-4 was then subjected to a standard deacetylation procedure
that exposed its phenolic handle and gave 2-5 in quantitative yield (Figure 3.13).
Alkylation of 2-5 with propargyl bromide afforded the intended phenanthrene scaffold
3-1 in good yield (Figure 3.13) and its formation was confirmed by the appearance of a
triplet at 2.61 ppm and a doublet between 4.99–5.00 ppm in its 1H NMR spectrum
(Figure 3.14).
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Figure 3.12. Generation of a radical species from the reaction of 2-2 with FeCl3.

Figure 3.13. Deacetylation of 2-4 and propargylation of the phenanthrene skeleton 2-5.
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Figure 3.14.

1H

NMR spectra of the intriguing structural features of intermediate 3-1.

125

3.3.3

Model Click Reactions Using the Phenanthrene Core 3-1

As delineated in the initial retrosynthetic map (Figure 3.6), the main objective of
this synthetic approach was to perform a late-stage [3+2]-cycloaddition as means of
conjugating 3-9 with the biotin derivative 3-14.

Given the importance of this key

merger, considerable model system exploration would have to first take place in order
to establish the viability of this approach and to probe for optimal coupling conditions.
The phenanthrene scaffold 3-1 made an ideal alkyne substrate for this model study
owing to its easy preparation and modest stereochemical complexity. Some of the azide
coupling partners featured in the study were synthesized, and several were derived
from other sources.192
While a number of methods exist to generate the active catalyst for the 1,3DCR,193 a commonly employed technique is to reduce Cu(II) salts, such as CuSO45H2O
in situ to form Cu(I) salts.194 Sodium ascorbate195 is typically used as the reducing agent
in a 3- to 10-fold excess,193 but other reducing agents, including hydrazine196 and tris(2carboxyethyl)phosphine (TCEP),197 have also been used with reasonable success. The
advantages to this strategy are that it is cheap, it can be performed in water, and does
not require deoxygenated atmosphere.198

Appropriately, the initial investigation

entailed the reaction of azide 6-azidochlorohexanol (prepared by the SN2 displacement
of 6-chlorohexanol with sodium azide) with 3-1 under these “standard click” conditions
(Figure 3.15). Disappointingly, only starting material was recovered, and there were no
detectable amounts of the desired product 3-1a. A survey of the literature revealed that
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the over-reduction of Cu(II) down to Cu0 by the reducing agent was a likely cause.
Ordinarily, this problem can be overcome by properly regulating the ratio of reducing
agent to catalyst and/or by the inclusion of copper-stabilizing agents such as
tris(benzyltriazolylmethyl)-amine

(TBTA).199

More

recently

though,

tris(2-

benzimidazolylmethyl)amines (Figure 3.16; 3-15) have been found to be superior
accelerating ligands for the Cu(I)-catalyzed azide–alkyne cycloaddition reaction.200-201
Incorporation of this catalyst into the reaction of 3-1 and the azide, 6-azidohexanol,
finally afforded detectable amounts of 3-1a (Figure 3.17).

However the recovery of a

high percentage of the starting material 3-1 indicated that these were not the ideal
conditions for coupling this azide–acetylene pair.

Cl
OCH 3

OH
NaN3 / DMF

O
HO

HO
N N
N

OCH3
O

N3

OCH3
O

H 3CO

OCH 3
0.1 M CuSO 4.5H 2O, NaAsc
t-BuOH, H2O

O

H3CO

OCH 3

OCH3

3-1

3-1a

Figure 3.15. Attempted coupling of 3-1 with 6-azidohexanol using standard “click”
conditions.
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Figure 3.16. Tris(2-benzimidazolylmethyl)amine (3-15).

Figure 3.17. Model study utilizing tris(2-benzimidazolylmethyl)amine.
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Initial attempts at maximizing product yield focused on the adjustment of the
solvent/co-solvent systems. These were altered as shown in Figure 3.18, but failed to
offer any dramatic improvement in product yield.

Then, as a means of probing

functional group tolerance, the complexity of the azide partner was varied and these
results are presented in Figure 3.19. Even with these series of successful clicks, there
was the lingering issue of poor product yield that had to be further investigated.
It was hypothesized that the reaction’s dependence on a copper-stabilization
agent such as 3-15, was an indication that the generated Cu(I) was too short-lived.

Entry

Cu(II) saltb

3-15

NaAsca

Solvent

1

0.01 eq

0.0001 eq

0.1 eq

1:1 H2O:THF

2

0.01 eq

0.0001 eq

0.1 eq

1:1 H2O:EtOH

3

0.01 eq

0.0001 eq

0.1 eq

1:1 H2O:1,4-dioxane

4

0.01 eq

0.0001 eq

0.1 eq

1:1 H2O:CH2Cl2

5

0.02 eq

0.002 eq

0.1 eq

1:2 H2O:tBuOH

6

0.02

0.001 eq

0.3 eq

1:1 H2O:CH3CN

a

Sodium ascorbate

b

Copper(II) sulfate

Figure 3.18. Attempts at optimizing the yield of 3-1a.
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Figure 3.19. Click reaction of 3-1 using more complex azide partners.

Furthermore, due to the second-order dependence on Cu(I) concentration, product
yields were being compromised because of this. Therefore, other methods of generating
the Cu(I) species had to be sought. One such possibility is the oxidation of copper metal
with an amine salt to generate the Cu(I) catalyst. However, there are considerable
disadvantages with this strategy; of particular concern are the longer reaction times and
the slightly acidic environment that is needed to dissolve the metal, which could be
damaging to any acidic-sensitive functional groups such as the secondary hydroxy that
is present in 3-9.
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With the instability of the Cu(I) oxidation state in the presence of oxygen well
documented, the reaction conditions had to be adjusted such that they excluded
oxygen.202 Consequently, another method was employed that utilized a copper salt
such as CuBr, or CuI, to source the Cu(I) catalyst.193 This method was an attractive
possibility for three reasons:

1.

The direct use of Cu(I) salts would bypass the need for a reducing agent.

2. Organic solvents could be utilized in lieu of H2O.
3. A deoxygenated environment would ensure the stability of the Cu(I)
oxidation state and obviate the need for a copper-stabilizing agent.

Encouragingly, a preliminary implementation of this solution-phase Cu(I)catalyzed coupling reaction using CuI, TEA and CH3CN was able to furnish detectable
quantities of 3-1a (Figure 3.20). Although only partially successful, this early result
seemed to highlight the inherent sensitivity of these types of reactions to the choice of
base.203 In fact, if an “incompatible” base is selected, the substrate could be prone to
numerous side reactions.204 This base-dependence is believed to revolve around the
formation of the active copper acetylide complex (D, Figure 3.4), which is dependent on
the deprotonation of the ̟-complex D (Figure 3.4). Although this deprotonation occurs
without the need for base under conditions involving water, it is disfavored under
organic solvents; thus the need for a base.
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Bases such as diisopropylethylamine

(DIPEA) and 2,6-lutidine were identified in the literature as being suitable choices that
offered improved results and kept side product formation to a minimum.178-179,193
Additionally, certain solvents such as acetonitrile, have the ability to act as “nitrogentype donors” thereby preventing the degradation of Cu(I) by oxidation or
disproportionation.205 Gratifyingly, a model based on these findings was able to furnish
the triazoles 3-1a and 3-1d in high yield (Figure 3.21).

3.3.4

Construction of 3-9’s Indolizidine Moiety

With the phenanthrene scaffold 3-1 secured and optimal “clicking” conditions
established, efforts were now directed towards construction of the indolizidine
periphery. Reduction of 3-1 with lithium aluminum hydride would seem like a risky

Figure 3.20. Click reaction of 3-1 using a Cu(I) source.
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Figure 3.21. The click reactions of 3-1 using a Cu(I) source and DIPEA and 2,6-lutidine
as bases.

maneuver as lithium aluminum hydride can reduce alkynes.206-207 To safeguard against
this possibility, the reaction had to be carried out at 0 °C in order to effect the
conversion from 3-13-2; (see Figure 3.22) however, it was particularly pleasing to
observe the same transformation occur at ambient temperature without incident.
Functional group conversion of 3-2 using phosphorous tribromide (PBr3) afforded 3-3,
which was then coupled with the glutamate diester 1-42b. It is noteworthy to note that
in coupling these two fragments, the order of addition of the reactants does matter.
This may be due to the fact that the glutamate diester is used in excess and is
introduced into the
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Figure 3.22. Advancement of 3-1 to the pentacyclic intermediate 3-7.
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system as a hydrochloride salt, and this may react prematurely with the alkyne.
Therefore, addition of the chiral auxillary 1-42b must occur first, followed by K2CO3
and then the benzylic bromide 3-3. The resulting crude aminal 3-4 was subjected to a
lactamization procedure using acetic acid and methanol to give rise to 3-5. The 1H
NMR spectrum confirmed the formation of intermediate 3-5 and some of these
characteristic peaks are presented in Figure 3.23. With the construction of the E ring of
3-9 now complete, the next set of operations focused on the construction of 3-9’s D ring.
Accordingly, base-mediated hydrolysis of the methyl ester function within 3-5 using 2
N KOH furnished the carboxylic acid derivative 3-6 in quantitative yield. With the
stage now set for the key intramolecular acylation, treatment of 3-6 with
trifluoromethanesulfonic anhydride for 48 h induced ring closure and furnished 3-7 in
good overall yield. This type of intramolecular acylation has been accomplished in past
syntheses using strong Lewis acids such as SnCl4 and AlCl3, but these approaches
involved the mandatory formation of the acid chloride and were deemed to be too
harsh for the alkyne present in 3-6.

On the contrary, the procedure involving

trifluoromethanesulfonic anhydride was gentler and required no Lewis acid, relying
instead on the formation of a mixed anhydride to effect ring closure. Similarly, another
mild but effective acylation procedure using TFAA and BF3Et2O was able to transform
3-6 3-7 in good yield as well. The pentacylic ketone 3-7 was confirmed via 1H NMR
spectrosocopy and some of its intriguing structural features are illustrated in Figure
3.24.

135

Figure 3.23.

1H

NMR spectra of the intriguing structural features of intermediate 3-5.
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Figure 3.24.

1H

NMR spectra of the intriguing structural features of intermediate 3-7.
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3.3.5

Functionalization of the Indolizidine Moiety

The next planned synthetic operation was the asymmetric reduction of the
ketone in 3-7 to install 3-9’s second stereocenter. While there are several reagents
capable of accomplishing such reactions, chiral oxazaborilidines are among the most
widely utilized catalysts available.208

While an attractive possibility, these

oxazaborilidine-mediated reductions require the generation of a chiral catalyst via
complexation of a Lewis basic nitrogen with a borane reagent (Figure 3.25).

This

complexation is rapid and reversible but because 3-7 possesses a similar moiety, it was
reasoned that similar complexation may take place at this site as well (Figure 3.26),
thereby compromising overall selectivity.

The use of a borane reagent may also

endanger 3-7’s alkyne motif.

Figure 3.25. Complexation of the chiral oxazaborolidine with a borane reagent.
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Figure 3.26. The postulated complexation of the borane reagent at the indolizidine’s
nitrogen.

Interestingly, however, 3-7 possesses some subtle structural features resulting
from the planarity of the phenanthrene backbone that are only evident in the threedimensional model as represented in Figure 3.27. In fact, the C-14 ketone seems to be
accessible from two faces, each with its own distinct spatial environment. Access to the
A-face seems favorable while an apical C-13 methylene unit renders the B-face highly
inaccessible.

Therefore, by exploiting this unique conformational state of 3-7, the

stereoselective reduction was achieved using the reagent K-Selectride® (potassium trisec-butylborohydride) whose facial selectivity afforded 3-8 in good yield. As illustrated
in Figure 3.28, approach of this bulky hydride is only favored from the A-face, as an
approach from the B-face is effectively blocked by the “protruding” apical C-13
methylene unit.
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Figure 3.27. The two unique faces of intermediate 3-7.
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Figure 3.28. Approach of the bulky hydride from face A of intermediate 3-7.
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A similar model was adopted by Buckely and Rapoport in their synthesis of Stylophorine [(S)-1-1].35 Though highly effective, this synthetic operation came with
considerable risk to the alkyne. Initial implementations of this reduction resulted in the
reduction of the 3-7’s alkyne to give the corresponding alkene.

It was therefore

established that the experimental conditions had to be kept at -78 °C to safeguard
against reduction of the alkyne by the Selectride. The formation of intermediate 3-8 was
verified using

1H

NMR spectroscopy and some of these structural features are

illustrated in Figure 3.29. The triplet at 3.27 ppm corresponds to intermediate 3-8’s
alkyne proton while the set of multiplets between 2.23 and 2.75 ppm correspond to 3-7’s
indolizidine periphery. The broad peak at 3.06 ppm corresponds to 3-8’s hydroxy
moiety, confirming that the reduction of the ketone 3-7 was successful.
A controlled reduction of 3-8 with lithium aluminum hydride in THF at -10 °C
finally provided the propargyl-tagged analogue 3-9 (Figure 3.30). Again, because of the
caliber of the reducing agent, there existed the likelihood of reducing the alkyne motif.
Therefore, as a precautionary measure, the order of addition was modified such that the
hydride was added to substrate 3-8 at -10 °C, and experimental conditions were
carefully maintained at 0 °C thereafter.
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Figure 3.29.

1H

NMR spectra of the intriguing structural features of intermediate 3-8.

Figure 3.30. Final stages in the synthesis of the propargyl tagged subtarget 3-9.
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3.4

Synthesis of the Azide-Functionalized Biotin Derivative 3-14
Originally, efforts towards a biotin substrate suitable for the [3+2]-cycloaddition

involved the functionalization of biotin itself124 as delineated in the scheme in Figure
3.31. However, this approach was discontinued due its low yields and the numerous
functional group manipulations needed to furnish 3-16.

A new method was

subsequently sought: one that limited the number of synthetic operations on the biotin
substrate while offering improved yields.156
As depicted in its earlier retrosynthesis (Figure 3.6), 3-14 incorporates a
functionalized polyethylene glycol (PEG) moiety. PEG is a widely used biomaterial due
to its high solubility in water and in most organic solvents. Moreover, PEG is nontoxic,
and more importantly, is resistant to protein adhesion.209-210 Therefore, it is anticipated
that the inclusion of this moiety in 3-14 would help in the solubility of the target probe
3-17.
The synthesis of 3-14 synthesis commenced with the mesylation of commercially
available tetraethylene glycol to furnish the dimesylate 3-10. A standard azidization
procedure then converted 3-10 to 3-11, which, after treatment with NaHCO3, was
subjected to an elegant desymmetrization protocol with PPh3 and H3PO4 to give the
amino-PEG-azide, 3-12 (Figure 3.32).211
Coupling of the functionalized PEG unit 3-12 to D-(+)-biotin was then
accomplished using N,N'-dicyclohexylcarbodiimide (DCC) and DIPEA (Figure 3.33).
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Figure 3.31. Synthesis of the biotin-azide derivative 3-16.
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Figure 3.32. The heterobifunctionalization of tetraethylene glycol leading up to 3-12.

Figure 3.33. Peptide coupling of 3-12 to biotin via activation as the NHS ester.
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Although yields were markedly improved by first activating biotin with Nhydroxysuccinimide212 (Figure 3.29), a more robust coupling procedure employed the
peptide coupling agent O-benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU), which furnished 3-14 in quantitative yield (Figure 3.34). The 1H
NMR data matched those previously reported.156

3.5

Conjugation of 3-9 with the Biotin-PEG-Azide Derivative 3-14
With the synthesis of 3-9 and 3-14 now complete, the target compound 3-17

would now appear to be attainable from the click reaction of these two subtargets.
However, as a prerequisite to this conjugation, a final model study was set up using the
phenanthrene core 3-1 and the biotin conjugate 3-14 (Figure 3.35). Using conditions
established earlier (see Section 3.3.3), 3-1e was afforded in moderate yield and its
formation was verified by MALDI-TOF MS (Figure 3.36) and DART-ESI MS (Figure
3.37). The successful union of these two precursors to ultimately afford 3-1e was a very
positive development and established a precedent for the late-stage coupling of 3-9 and
3-14. Indeed, upon exposure to CuI, the crucial [3+2]-cycloaddition of 3-9 and 3-14
proceeded smoothly and secured the desired target 3-17 (Figure 3.38).
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Figure 3.34. Peptide coupling of 3-12 to biotin using HBTU.
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Figure 3.35. Model-click-study involving the phenanthrene backbone, 3-1, and the biotin-azide conjugate 3-14
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Figure 3.36. MALDI-TOF spectrum of 3-1e.
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[M+Cu]+ adduct.
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Figure 3.38. Synthesis of the target 3-17 via click chemistry
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3.6

Purification and Characterization of the Affinity Probe 3-17
Up until this point, the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of

terminal alkynes and azides has served as powerful tool in the conjugation of 3-9 and 314; however, an obvious disadvantage to this approach is the involvement of a copper
catalyst. The presence of copper is clearly evident from the MALDI-TOF spectrum of a
reaction mixture of 3-17 (Figure 3.39) and the ESI spectrum of 3-1e (Figure 3.37) which
both feature an [M+Cu]+ adduct.
Although living systems require copper for specific processes, excessive amounts
of this metal can be cytotoxic and affect neurological systems. This stems from the fact
that copper readily participates in single-electron transfer processes which can catalyze
toxic reactions, especially the in vivo reduction of hydrogen peroxide to form hydroxy
free radicals.213 Therefore, the biotinylated probe 3-17 must be exhaustively purified
prior to its in vivo evaluation.
By taking advantage of 3-17’s ready MALDI-TOF ionizability, the reaction
between 3-9 and 3-14 can be easily monitored.

Compound 3-17 has characteristic

fragmentation patterns, one of which is shown in Figure 3.35.

The use of other

methods, however, such as HPLC and/or TLC is complicated due to the dominating
presence of 2,6-lutidine. This is best illustrated by the HPLC trace in Figure 3.40. The
high concentration and strong absorptive properties of 2,6-lutidine easily overwhelm all
other components in the reaction. This particular problem was overcome by relying on
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[M-OH]

[M+Na]+
[M+Cu]+

Figure 3.39. MALDI-TOF MS fragmentation of the probe 3-17.
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Figure 3.40. HPLC trace of the reaction mixture of the conjugation of 3-9 and 3-14.
The major peak at 4.433 min is that of 2,6-lutidine.

the unique absorptive properties of each component in the reaction. Each has a
characteristic chromophore which can be used as a unique identifier or “fingerprint” as
shown in Figures 3.41, 3.42, and 3.43. Using this approach allowed the principal peaks
of the chromatogram to be easily mapped and also facilitated the monitoring of the
reaction’s progress as shown in Figure 3.44. Unfortunately, the similarity in retention
times between 2,6-lutidine and 3-17 precluded preparative HPLC as a means of
purification.
In 2001, Sharpless and co-workers defined a set of criteria that a process must
meet in order to be classified as a click reaction.180 One of these requirements was that
“purification if required must be by non-chromatographic methods, such as
crystallization or distillation.” In order to adhere to these guidelines, initial efforts
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Figure 3.41. HPLC trace and chromophore (inset) of the biotin derivative 3-14

N

Figure 3.42. HPLC trace and chromophore (inset) of 2,6-lutidine.
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Figure 3.43. HPLC trace and chromophor
chromophore (inset) of 3-9..
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2,6-lutidine

3-17

3-9

3-14
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Figure 3.44. A chromatogram mapped with the chromophores of the reaction’s components.
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towards the purification of 3-17 relied on standard extraction and recrystallization
procedures.

Unfortunately, these attempts were complicated by 3-17’s limited

solubility and were unsuccessful in removing 2,6-lutidine from the reaction mixture.
Other attempts utilized reversed phase chromatography and freeze drying from
1,4-dioxane. This approach seemed to remove most of the 2,6-lutidine but was plagued
with low recovery of the sample. Even though the use of chromatography as a means
of purification seemed to go against Sharpless’ philosophy of click chemistry, its partial
success inspired a return to more “traditional” purification methods. Subsequently, 317 was purified successfully using normal-phase silica gel chromatography (2:0.1
CH2Cl2–MeOH), and this proved to be very effective in removing the 2,6-lutidine and
residual copper as evident by the absence of the [M+Cu]+ adduct in the MALDI-TOF
analysis (Figure 3.45). The HPLC trace of the purified sample revealed an impurity at
4.48 min, which was later determined to be 3-8a, a product from the click reaction of the
unreduced amide 3-8 and the biotin unit 3-14 (Figure 3.46). In the end, after a sequence
of rigorous chromatographic separations, 3-17 was finally obtained with ~95% purity
and submitted to our biological collaborator, Dr. Y.-C. Cheng at Yale University School
of Medicine.
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Figure 3.45. MALDI-TOF analysis of 3-17. The [M+Cu]+ adduct is absent after
purification.
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Figure 3.46. HPLC trace and chromophore (inset) of the purified probe 3-17
17.

160

3.7

Planned Affinity Studies
Once synthesized, biotinylated probes such as 3-17, can be utilized in various

target identification strategies. In a typical affinity-based approach, the biotinylated
molecule is adhered to an avidin-functionalized resin, creating an extremely stable,
noncovalent affinity matrix. This matrix can then incubated with the cell lysate of
interest and later eluted together with any bound protein. Another approach is to first
incubate the cell lysate with the biotinylated probe which can be retrieved using avidinfunctionalised resin together with any bound protein.

In both approaches, the

biotinylated probes and any attached proteins may be eluted from the avidin resin by 8
M guanidine–HCl, pH 1.5, or by boiling in a denaturing SDS-PAGE loading dye.
Commercially available alternatives such as CaptAvidin resin (Invitrogen), allow for
elution under gentler conditions.
The planned affinity study of 3-17 is illustrated in Figure 3.47. First, streptavidinagarose beads will be pre-treated with a HepG2 cellular lysate in order to remove any
non-specific binding proteins. Compound 3-17 would then be immobilized onto a
streptavidin–agarose resin and incubated with HepG2–cellular lysate. Elution of any
bound proteins would then occur using SDS loading buffer, followed by gel
electrophoresis or trypsin digestion. Any cellular binding partners of 3-17 would then
be elucidated by MS/MS spectrometry or LC–MS.92
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Figure 3.47. Planned affinity studies of the synthesized probe 3-17.
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3.8

Conclusions
In conclusion, the synthesis of a biotin conjugate of DCB-3503 has been

accomplished using “click” chemistry.

The synthesized probe 3-17 managed to

incorporate all of the structural features of DCB-3503 (1-62b) required for in vitro
binding and should be well suited for use in the aforementioned target identification
study.
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CHAPTER 4
BIOCONJUGATION VIA PEGYLATION AND
CLICK CHEMISTRY: A SECOND
NONCLASSICAL APPROACH
4.1

4. BIOCONJUGATION VIA PEGYLATION AND CLICK
CHEMISTRY: A SECOND NONCLASSICAL APPROACH
Background and Significance
The synthesis of biotinylated probes such as 3-17 and their subsequent use in

affinity studies is based on the assumption that a crucial binding event between the
molecular probe and its target may ultimately lead to the identity of the targeted
protein(s). Furthermore, another assumption is that the bioactivity elicited by the probe
is a direct consequence of this binding event. Therefore, the affinity of a molecular
probe for its target is a critical concern, as the quality of this interaction has proven to be
a key factor in the success of target identification experiments.93,100 Other variables such
as probe construction, particularly linker length and composition, may also play a
role.214 For example, in 2006 Whitesell and co-workers utilized a biotinylated derivative
of withaferin A (Figure 4.1), identifying annexin II as being its covalently bound
target.215 Shortly thereafter in 2007, using a biotinylated probe different from that of
Whitesell (Figure 4.1), Mohan and co-workers reported the identification of the protein
vimentin as a second covalent target of withaferin A.216-217 Oddly, Mohan and coworkers were unable to detect annexin II binding even though their probe was outfitted
with a long aliphatic linker. In addition to demonstrating that bioactive small
164

Figure 4.1. Whitesell’s and Mohan’s biotinylated derivatives of withaferin A.
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molecules may have more than one binding partner, this example also illustrated the
effect of linker arm construction in target identification experiments.
In another study, Sato and co-workers synthesized several uniquely rigid linkers
that were comprised of repeating polyproline units (Figure 4.2). The “rod-like” rigidity
of these linkers was attributed to the formation of a stable left-handed helix. Studies
featuring such a rigid linker ultimately led to the identification of glyoxylase 1 (GLO1),
as a new target of indomethacin.218
Morocho et al. reported the synthesis of several biotinylated phosphoramidites,
some with exceptionally long tethers ranging in length from 22 to 39 atoms (Figure
4.2).219 These “super-long tethering arms” improved capturing efficiency from 40–45%
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Figure 4.2. Sato and co-workers’ approaches to the biotinylation of indomethacin.
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(Bt19AU, 22 atoms) to 90–95% (Bt34Ach, 39 atoms) as compared to the 16-atom,
commercially available, Biotin TEG (15-atom triethylene glycol spacer), which only
managed a capturing efficiency of 35–40%. Aside from featuring slightly proprietary
linking units, these tethers also comprised several polyethylene subunits (derived from
polyethylene glycol; PEG) that were designed to improve solubility and enhance
hydrophilicity.
In light of these studies, it is clear that a correlation exists between linker arm
length/composition and the molecular probe’s ability to interact with its potential
targets.

The design of 3-17 took into account most of these considerations; by

incorporating a long PEG linker between the active head unit and the biotin moiety.
However, there exists the opportunity of incorporating into 3-17 a much longer PEGbased tether, similar to the one reported by Morocho et. al.219
accomplishing this via click chemistry is illustrated in Figure 4.4.

One way of
First, the active

member is outfitted with an alkyne-functionalized PEG spacer, followed by conjugation
with a biotin–PEG derivative such as 3-14 to afford a probe with a super long tether.
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Figure 4.3. Structures of biotinylated phosphoramidites bearing super-long linkers.
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Figure 4.4. A generic approach to the synthesis of a biotinylated probe bearing a super-long tether by employing “click”
chemistry.
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Aside from the biocompatibility enhancements that this modification would
offer, there are additional benefits to this approach:

1.

The enhanced hydrophilic nature of this type of linker would minimize
nonspecific binding interactions.220

2.

The exceptional length of such a tether would keep the probe separate
from the steric bulk of the resin, thereby minimizing unfavorable
interactions that could otherwise block potential target protein binding.

3.

The added conformational flexibility may allow the probe to assume an
optimal binding stance during affinity studies.

Accordingly, a new probe 4-14, consistent with this approach is presented in
Figure 4.5 alongside the original probe 3-17.
In recent years, PEGylation,221 or the process of attaching polyethylene glycol
(PEG) chains to molecules, has found considerable utility in drug delivery222 and other
pharmaceutical applications. This is due, in part, to PEG’s unique ability to be soluble
in both organic and aqueous solvents. In fact, PEG has been shown to bind 2–3 water
molecules per ethylene oxide unit in solution studies.223-225 Additionally, PEG shows
little toxicity, and as a result, is approved by the FDA for use as a drug delivery
vehicle.226-227

The PEGylated probe 4-14 would not only assume many of these

properties, but its biological activity would also be retained.228 In general, PEGylated
molecules exhibit activity similar to that of a freely soluble molecule, due in part to
PEG’s high mobility.
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Figure 4.4. Two- and three-dimensional models of the new probe 4-14 and its shorter
variant 3-17.
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4.2

Retrosynthetic Analysis and Strategy of the Probe 4-14
The synthetic blueprint of the PEGylated probe 4-14 has been fashioned such that

it closely resembles that of its non-PEGylated variant 3-17.

Similarly, 4-14 is also

expected to arise from a similar chemoselective ligation procedure, involving a suitable
alkyne–azide pair. Accordingly, retrosynthetic cleavage across the triazole moiety of 414 (Figure 4.5) reveals 4-9 and 3-14 as being the respective alkyne–azide coupling
partners. The probe 4-9 is clearly just a PEGylated variant of 3-9, while the biotin
derivative 3-14 was utilized previously to construct the original probe 3-17.
The synthesis of 4-9 is expected to closely mimic the somewhat linear
construction of 3-9. In accordance with this strategy, PEGylation or attachment of the
bifunctionalized PEG moiety is expected to take place in the early stages of the
synthesis. Appropriately, the retrosynthetic transforms consistent with this strategy are
delineated in Figure 4.6; compound 4-8 can be accessed from the asymmetric reduction
of the pentacyclic ketone 4-7. The Rapoport-inspired intramolecular acylation of 4-6 is
expected to give rise to the ketone 4-7.

Formation of the carboxylic acid 4-6 is

envisioned to take place by the alkylation of a functionalized derivative of 4-1 with a
chiral auxillary 1-42b. Severance of the ether linkage at 4-1’s phenolic position reveals a
bifunctionalized derivative of tetraethylene glycol serving as the linker arm.

172

[3+2] cycloaddition

Figure 4.5. Retrosynthesis of the PEGylated probe 4-14.
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intramolecular
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reduction

N-alkylation

lactamization

PEGylation

Figure 4.6. Retrosynthesis of the PEGylated alkaloid 4-9.
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4.3

Synthesis of the PEGylated Alkaloid 4-9

4.3.1

Construction of the PEG-based Linker Arm

PEGylation is generally accomplished by first chemically modifying the terminal
hydroxy groups of the native PEG moiety before attachment to the substrate.
Conventional

approaches

have

often

involved

the

monofunctionalization

of

monomethoxy PEG (mPEG), converting the terminal hydroxy into either an active ester,
tresylate or active carbonate. While this approach is well suited to the pegylation of
proteins, liposomes and polypeptides, it does not facilitate the linkage of two molecular
entities. Recently, the need for heterobifunctional PEG derivatives has intensified and
has resulted in the introduction of numerous functionalities as end groups.229 For
example, Nagasaki, Kataoka and co-worker were able to synthesize a heterobifunctional
PEG derivative comprising of aldehyde and thiol end groups.230 As forecasted by the
retrosynthetic plan in Figure 4.6, the appropriate linker arm would have to feature an
alkyne as one of the end groups.

The other end of this linker would have to be

activated so that attachment to substrate 2-5 could occur under mild conditions. An
ether linkage, as opposed to amide or ester bond, is desired between the PEG moiety
and the substrate, in order to ensure stability and to preserve any PEG-induced
pharmacological changes.231-232
The regulation of the molar equivalents of a reagent is a strategy that is
commonly used in the monofunctionalization of end groups. Therefore, treatment of
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tetraethylene glycol with one equivalent propargyl bromide in sodium hydride
afforded the monoalkylated PEG derivative 4-10 (Figure 4.7).156 After chromatographic
purification, 4-10 was converted to its corresponding bromo- derivative 4-12 using
phosphorous tribromide.233 This seemingly basic transformation proved problematic at
first, due to the in situ generation of HBr. As illustrated by the NMR spectrum in Figure
4.8, this generated HBr subsequently reacted with the alkyne motif as evident by the
presence of signals at 5.45 and 5.80 ppm, which were consistent with those of allylic
protons. This complication was overcome by lowering the reaction temperature to -30
°C. Alternatively 4-10 was also converted to either its tosylate (4-11) or mesylate211 (413) derivatives (Figure 4.7).

4.3.2

PEGylation of the Phenanthrene Core 2-5

The phenanthrene core 2-5 was then pegylated using the bifunctionalized PEG
derivative 4-12 under mild conditions (refluxing acetone, K2CO3) to afford 4-1 in good
yield (Figure 4.9). PEGylation using either the tosylate (4-11) or mesylate (4-13) variants
of 4-10 worked best using a K2CO3 and a toluene–acetone system (Figure 4.9).
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Figure 4.7. Synthesis of the heterobifunctional PEG derivatives.
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Figure 4.8.

1H

NMR spectrum of the action of in situ HBr on 4-12.

178

OCH 3

O

HO

O

O

Br

O

OCH3
O

O
O

O

O

4-12
OCH3

OCH3
K2CO3 / Acetone

O

H3CO

O

H3CO
OCH3

OCH 3

4-1

2-5

OCH 3

O

HO

O

O

X

O

OCH3
O

O

O

O

O

X = OTs, 4-11
X = OMs, 4-13

OCH3

OCH3
O

H3CO

K2CO3 / Toluene

O

H3CO
OCH3

OCH 3

4-1

2-5

Figure 4.9. PEGylation of the phenanthrene skeleton 2-5.

4.3.3

Model Click Reaction Studies Using the PEGylated Phenathrene Core 4-1

It was hypothesized that the change in the chemical environment of the alkyne,
caused by insertion of the PEG-spacer, could impact its ability to successfully undergo a
[3+2]-cycloaddition. In hopes of disproving this hypothesis, a model click study was set
up using the PEGylated phenanthrene core 4-1 and the derivatized biotin conjugate 3-14
(Figure 4.10). Gratifyingly, 4-1a was synthesized using established clicking conditions,
and its formation was confirmed using MALDI-TOFMS analysis (Figure 4.11).
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Figure 4.10. Clicking the PEGylated core 2-5 to the biotin derivative 3-14.
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Figure 4.11. MALDI-TOFMS spectrum of 4-1a.
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4.3.4

Construction of the Indolizidine Moiety

With the PEGylated phenanthrene scaffold 4-1 synthesized, the construction of
the indolizidine portion of 4-9 proceeded with the reduction of 4-1’s ester function
using lithium aluminum hydride.

This seemingly straightforward transformation

highlighted the risk associated with the use of hydride reagents on substrates
possessing alkynes as evident by the formation of the unwanted alkene 4-2a (Figure
4.12). Unlike the similar conversion of 3-13-2, which was fashioned under ambient
conditions, the reduction of 4-1 could only be accomplished by keeping the temperature
at 0 °C. Compound 3-2’s unusual resistance to over-reduction by hydride agents such
as LiAlH4 may be attributable to electronic and steric factors.

Figure 4.12. Reduction of 4-1’s ester and alkyne functionalities by LiAlH4 at ambient
temperature.
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Conversion of 4-2’s hydroxy group to the corresponding bromide 4-3 using
phosphorous tribromide also proved problematic (Figure 4.13). The 1H NMR spectrum
of 4-3 revealed signals at 5.55 and 5.88 ppm that were consistent with those of allylic
protons; indicating that hydrobromination of the triple bond was taking place (Figure
4.14). In an attempt to counteract this undesired side reaction (caused by the in situ
generation of HBr), pyridine was employed to act as a proton scavenger.
Unfortunately, the extremely reactive nature of 4-3’s benzylic bromide resulted only in
N-alkylation of pyridine (Figure 4.13; 4-3b). Treatment of 4-3b with the chiral auxiliary
1-42b, failed but modest amounts of 4-2 were recovered by treatment of the quaternary
amine with 2 N KOH. A more sterically hindered proton scavenger, 2,6-lutidine,234 was
then employed, and this also resulted in the N-alkylation of the base.

These

complications were ultimately overcome by employing 2,6-di-tert-butyllutidine.

Its

extremely large steric footprint deterred nucleophilic attack at 4-3’s benzylic position
and instead allowed it to function as an effective proton sponge (Figure 4.16).
Intriguingly, this problem was not observed in the analogous conversion of 3-23-3,
even with the presence of excess reagent, highlighting the unusual stability of this
particular alkyne motif.
Alkylation of 4-3 with the chiral auxiliary 1-42b proceeded smoothly to afford 44, which then underwent lactamization using methanolic–acetic acid to furnish 4-5 in
good yield (Figure 4.16). Hydrolysis of 4-5’s methyl ester using 2 N KOH gave the
resulting carboxylic acid 4-6. The intramolecular acylation of 4-6 was then effected
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Figure 4.13. Complications in the conversion of 4-24-3 using PBr3.
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Figure 4.14.

1H

NMR spectrum of the bromo- derivative 4-3a.
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Figure 4.15. Successful conversion of 4-24-3 using a bulky proton scavenger.

using trifluoromethanesulfonic anhydride or the TFAA/BF3Et2O system to give rise to
the pentacyclic ketone 4-7 (Figure 4.16). The overall yield of 4-7 was quite modest after
this sequence of operations, an outcome which was attributed to 4-7’s enhanced
aqueous solubility.

4.3.5

Functionalization of 4-14’s Indolizidine Moiety

Installation of 4-9’s second stereogenic center would again exploit the unique
conformational state of 4-7. Therefore, treatment of 4-7 with the bulky hydride, KSelectride®, effected its conversion to 4-8. As in the conversion of 3-73-8, it is
186

Figure 4.16. Advancement of 4-3 to the pentacyclic intermediate 4-7.
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important that reaction conditions be kept at -78 °C to avoid over-reduction to the
alkene. Finally, careful reduction of 4-8 with lithium aluminium hydride at -10 °C
secured 4-9, the pegylated variant of 3-9 (Figure 4.17).

4.4

Conjugation of the biotin derivative 3-14 to the-PEGylatedAnalogue 4-9
Although the early incorporation the alkyne-functionalized PEG-spacer was met

with several challenges, such an approach was designed to facilitate the [3+2]cycloaddition of intermediates at any stage of the synthesis. Indeed, as demonstrated
by the model study in Figure 4.18, conjugation of the representative intermediate 4-5
with 3-14 successfully furnished the triazole bearing compound 4-5a.

The mass

spectrum of 4-5a (Figure 4.19) confirmed its ionizability under MALDI-TOF conditions.
Having now secured both of the required fragments, the pegylated alkaloid 4-9
was immediately conjugated with the biotin derivative 3-14 through the established
click protocol to finally afford 4-14 (Figure 4.20).
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Figure 4.17. Final steps in the synthesis of the PEGylated derivative 4-9.
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4-9

Figure 4.18. Biotinylation of the PEGylated derivative 4-5 with 3-14.
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Figure 4.19. MALDI-TOFMS spectrum of 4-5a.
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Figure 4.20. Completed synthesis of the probe 4-14 bearing a long tether.
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4.5

Modeling Studies on Streptavidin Binding to the Biotinylated
Probes 3-17 and 4-14
Streptavidin is a tetrameric protein that when bound to biotin, creates one of the

tightest, noncovalent, interactions known between a protein and a small ligand.102 The
crystal structure of the binding site in the streptavidin-biotin complex indicates that
specific hydrogen bonding in addition to sterics, make this binding site complementary
to biotin.101 Furthermore, biotin seems to bind within a deep cleft inside the core of
streptavidin, leaving a distance of only about 10 Å from the bound biotin molecule to
the surface of the protein (Figure 4.21).

10.007 Å

Figure 4.21. X-ray crystal structure of the streptavidin–biotin complex.
The captured biotin fragment resides in a deep pocket, the distance
between it and the surface of the protein is 10.007 Å (PDB code: 1STP).
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Modeling studies were then conducted in order to examine how biotinylated
probes 3-17 and 4-14 would sit inside the binding pocket of streptavidin during the
subsequent affinity studies. First, the lowest energy conformations of both probes was
determined (Figures 4.22 and 4.23) using the MM4 force-field in SYBYL 8.0 (Tripos
Associates). The fit was then accomplished by superimposing ligands 3-17 and 4-14
onto the pre-docked biotin moiety that lay inside the streptavidin–biotin complex. The
resulting renderings are presented in Figures 4.24, 4.25, 4.26 and 4.27.
The length of probe 3-17’s linker was measured to be 18.525 Å before
streptavidin capture (Figure 4.24), while the length of linker outside the streptavidin
surface was found to be 9.015 Å after capture (Figure 4.25). On the other hand, the

Figure 4.22. Lowest energy conformation of 3-17 with a calculated energy of 42.2243
kcal mol-1
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Figure 4.23. Lowest energy conformation of 4-14 with a calculated energy of 44.4817
kcal mol-1

length of the longer linker in probe 4-14 was found to be 33.027 Å before-streptavidin
capture, and a staggering 21.365 Å of it remained outside the protein’s surface after
capture. Probe 4-14’s added length is expected to provide conformational flexibility.

4.6

Conclusions
The synthesis of a biotin conjugate of DCB-3503 (1-62b) bearing an exceptionally

long, PEG-based tether has been achieved. Modeling studies indicate that a portion
(21.365 Å) of the synthesized probe 4-14 remains sufficiently exposed even after
streptavidin capture, making it suitable for targeting any potentially elusive binding
partners of DCB-3503 (1-62b).
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Figure 4.24. Molecular modeling of the binding between streptavidin and the biotinylated probe 3-17.
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram)
associated with the PDB accession code 1STP. Compound 3-17 was minimized using the MM4 force field (SYBYL 8.0,
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package. Molecular graphics
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081). Depicted in the figure is the
full length of 3-17’s linker arm (18.525 Å) and a snapshot of how 3-17 is oriented once placed into the streptavidin binding
pocket.
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Figure 4.25. Molecular modeling of the binding between streptavidin and the biotinylated probe 3-17.
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram)
associated with the PDB accession code 1STP. Compound 3-17 was minimized using the MM4 force field (SYBYL 8.0,
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package. Molecular graphics
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081). Depicted in the figure is the
length of 3-17’s linker arm (9.015 Å) that remains outside of the binding vicinity of streptavidin.
197

O

NH H
H

Resin

O
N
H

HN

O

O

O

N N
N

OCH 3
O

S

O

O

O

O

HO

33.027 Å

Streptavidin-biotin
complex

H
N

H3CO
OCH 3

4-14

Streptavidin-biotin complex

Figure 4.26. Molecular modeling of the binding between streptavidin and the biotinylated probe 4-14.
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram)
associated with the PDB accession code 1STP. Compound 4-14 was minimized using the MM4 force field (SYBYL 8.0,
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package. Molecular graphics
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081). Depicted in the figure is the
full length of 4-14’s linker arm (33.027 Å) and a snapshot of how 4-14 is oriented once fitted into the streptavidin binding
pocket.
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Figure 4.27. Molecular modeling of the binding between streptavidin and the biotinylated probe 4.-14.
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram)
associated with the PDB accession code 1STP. Compound 4-14 was minimized using the MM4 force field (SYBYL 8.0,
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package. Molecular graphics
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081). Depicted in the figure is the
length of 4-14’s linker arm (21.365 Å) that remains outside of the binding pocket of streptavidin.
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CHAPTER 5
CoMFA STUDIES OF THE TYLOPHORA
ALKALOIDS
5. CoMFA STUDIES OF THE TYLOPHORA ALKALOIDS
5.1

Background and Significance

5.1.1

Introduction
Since first being isolated in 1935,13 tylophorine (1) and the rest of the

phenanthroindolizidine alkaloids have continued to be the focus of study in the field of
cancer therapeutics. Their pronounced cytotoxicity and unique modes of action have
inspired renewed efforts to further their development as antitumor agents.

More

recently, phenanthroindolizidine alkaloids have demonstrated inhibitory effects toward
NF-κB binding-mediated transcription.55,74,86-87

The NF-κB pathway has been

implicated as one of the avenues of resistance to chemotherapy.

Although the

inhibitory mechanisms of these compounds are still largely unknown, these
phenanthroindolizidine alkaloids are presumed to elicit their phenotypic responses
through unique and specific binding events that involve their targets.

Therefore,

optimization of the structural features associated with this binding event could result in
an enriched affinity with the target(s) and possibly enhance potency.
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5.1.2

Early Structure–Activity Relationship (SAR) Studies of the Tylophora
Alkaloids

In their structure–activity relationship (SAR) studies of several non-alkylating
antitumor agents including tylophorine (1-1), Zee-Cheng and Cheng identified a
structural feature that was common to all of them.235 Comprising of a nitrogen atom
triangulated to two oxygens, this arrangement of atoms was postulated to play a role in
the in vivo binding of the drug to the appropriate receptor (Figure 5.1). In a subsequent
SAR study focused on both the phenanthroindolizidine and phenanthroquinolizidine
alkaloids, Zee-Cheng and Cheng235 and Gupta and co-workers236 were able to conclude
that these alkaloids could share the same site of action because they had several
structural features in common. These features, presented in Figure 5.2, were thought to
consist of two planar, oxygenated, aromatic systems and a lone pair bearing-nitrogen
that was positioned equidistantly between them.
Then, after evaluating the cytoxicities of seven phenanthroindolizidine alkaloids
against several drug-resistant cell lines, Staerk and co-workers237 implied that a rigid
phenanthrene framework was a prerequisite for cytotoxicity. As the SAR profile of
these potent alkaloids began to emerge, Staerk and co-workers released another study22
in which he reflected upon the 1965 failure of tylocrebine (1-3) during Phase I clinical
trials, due to ataxia. Staerk and co-workers proposed that a more polar analogue of
tylocrebrine (1-3) would be unable to pass the blood–brain barrier, thus keeping CNS
effects to a minimum.
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OCH 3
H 3CO
H
N
H 3CO
OCH 3

Figure 5.1. Zee-Cheng and Cheng’s proposed triangulation of the nitrogen and oxygen
atoms.235

Figure 5.2. The proposed SAR model for receptor binding by Zee-Cheng and Cheng
and Gupta and co-workers.236
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5.1.3

CoMFA and In Silico Screening
Advances in modern drug discovery have resulted in a significant increase in the

number of synthetic and naturally occurring molecules that are available for use in
biological assays. Traditionally, the search for lead compounds has involved the highthroughput screening of all members in a chemical library that have been obtained
through synthetic or isolative means.

However, the recent development of virtual

screening methods, has extended this search to compounds whose physical existence
has not yet being achieved through synthesis or isolation. An obvious advantage to this
approach is that once a lead compound is identified, its activity may be further enriched
by making sensible modifications to its structural composition and the resulting
derivatives stored in a virtual library. These members can then be screened in silico to
identify even more active members, bypassing the immediate need for synthesis and
biological assays.
One way of accomplishing this would be to establish a classical quantitative
structural–activity relationship (QSAR) model, which would correlate the biological
activities of a set of compounds with their physiochemical properties. In their QSAR
study on phenanthrene-based tylophorine derivatives,238 Liao and co-workers were able
to use their computational model to predict the activities of ten theoretical tylophorine
analogues that were derived from modifications made to the indolizidine motif.
However, as with most conventional QSAR studies, neither the chiralities nor the threedimensional aspects of the compounds were considered during development of the
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model.
CoMFA (Comparative Molecular Field Analysis) is a 3D QSAR technique based
on data from known active molecules. The aim of CoMFA is to derive a correlation
between the biological activity of a set of molecules and their three-dimensional shape,
as well as from their electrostatic and hydrogen bonding characteristics.
The first stage is the construction of the CoMFA model. The biologically active
forms are first properly aligned and their corresponding IC50’s (or EC50, LC50) entered.
The series of conformers are then superimposed, and their surrounding molecular fields
are calculated. The generated QSAR is then subjected to several validation techniques
after which the model’s predictive ability is tested. This is typically done using the
original compounds in the set to “back-predict”, and the results compared. If
acceptable, the CoMFA or 3D-QSAR model can then applied to a set of analogues and
predict

their

target

properties.

Additionally,

the

relationship

between

steric/electrostatic properties and biological activity can be represented as a CoMFA
contour map, highlighting key features about potential ligand–receptor interactions.
These findings would allow the properties of the lead compound to be optimized and
prioritize active compounds for synthesis or further screening. The CoMFA approach
has been used with great success to identify potent antineoplasmatic agents.239

204

5.2

Creation of the CoMFA Model

5.2.1

CoMFA Methodology

All molecular structures were modeled with the SYBYL 8.0 molecular modeling
program (Tripos Associates, Saint Louis, MO) on a Linux PC (2 GHz Intel Xeon
processor).

Each structure was energy minimized using the MM4 force field, and

electrostatic charges were assigned by the Gasteiger–Hückel method. CoMFA potential
fields were calculated at each lattice intersection of a regularly spaced grid of 2.0 Å.
Generation of a CoMFA model usually consists of the following steps:

1. A set of molecules whose activities have been measured are superimposed onto
each other.
2. CoMFA interaction energies are computed for each molecule in the set.
3. Statistical analyses, e.g., partial least squares (PLS), are conducted to correlate the
CoMFA fields with biological activities of each molecule.
4. The coefficients from the computations are interpreted, and the model is
validated using a cross-validation analysis.
5. The predictive ability of the model is tested using compounds with measured
biological activities.
6. The model is then applied to set of compounds whose biological activities are yet
to be established.
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5.2.2

Training Set Selection

The biological data used for the CoMFA training set was derived from a study by
Cheng and co-workers87 on the effect of tylophorine and several of its analogues on the
growth of HepG2 cells (Table 5.1). Typically, the minimum number of compounds
needed for a CoMFA training set is 10 and these compounds should have good
structural diversity. The selected set consisted of 12 compounds that seemed to satisfy
the criteria of being fairly diverse in their biological activities and molecular
architectures (Figure 5.3).

Table 5.1. The GI50 values of a set of tylophora alkaloids on the growth inhibition of
HepG2 cells by Cheng and co-workers.87

Compound
(+)-(S)-tylophorine [S-(1-1)]b
(-)-(R)-tylophorine [R-(1-1)]
(-)-antofine (5-1)
Rac-cryptopleurine (5-2)
Precursor # 1 (5-3)
Precursor # 2 (5-4)
(-)-Ficuseptine C (5-5)

HepG2 GI50 (µM)
2.3 ± 0.3
8.6 ± 3.6
5.4 ± 1.4
3 ± 0.7
3.1 ± 1.0

PBT # 28 (5-6)
PBT # 31 (5-7)
PBT # 32 (5-8)
PBT # 33 (5-9)
PBT # 34 (5-10)
a
b

HepG2 GI50 a(nM)
11 ± 4
33 ± 2
4.9 ± 0.4
1.5 ± 0.2
1723 ± 417
>10,000
371 ± 27

Values are means ± SD of three experiments, with each data point done in triplicate.
Published86
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Figure 5.3. Structures of the 12 tylophora alkaloids and PBTs used in the CoMFA
study.
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5.2.3

Structure Preparation and Alignment

All structures from the training data set were constructed using the SYBYL
sketcher, and their conformations were arrived at by optimization via minimization
with the MM4 force field. Electrostatic charges were then assigned using the Gasteiger–
Hückel method.
Structural alignment is one of the most sensitive parameters in 3D-QSAR
analyses. The accuracy of the prediction of a CoMFA model and the reliability of the
contour models strongly depend on the structural alignment of the molecules. The
method chosen for this study was alignment by substructure because the
pharmacophore for this family of compounds is still unknown. Several substructures
were tested, ranging from a simple phenanthrene to the modified phenanthrene shown
in Figure 5.4, which proved to be the best core structure for the alignment. During the
alignment process, each molecule was retrieved from the set and aligned on the
substructure; however, compounds 5-3 and 5-4 were not able to be aligned using this
substructure and were therefore disqualified from use in the training set. Additionally,
the study by Cheng and co-workers featured rac-cryptopleurine (5-2), which was tested
in racemic form during the study, and proved to be the most potent member. In order
to keep 5-2 in the training set, it was assumed that both the R [(R)-5-2)] and S [(S)-5-2)]
isomers contributed equally towards the observed biological activity. With all these
considerations taken into account, the alignment was performed, and these results are
presented in Figure 5.5.
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Figure 5.4. The substructure utilized in the superimposition of the training set
molecules.

Figure 5.5. Plot of all 11 superimposed compounds used for the 3D-QSAR analysis.
During the alignment, all of the other molecules were superimposed onto the
template molecule, while maintaining their molecular geometry. Oxygen is shown
in red, carbon in white, hydrogen in cyan and nitrogen in blue.
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5.2.4

Preparation of the Biological Data

The main goal of a CoMFA model is to relate structural information to biological
data. The experimental GI50 values for all molecules in the training set were converted
to their corresponding negative logs (pGI50, Table 5.2).

5.2.5

CoMFA Field Calculation
After superposition of the molecules, the CoMFA field was calculated using

default SYBYL parameters (grid spacing = 2 Å, truncation cutoff = 30 kcal/mol). In a
CoMFA field analysis, each compound was placed in a three-dimensional lattice and
the steric and electrostatic fields at the various grid points of the lattice was calculated.
Generally, depending on the dimensions of this box, a few to several thousand points
were generated. The results of this analysis are displayed in Table 5.3 and range from
136 to 176 for this training set.
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Table 5.2. The pGI50 of tylophora alkaloids and PBTs on the growth inhibition of
HepG2 cells.

Compound
(+)-(S)-tylophorine [(S)-1-1)]
(-)-(R)-tylophorine [(R)-1-1)]
(-)-antofine (5-1)
(R)-cryptopleurine [(R)-5-2)])
(S)-cryptopleurine [(S)-5-2)]
Precursor # 1 (5-3)
Precursor # 2 (5-4)
(-)-Ficuseptine C (5-5)
PBT # 28 (5-6)
PBT # 31 (5-7)
PBT # 32 (5-8)
PBT # 33 (5-9)
PBT # 34 (5-10)

HepG2 pGI50
7.96
7.48
8.31
8.82
8.82
5.76
5.00
6.43
5.64
5.07
5.27
5.52
5.51

Table 5.3. Results from the CoMFA field analysis.

Compound
(+)-(S)-tylophorine [(S)-1-1)]
(-)-(R)-tylophorine [(R)-1-1)]
(-)-antofine (5-1)
(R)-cryptopleurine [(R)-5-2)])
(S)-cryptopleurine [(S)-5-2)])
(-)-Ficuseptine C (5-5)
PBT # 28 (5-6)
PBT # 31 (5-7)
PBT # 32 (5-8)
PBT # 33 (5-9)
PBT # 34 (5-10)

HepG2 pGI50
(experimental)
7.96
7.48
8.31
8.82
8.82
6.43
5.64
5.07
5.27
5.52
5.51
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CoMFA Field
176
174
160
158
158
136
152
142
144
152
152

5.2.6

Derivation and Validation of the CoMFA Model

The field matrix resulting from the CoMFA field calculation was then analyzed
by the Partial Least Squares (PLS) method to give r2 and q2 values (Table 5.4). PLS, the
statistical method used in deriving the 3D-QSAR models, is an extension of multiple
regression analysis in which the original variables are replaced by a small set of their
linear combinations.240 The r2 value is the Pearson correlation coefficient, which is the
correlation between the calculated activities and the observed cytotoxic activities; it is
an indication of the quality of the data fit rather than the quality of prediction. The q2 is
the predicted value based on a leave-one-out (LOO) cross-validation method.241 In the
LOO cross validation method, one compound is excluded from the training set, and a
PLS model is derived from the remaining compounds. This model is used to predict the
biological activity value of the compound that was not included in the model. This
procedure is repeated after exclusion of another compound until all compounds have
been excluded once.
For this study, the r2 was found to be 0.935 and q2 was 0.567 with the optimum
number of components set to 3. Generally, the q2 is expected to be lower than r2, and
values greater than 0.5 indicate good predictive power. The CoMFA model was then
checked by predicting the activities of the compounds in the training set, and the values
were compared to the experimental data (Table 5.5 and Figure 5.6).
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Table 5.4. Results from the LOO cross validation method.

q2
r2
No. of Compounds
Steric
Electrostatic
Optimum No. of Components
Grid spacing (Å)

CoMFA
0.567
0.935
11
0.511
0.489
3.0
2.0

Table 5.5. CoMFA predictions for compounds in the training set.

Compound
(+)-(S)-tylophorine [(S)-1-1)]
(-)-(R)-tylophorine [(R)-1-1)]
(-)-antofine (5-1)
(R)-cryptopleurine [(R)-5-2)])
(S)-cryptopleurine [(S)-5-2)])
(-)-Ficuseptine C (5-5)
PBT # 28 (5-6)
PBT # 31 (5-7)
PBT # 32 (5-8)
PBT # 33 (5-9)
PBT # 34 (5-10)

HepG2 pGI50
(experimental)
7.96
7.48
8.31
8.82
8.82
6.43
5.64
5.07
5.27
5.52
5.51
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CoMFA Field
176
174
160
158
158
136
152
142
144
152
152

HepG2 pGI50
(predicted)
7.81
7.578
8.385
8.842
8.842
6.438
5.653
5.205
5.328
5.317
5.499

Residual
0.15
0.10
0.08
0.02
0.02
0.01
0.01
0.14
0.06
0.21
0.01

10
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Predicted pGI50
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Figure 5.6. Plot of the experimental pGI50 values versus the predicted pGI50 results.

5.2.7

Generation of the CoMFA Contour Map
The contour plot representations of the CoMFA results for the tylophora

alkaloids are presented in Figures 5.
5.7 and 5.9 using (R)-cryptopleurine [(R)-5-2)]
[(
as the
reference structure.

The green
green-colored
colored regions indicate areas where steric bulk

enhances HepG2 inhibitory activity, while the yellow contours indicate regions where
steric bulk is detrimental to biological activity. The blue polyhedron regions indicate
that electron-rich
rich substituents will reduce the biological activity
activity, while the red regions
indicate that the electron-rich
rich groups are beneficial to the activity
activity.
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Figure 5.6. CoMFA contour map using compound (R)-5-2 as the reference structure.

Figure 5.7. CoMFA contour map using compound (R)-5-2 as the reference structure.
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5.3

Screening New Analogues Using CoMFA
One of the goals of in silico screening is to optimize the properties of a lead

compound which in this case is DCB-3503 (1-62b). The CoMFA contour maps (Figure
5.6 and Figure 5.7) revealed that the addition of electron-withdrawing groups to the
“southern” ring of DCB-3503 (1-62b) would most likely enhance its biological activity.
Accordingly, modifications were made to 1-62b’s southern ring to incorporate F, Cl, Br,
CF3 (Table 5.6, compounds 4–15) as the electron-withdrawing groups in place of the C-6
and C-7 methoxy motifs. Compounds 1-62b and (S)-1-1 have already been synthesized
and evaluated both in vivo and in vitro against the HepG2 cell line,86 and these were
included in the set to test the predictive powers of the model. As illustrated in Table 5.7
and Figure 5.9, the CoMFA model was able to accurately predict the biological activities
of 1-62b and (S)-1-1.
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Table 5.6. Biological activities for 20 tylophorine derivatives as predicted by the
CoMFA model.

Compound No.
5-11
5-12
5-13
5-14
5-15
5-16
5-17
5-18
5-19
5-20
5-21
5-22
5-23
5-24
5-25
5-26
5-27
5-28
5-29
5-30
a Published86
b

Triaz =

c

PEG =

R
R1 = R2 = R3 = R4 = OCH3, R5 = OH
R1 = R2 = R3 = R4 = OCH3, R5 = H
R1 = R2 = R3 = R4 = OCH3, R5 = NH2
R1 = R2 = R3 = OCH3, R4 = F, R5 = OH
R1 = R2 = R4 = OCH3, R3 = F, R5 = OH
R1 = R2 = OCH3, R3 = R4 = F, R5 = OH
R1 = R2 = R3 = OCH3, R4 = Cl, R5 = OH
R1 = R2 = R4 = OCH3, R3 = Cl, R5 = OH
R1 = R2 = OCH3, R3 = R4 = Cl, R5 = OH
R1 = R2 = R3 = OCH3, R4 = Br, R5 = OH
R1 = R2 = R4 = OCH3, R3 = Br, R5 = OH
R1 = R2 = OCH3, R3 = R4 = Br, R5 = OH
R1 = R2 = R3 = OCH3, R4 = CF3, R5 = OH
R1 = R2 = R4 = OCH3, R3 = CF3, R5 = OH
R1 = R2 = OCH3, R3 = R4 = CF3, R5 = OH
R1 = Triazb, R2 = R3 = R4 = OCH3, R5 = OH
R1 = (3-hydroxypropyl)O- R2 = R3 = R4 = OCH3, R5 = OH
R1 = C5H11O, R2 = R3 = R4 = OCH3, R5 = OH
R1 = PEGc, R2 = R3 = R4 = OCH3, R5 = OH
R1 = HC≡C-O, R2 = R3 = R4 = OCH3, R5 = OH
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n
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

pGI50
7.615
7.801
7.87
8.183
8.185
8.066
8.241
8.15
8.093
8.256
8.117
8.067
7.866
7.91
7.542
8.309
7.952
7.623
7.319
7.86

Table 5.7. Comparison of the experimental and predicted pGI50 values for DCB-3500
[(S)-1-1] or 5-12) and DCB-3503 (1-62b or 5-11)

Compound
DCB-3503 (1-62b or 5-11)
DCB-3500 [(S)-1-1] or 512)

HepG2 GI50
(experimental)86
35 ± 5

HepG2 GI50
(experimental)
7.46

HepG2 pGI50
(predicted)
7.62

Residual
0.16

11 ± 4

7.96

7.80

0.16

7.85

Predicted pGI50

7.8

7.75

7.7

7.65

7.6
7.4

7.5

7.6

7.7

7.8

7.9

8

Experimental pGI50

Figure 5.9. Plot of experimental versus predicted pGI50s for DCB-3500 [(S)-1-1] or 5-12)
and DCB-3503 (1-62b or 5-11)
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5.4

Discussion
Compound 5-13 was derived from DCB-3503 (1-62b) by replacing the C-14

hydroxy group with an amino group. The remainder of Table 5.6’s entries (compounds
5-26 to 5-30), feature modification at the C-3 position: replacing the methoxy group with
triazole (5-26), PEG (5-29), propyl hydroxy (5-27) and propargyl (5-30) motifs. In all,
eighteen new analogues of DCB-3503 (1-62b) were screened in silico using CoMFA, and
these results are presented in Table 5.6 and Figure 5.10. Compound 5-26, bearing the
triazole, is predicted to have the greatest potency followed by compounds 5-20 and 517, which feature Br and Cl groups at the C-6 position, respectively. In fact, the general
trend observed with the CoMFA model is that, addition of an electron-withdrawing
substituent at the C-6 position seems to enhance potency more than a similar
modification at the C-7 position. Furthermore, modifications at both the C-6 and C-7
positions (compounds 5-16, 5-19 and 5-22) results in an increase in the predicted
activity, but these values are still lower than their monosubstituted counterparts.
Compound 5-16 is of specific interest because it was specifically designed to be more
polar than DCB-3503 (1-62b). This was done in direct response to Staerk’s postulation22
that penetration of the blood–brain barrier by these alkaloids could be reduced with the
use of more polar analogs. Sharma et al. reported the synthesis of several analogues242
of septicine, one of which demonstrated elevated cytotoxity due to the addition of two
fluorine substituents in place of the methoxy groups on the “southern” ring (Figure
5.11).
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Interestingly, compound 5-25, bearing two CF3 groups at both the C-6 and C-7
positions, was projected to have a slightly lower potency than DCB-3503 (1-62b). This
reduction in activity may be attributed to the diminished electron-withdrawing effect of
the CF3 group at these positions, an assumption that is supported by the fact that all
compounds bearing aryl halogens showed superior activity than their CF3-bearing
counterparts.

5.5

Conclusions
3D QSAR studies were performed using CoMFA on a set of phenanthrolizidine

alkaloids with inhibitory activity against the HepG2 cell line. A satisfactory CoMFA
model was obtained with LOO cross-validation q2 and non-cross-validated r2 values of
0.567 and 0.935, respectively. The developed model demonstrated promising predictive
abilities as discerned by the results of external test set.

Additionally, the CoMFA

contour plots derived from the 3D-QSAR study revealed that modification(s) to the
southern portion of the phenanthrene framework under the blue contour region greatly
altered biological activity. Furthermore, it was found that addition of an electronwithdrawing substituent at the C-6 position of the phenanthrene seemed to enhance
potency more than a similar modification at the phenanthrene’s C-7 position. As such,
the CoMFA model provides a guide for the design of analogues of DCB-3503 (1-62b)
with greater inhibitory powers. Several of these compounds that are predicted to be of
enhanced potency relative to DCB-3503 (1-62b) are under synthesis.
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Figure 5.10. Bar graph representation of predicted pGI50s for the 20 tylophora
derivatives.
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Figure 5.11. Sharma’s difluoro-substituted septicine analogue.
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EXPERIMENTAL
6. Experimental
1H

(300 MHz) and 13C (75 MHz) and NMR spectra were recorded at 25 ºC with a

Varian Mercury 300. Chemical shifts are given in δ-units (ppm) relative to an internal
standard of TMS for 1H, and relative to the signal for CDCl3 or pyridine-d5 for 1H and
13C

unless otherwise stated.

Apparent first-order multiplicities are indicated by s,

singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, quartet;
m, multiplet. Analytical TLC was performed on Silica Gel 60 F254 (0.2-mm aluminumbacked plates, E. Merck) by detection with 254 nm UV light and then spray–heat
development using a p-anisaldehyde–sulfuric acid reagent. Column chromatography
was run by using silica gel, 63–200 mesh. High-resolution DART mass spectra were
obtained on a JEOL AccuTOF-DART workstation with an ESI source. MALDI-TOF
mass spectra were obtained on a Voyager-DE PRO BioSpectrometry Workstation. All
solvents were dried and distilled by standard methods unless otherwise stated.
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(E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (1-27).
In a 1 L round-bottomed flask was added 3,4-dimethoxyphenylacetic acid (19.7 g, 100
mmol) and 3,4-dimethoxybenzaldehyde (16.69 g, 100.0 mmol) in acetic anhydride (55.0
mL, 583 mmol) to give a yellow suspension. TEA (35.0 mL, 249 mmol) was added and
the reaction mixture was stirred at 100 ºC. After 24 h the darkened mixture was cooled
to room temperature, followed by the slow addition of 50 mL of H2O. The reaction
mixture was then poured into aqueous K2CO3 (75.0 g in 250 mL of water) and refluxed
until the dissolution of all solids. After cooling to room temperature, the solution was
extracted with ether (3 x 50 mL) and carefully acidified with 2 N hydrochloric acid to
produce a yellow precipitate. The isolated solid was then recrystallized from MeOH to
give 1-27 (26 g, 76 mmol, 75% yield) as a beige solid. . 1H NMR (300 MHz, CDCl3) δ 7.74
(s, 1H), 6.86 (d, J = 8.2, 1H), 6.75 (d, J = 1.9, 1H), 6.78 (d, J = 1.9, 1H), 6.75 (d, J = 1.9, 1H),
6.65 (d, J = 8.4, 1H), 6.47 (d, J = 2.0, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.73 (s, 3H), 3.74 (s,
3H).

13C

NMR (75 MHz, CDCl3) δ 55.96, 56.07, 110.58, 111.62, 112.56, 113.03, 122.34,

125.50, 127.53, 128.92, 138.05, 138.40, 148.27, 148.73, 149.42, 150.08, 168.81, 189.56. The
NMR data matched those reported in the literature.55 HRDARTMS: Calcd for C19H20O6
m/z 344.12599; [M + H]+ m/z 345.13454 (calcd 345.13381).
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Preparation of (E)-Methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (147).
To a solution of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (1-27, 10.05 g, 29.20 mmol)
in 500 mL of dry MeOH was added concd H2SO4 (10 mL), and the solution was stirred
at 65 ºC for 12 h. The reaction mixture was then concentrated using a rotary evaporator,
and the resulting slurry was then filtered. After being washed several times with ice
cold MeOH, the filtrate was then purified by column chromatography (1:2 hexane–
EtOAc) to give (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester 1-47
(9.70 g, 27.1 mmol, 93% yield) as a pale-yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.73
(s, 1H), 6.88 (d, J = 8.2, 1H), 6.79 (d, J = 1.9, 1H), 6.77 (d, J = 1.9, 1H), 6.74 (d, J = 1.9, 1H),
6.68 (d, J = 8.4, 1H), 6.49 (d, J = 2.0, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.76 (s,
3H), 3.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 52.53, 55.95, 56.09, 110.59, 111.61, 112.57,
113.00, 122.36, 125.48, 127.56, 128.90, 138.03, 138.40, 148.29, 148.71, 149.40, 150.09, 168.80,
189.54. The NMR data matched those reported in the literature.55 HRDARTMS: Calcd
for C20H22O6 m/z 358.14164; [M + H]+ m/z 359.14299 (calcd 345.14946).
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Preparation of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52).
(E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47, 4.75 g, 13.3
mmol) was dissolved in 200 mL of dry CH2Cl2 and stirred over an ice bath for 15 min. A
solution of FeCl3 (12.9 g, 80.0 mmol) in 100 mL EtOAc was then added dropwise, and
stirring was continued. After 3 h, 150 mL of H2O was added, and the reaction mixture
was stirred for an additional 2 h. The mixture was poured from the reaction vessel into
a separatory funnel and the phases separated. The organic phase was then dried over
Na2SO4 and filtered. The solvent was removed by rotary evaporation, and the crude
product was purified by column chromatography (0.2:2 hexane–EtOAc) to give methyl
2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52, 4.35 g, 12.19 mmol, 92% yield).
1H

NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 8.41 (s, 1H), 7.78 (s, 1H), 7.74 (s, 1H), 7.25 (s,

1H), 4.13 (s, 3H), 4.12 (s, 3H), 4.07 (s, 3H), 4.02 (s, 3H), 4.00 (s, 3H).

13C

NMR (75 MHz,

CDCl3) δ 52.27, 56.06, 56.28, 100.20, 102.81, 107.00, 109.44, 116.16, 130.61, 138.04, 149.22,
165.17, 182.43, 192.72.

The NMR data matched those reported in the literature.55

HRDARTMS: Calcd for C20H20O6 m/z 356.12599; [M+H]+ m/z 357.13381 (calcd
357.12550).
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Preparation of (2,3,6,7-tetramethoxyphenanthren-9-yl)-methanol (1-53).
To a suspension of lithium aluminum hydride (1.44 g, 37.9 mmol) in 50 mL of THF at 0
ºC under a nitrogen atmosphere, was added dropwise, a solution of methyl 2,3,6,7tetramethoxyphenanthrene-9-carboxylate (1-52, 4.50 g, 12.6 mmol) in 200 mL of dry
THF. The solution was stirred at room temperature for an additional 4 h, then brought
back to 0 ºC, at which point 50 mL of EtOAc was added dropwise, followed by careful
addition of sodium sulfate decahydrate (10.0 g, 31.0 mmol). After stirring for 5 h, the
solution was filtered, and the solvent was removed by rotary evaporation. The product
was purified by column chromatography (0.2:2 hexane–EtOAc) to give 1-53 (4.02 g, 12.3
mmol, 97% yield). 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 7.66 (s, 1H), 7.48 (s, 1H),
7.46 (s, 1H), 7.09 (s, 1H), 5.04 (s, 2H), 4.08 (s, 3H), 4.07 (s, 3H), 4.01 (s, 3H), 3.95 (s, 3H).
13C

NMR (75 MHz, CDCl3) δ 56.09, 64.87, 102.81, 103.29, 104.92, 108.47, 124.14,

124.75,125.14, 125.97, 132.20, 137.78, 138.12,147.61, 149.14. The NMR data matched those
reported in the literature.55 HRDARTMS: Calcd for C19H20O5 m/z 328.13107; [M]- m/z
328.13154 (calcd 328.13107).
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Preparation of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63).
A stirred solution of 2,3,6,7-tetramethoxyphenanthren-9-yl-methanol (1-53, 5.20 g, 15.8
mmol) in 346 mL of freshly distilled CHCl3 was cooled to 0 ºC. After stirring for 15 min,
a solution of phosphorous tribromide (4.29 g, 15.84 mmol) in 60 mL CHCl3 was added
dropwise. The reaction mixture was then stirred for an additional 2 h at room
temperature and then poured over ice, and the two layers separated. The organic phase
was dried over MgSO4, filtered and rotary evaporated to give 9-(bromomethyl)-2,3,6,7tetramethoxyphenanthrene (1-63, 6.07 g, 15.5 mmol, 98% yield) as a yellow solid that
was then placed under vacuum for 1 h and used without further purification.
1H

NMR (300 MHz, CDCl3) δ 7.80 (s, 1H), 7.72 (s, 1H), 7.64 (s, 1H), 7.50 (s, 1H), 7.15 (s,

1H), 4.96 (s, 2H), 4.10 (d, J = 2.0, 6H), 4.08 (s, 3H), 4.00 (s, 3H).

13C

NMR (75 MHz,

CDCl3) δ 33.98, 56.18, 102.89, 103.52, 105.10, 108.56, 124.24, 125.45, 125.81, 126.56, 127.34,
128.93, 149.46. The NMR data matched those reported in the literature.55 HRDARTMS:
Calcd for C19H19BrO4 m/z 390.04667; [M] m/z 390.03819 (calcd 390.04667).
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Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b).
To a stirred solution of L-(+)-glutamic acid (6.00 g, 40.8 mmol) in 300 mL of methanol at
-10 ºC was added slowly thionyl chloride (40 mL, 548 mmol). Stirring was continued at
30 ºC for an additional 6 h after which time the solvent was removed by rotary
evaporation, and the residue was concentrated in vacuo to give 1-42b (8.42 g, 40.0 mmol,
98% yield) as a white crystalline solid. 1H NMR (300 MHz, pyridine) δ 4.86 (t, J = 6.5,
1H), 3.70 (s, 3H), 3.50 (s, 3H), 3.12 – 2.90 (m, 2H), 2.84 – 2.62 (m, 2H). 13C NMR (75 MHz,
pyridine) δ 26.65, 30.48, 53.11, 171.14, 172.99. The NMR data matched those reported in
the literature.55 HRDARTMS: Calcd for [C7H14NO4]+ m/z 176.09173; [M]+- m/z 176.0905
(calcd 176.09173).

Preparation of (S)-dimethyl 2-((2,3,6,7-tetramethoxyphenanthren-9yl)methylamino)pentanedioate (1-64).
To a stirred solution of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63, 4.80
g, 12.3 mmol) in 420 mL of DMF was added 1-42b (12.98 g, 61.30 mmol), and stirring
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was continued for 15 min. K2CO3 (8.48 g, 61.3 mmol) was added, and the reaction
mixture was allowed to stir at 70 ºC overnight.

The solution was then rotary

evaporated, and the resulting crude product was partitioned between CHCl3 and H2O.
The organic layer was then dried over MgSO4 and concentrated in vacuo to afford the
crude of 1-64 as a dark-yellow oil that was used without further purification.55
HRDARTMS: Calcd for C26H31NO8 m/z 485.20497; [M+H]+ m/z 486.21025 (calcd
486.21279).

Preparation of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9yl)methyl)pyrrolidine-2-carboxylate (1-65).
The crude diester, 9 (4.80 g, 9.89 mmol), was dissolved in 80 mL of MeOH and 35 mL of
HOAc and stirred for 3 h at 45 ºC. The mixture was then cooled to room temperature,
concentrated in vacuo, and the residue was chromatographed over silica gel (0.2:2
hexanes–EtOAc) to afford (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9yl)methyl)pyrrolidine-2-carboxylate (1-65, 3.90 g, 8.60 mmol, 87% yield) as a white
solid. 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 1H), 7.72 (s, 1H), 7.57 (s, 1H), 7.36 (s, 1H),
7.13 (s, 1H), 5.45 (d, J = 14.5, 1H), 4.37 (d, J = 14.5, 1H), 4.08 (s, 6H), 4.00 (s, 5H), 3.82 (dd,
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J = 9.1, 3.2, 1H), 3.54 (s, 3H), 2.64 – 2.49 (m, 1H), 2.36 (ddd, J = 16.9, 9.5, 3.8, 1H), 2.17 –
1.89 (m, 2H).

13C

NMR (75 MHz, CDCl3) δ 22.88, 29.95, 44.90, 52.41, 56.08, 56.22, 56.47,

102.79,103.17, 105.38, 108.31, 124.92, 125.67, 127.03, 138.26, 149.01, 149.16, 149.27, 149.70,
172.42, 174.78. The NMR data matched those reported in the literature.55 HRDARTMS:
Calcd for C25H27NO7 m/z 453.17875; [M+H]+ m/z 454.16560 (calcd 454.18658).

Preparation of (S)-5-Oxo-1-((2,3,6,7-tetramethoxyphenanthren-9yl)methyl)pyrrolidine-2-carboxylic acid (1-50).
To the alkylated pyroglutamate ester 1-65 (2.60 g, 5.73 mmol) in 1,4-dioxane (60 mL)
was added 2 N KOH (30 mL) and MeOH (48 mL). After vigorous stirring for 12 h, the
solution was cooled (4 ºC), acidified to pH 3 with 2 N HCl, and chilled overnight. The
resulting solid was then filtered, and the filter cake was rinsed with 10 mL of ice-cold
water to afford (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine2-carboxylic acid (1-50, 2.44 g, 5.56 mmol, 97% yield) as a white solid. 1H NMR (300
MHz, pyridine) δ 8.34 (s, 1H), 8.29 (s, 1H), 8.17 (s, 1H), 7.85 (s, 1H), 7.38 (s, 1H), 6.05 (d, J
= 14.4, 1H), 4.81 (d, J = 14.5, 1H), 4.27 (dd, J = 8.4, 3.9, 1H), 4.14 (s, 3H), 4.02 (s, 6H), 3.85
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(s, 3H), 2.74 (d, J = 16.8, 1H), 2.50 (s, 1H), 2.25 – 2.11 (m, 2H).

13C

NMR (75 MHz,

pyridine) δ 23.75, 30.68, 45.30, 56.04, 56.44, 59.70, 104.62, 105.16,106.64, 109.54, 125.92,
126.05, 126.20, 126.85, 127.63, 128.78, 138.32, 175.30, 175.49. The NMR data matched
those reported in the literature.55 HRDARTMS: Calcd for C24H25NO7 m/z 439.16310;
[M+H]+ m/z 440.16535 (calcd 440.17093).

Preparation of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2b]isoquinoline-11,14(9H,12H)-dione (1-45).
Method A: Trifluoromethanesulfonic anhydride (0.877 mL, 5.19 mmol) was added to a
well-stirred suspension of 1-65 (1.90 g, 4.32 mmol) in CH2Cl2 (130 mL) at -30 ºC. The
reaction mixture was allowed to reach room temperature slowly and was stirred for an
additional 48 h. The solvent was then evaporated, and the resulting residue passed was
through a plug of silica gel. The collected crude was then concentrated and added to a
stirred mixture of CH2Cl2 (75 mL) and 2 g of K2CO3 in water (50 mL) for 4 h. The
organic phase was then evaporated affording a dark oil, which was then
chromatographed over silica gel (0.1:2 MeOH–CHCl3) to give 1-45 (0.98 g, 2.34 mmol,
54% yield), which was recrystallized from acetone affording a bright yellow-solid.
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Method B: Trifluoroacetic anhydride (2.41 mL, 17.3 mmol) was added to a well stirred
suspension of the carboxylic acid 1-50 (1.90 g, 4.32 mmol) in CH2Cl2 (130 mL). The
mixture was stirred at room temperature for 15 min, and boron trifluoride diethyl
etherate (1.06 mL, 8.65 mmol) was added. The mixture was stirred at room temperature
for 24 h, then the solvents were evaporated. To the resulting residue was added a
mixture of CH2Cl2 (100 mL) and 4 g of K2CO3 in water (50 mL) for 4 h. The organic
phase was dried, then evaporated affording 1-45 (1.17 g, 2.77 mmol, 64% yield) as a
bright-yellow solid. 1H NMR (300 MHz, CDCl3) δ 9.01 (s, 1H), 7.64 (d, J = 6.1, 2H), 7.13
(s, 1H), 5.57 (d, J = 18.0, 1H), 4.50 (d, J = 21.1, 11.2, 1H), 4.32 (t, J = 5.8, 1H), 4.11 (s, 3H),
4.07 (s, 3H), 4.05 (s, 3H), 4.02 (s, 3H), 2.58 – 2.47 (m, 4H).

13C

NMR (75 MHz, CDCl3) δ

23.59, 30.97, 41.04, 55.98, 56.19, 58.57, 65.85, 102.83, 103.06, 103.18, 104.55, 122.81,123.94,
124.52, 124.95, 127.06, 137.50, 138.30, 155.64, 206.49, 220.10. The NMR data matched
those reported in the literature.55 HRDARTMS: Calcd for C24H23NO6 m/z 421.15254;
[M+H]+ m/z 422.16064 (calcd 422.16036).
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Preparation of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66).
To a solution of 1-45 (0.8 g, 1.898 mmol) in THF (25 mL) was added lithium tri-secbutylborohydride (2.088 mL, 2.088 mmol) in THF at -30 ºC under N2. After stirring at 30 ºC for 10 min and 3 h at room temperature, a mixture of i-PrOH (3 mL) and H2O (3
mL) was added, and the mixture was stirred at 0 ºC in the presence of silica gel (200 mg)
for 0.5 h. The mixture was filtered through a Celite pad, and the filtrate was evaporated
in vacuo. The residue was purified by flash column chromatography ( 0.1:2 MeOH–
CHCl3) to afford 1-66 (0.72 g, 1.7 mmol, 89% yield). 1H NMR (300 MHz, CDCl3) δ 7.68
(s, 1H), 7.62 (s, 1H), 7.58 (s, 1H), 6.61 (s, 1H), 5.07 (s, 1H), 4.99 (d, J = 17.6, 1H), 4.26 (d, J
= 17.8, 1H), 4.09 (s, 3H), 4.06 (s, 6H), 3.85 (d, J = 8.3, 1H), 3.65 (s, 3H), 3.08 (s, 1H), 2.73 –
2.45 (m, 3H), 2.31–2.20 (m, 1H).

13C

NMR (75 MHz, CDCl3) δ 19.36, 30.97, 41.04, 56.19,

58.57,65.85, 102.83, 103.06, 103.18, 104.55, 124.52, 137.50, 138.22, 148.86, 149.14, 149.28,
149.38, 165.22. The NMR data matched those reported in the literature.55 HRDARTMS:
Calcd for C24H25NO6 m/z 423.16819; [M+H]+ m/z 424.17545 (calcd 422.17601).
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Preparation of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (1-62b).
To a suspension of lithium aluminum hydride (0.323 g, 8.50 mmol) in 50 mL of THF at 0
ºC under a nitrogen atmosphere, was added dropwise a solution of 1-66 (0.40 g, 0.95
mmol) in 80 mL of dry THF. The solution was stirred at room temperature for an
additional 4 h, then brought back to 0 ºC, at which point 30 mL of EtOAc was added
dropwise, followed by careful addition of 7 g of sodium sulfate decahydrate. After
stirring for 5 h, the solution was filtered, and the solvent was removed by rotary
evaporation.

The product was purified by column chromatography (0.1:2 MeOH–

CHCl3) to give 1-62b (0.31 g, 0.75 mmol, 79% yield). 1H NMR (300 MHz, CDCl3) δ 7.28
(s, 1H), 7.19 (s, 1H), 7.13 (s, 1H), 6.75 (s, 1H), 4.99 (d, J = 14.0, 1H), 3.98 (s, 6H), 3.94 (s,
3H), 3.91 (s, 3H), 3.29–3.21 (m, 1H), 3.21–3.09 (m, 1H), 3.03–2.93 (m, 1H), 2.38–2.29 (m,
2H), 2.13–1.98 (m, 2H).

13C

NMR (75 MHz, CDCl3) δ 25.82, 32.27, 55.23, 56.03, 56.11,

56.24, 56.32, 62.62, 65.40, 68.19, 103.01, 103.43, 104.98, 108.39, 124.65, 125.15, 125.68,
126.09, 148.96, 149.04, 149.18, 149.47. The NMR data matched those reported in the
literature.55 HRDARTMS: Calcd for C24H27NO5 m/z 409.18892; [M+H]+ m/z 410.19678
(calcd 410.19675).
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Preparation

of

(E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic

acid (2-1)
In a 1-L round-bottomed flask was added 2-(3,4-dimethoxyphenyl)acetic acid (19.7 g,
100 mmol) and vanillin (15.28 g, 100.0 mmol) in Ac2O (55.0 mL, 583 mmol) to give a
yellow suspension. TEA (35.0 mL, 249 mmol) was added, and the reaction mixture was
stirred at 100 °C. After 24 h the darkened mixture was cooled to room temperature,
followed by the slow addition of 50 mL of H2O. The reaction mixture was then poured
into aqueous K2CO3 (75.0 g in 250 mL water) and refluxed until all solids dissolved.
After cooling to room temperature, the solution was extracted with ether (3 x 50 mL)
and carefully acidified with 2 N hydrochloric acid to produce a yellow precipitate. The
isolated solid was then recrystallized from MeOH to give (E)-3-(4-acetoxy-3methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1, 28 g, 75 mmol, 74.9% yield)
as a beige solid.

1H

NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 6.87 (dd, J = 8.2, 1.2, 2H),

6.82–6.73 (m, 3H), 6.63 (d, J = 1.5, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 3.45 (s, 3H), 2.34–2.22 (m,
3H).

13C

NMR (75 MHz, CDCl3) δ 20.73, 55.46, 56.04, 111.61, 112.87, 114.0, 122.32,

127.96, 131.79, 133.35, 140.64, 141.07, 148.91, 149.37, 150.60, 168.93, 172.86. The NMR
data matched those reported in the literature.86 HRDARTMS: Calcd for C20H20O7 m/z
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372.12090; [M+H]+ m/z 373.13023 (calcd 373.12873).

Preparation of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3methoxyphenyl)acrylate (2-2)
To a solution of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid
(9.58 g, 25.7 mmol) in 480 mL of dry MeOH was added concd H2SO4 (9.75 mL), and the
solution stirred at 65 °C for 12 h. The reaction mixture was then concentrated using a
rotary evaporator, and the resulting slurry was then filtered. After being washed
several times with ice-cold MeOH, the filtrate was then

purified by column

chromatography (1:2 hexane–EtOAc) to give (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4hydroxy-3-methoxyphenyl)acrylate (2-2, 7.88 g, 22.9 mmol, 89% yield) as a pale-yellow
solid.

1H

NMR (300 MHz, CDCl3) δ 7.72 (s, 1H), 6.91 (d, 1H), 6.81–6.76 (m, 1H), 6.76–

6.72 (m, 3H), 6.46 (s, J = 9.8, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.76 (s, 3H), 3.46 (s, J = 3.7,
3H).

13C

NMR (75 MHz, CDCl3) δ 52.50, 55.50, 56.10, 111.65, 112.22, 113.07, 114.32,

122.38, 126.20, 127.12, 128.98, 137.48, 140.77, 146.05, 147.06, 147.59, 148.71, 149.43, 168.83.
The NMR data matched those reported in the literature.86 HRDARTMS: Calcd for
C19H20O6 m/z 344.12599; [M+H]+ m/z 345.13656 (calcd 345.13381).
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Preparation of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4dimethoxyphenyl)acrylate (2-3).
(E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate (2-2, 4.56
g, 13.2 mmol) was added to TEA (23.0 mL, 164 mmol) and acetic anhydride (45 mL, 477
mmol), and the mixture was stirred at ambient temperature for 4 h. The solution was
rotary evaporated. The crude product was purified by column chromatography (2:1
hexane–EtOAc)

to

give

(E)-methyl

3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-

dimethoxyphenyl)acrylate (2-3, 4.86 g, 12.6 mmol, 95% yield) as a yellowish-orange
powder. 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 6.90–6.82 (m, 2H), 6.79–6.69 (m, 3H),
6.59 (s, 1H), 3.86 (s, 3H), 3.78 (s, 6H), 3.42 (s, 3H), 2.24 (s, 3H). 13C NMR (75 MHz, CDCl3)
δ 52.50, 55.50, 56.10, 111.65, 112.22, 113.07, 114.32, 122.38, 126.20, 127.12, 128.98, 137.64,
138.42, 146.05, 147.06, 147.59, 148.71, 149.43, 168.83. The NMR data matched those
reported in the literature.86 HRDARTMS: Calcd for C21H22O7 m/z 386.13655; [M+H]+ m/z
387.14021 (calcd 387.14438).
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Preparation of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4)
(E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate (2-3, 4.30
g, 11.1 mmol) was dissolved in 200 mL of dry CH2Cl2 and stirred over an ice bath for 15
min. A solution of FeCl3 (12.9 g, 80.0 mmol) in 100 mL EtOAc was then added dropwise
and stirring was continued. After 3 h, 150 mL of H2O was added and the reaction
mixture was stirred for an additional 2 h. The mixture was poured from the reaction
vessel into a separatory funnel, and the phases were separated. The organic phase was
then dried over Na2SO4 and filtered. The solvent was removed by rotary evaporation,
and the crude product was purified by column chromatography (1:2 hexane–EtOAc) to
give methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4, 3.76 g, 9.79
mmol, 88% yield)

1H

NMR (300 MHz, CDCl3) δ 8.49 (s, 1H), 8.28 (s, 1H), 8.05 (s, 1H),

7.64 (s, 1H), 7.25 (s, 1H), 4.05 (s, 6H), 4.00 (s, 3H), 3.94 (s, 3H), 2.41 (s, 3H).

13C

NMR (75

MHz, CDCl3) δ 20.94, 52.31, 55.94, 56.12, 102.78, 106.72, 110.27, 116.27, 123.60, 124.38,
125.49, 126.38, 128.58, 129.96, 141.90, 149.24, 149.29, 150.05, 168.09, 169.30. The NMR
data matched those reported in the literature.86 HRDARTMS: Calcd for C21H20O7 m/z
384.12090; [M+H]+ m/z 385.13106 (calcd 385.12873).
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Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5).
To a solution of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4, 8.60
g, 22.4 mmol) in 410 mL of dry MeOH was added concd H2SO4 (9 mL) and the solution
stirred at 65 °C for 12 h. The reaction mixture was then concentrated using a rotary
evaporator, and the resulting slurry was then filtered. After being washed several
times with ice cold MeOH, the filtrate was air dried to give methyl 3-hydroxy-2,6,7trimethoxyphenanthrene-9-carboxylate (2-5, 6.28 g, 18.4 mmol, 82% yield) and used
without further purification. 1H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 8.33 (s, 1H), 7.89
(s, 1H), 7.74 (s, 1H), 7.17 (s, 1H), 4.05 (s, 3H), 4.04 (s, 4H), 3.99 (s, 3H), 3.98 (s, 3H).

13C

NMR (75 MHz, CDCl3) δ 52.16, 55.92, 55.98, 56.11, 102.98, 106.13, 106.76, 108.75, 121.92,
124.13, 124.32, 125.23, 127.98, 130.67, 146.75, 147.91, 149.00, 149.34, 168.42. HRDARTMS:
Calcd for C19H18O6 m/z 342.11034; [M + H]+ m/z 343.12142 (calcd 343.11816).
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Methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1)
Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate

(2-5, 5.45 g, 15.92

mmol) was dissolved in 60 mL of DMF and placed under a nitrogen atmosphere. Then,
to the stirred solution at 0 °C, was added NaH (60% in oil, 0.84 g, 35.0 mmol) ,followed
by propargyl bromide (2.84 g, 19.1 mmol, 80% in toluene). Stirring was allowed to
continue overnight, after which time the reaction mixture was quenched with MeOH,
diluted with CH2Cl2 (25 mL) and washed with satd NaHCO3. The resulting organic
layer was then separated, dried over MgSO4 and concentrated under vaccum. The
dark-yellow crude product was then chromatographed over silica gel (1:2 hexane–
EtOAc)

to

afford

methyl

2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-

carboxylate (3-1, 5.45 g, 14.3 mmol, 90% yield) as a yellow solid.

1H

NMR (300 MHz,

CDCl3) δ 8.60 (s, 1H), 8.37 (s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.24 (d, J = 1.5, 1H), 4.99 (d, J
= 2.3, 2H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (d, J = 2.2, 6H), 2.61 (t, J = 2.6, 1H).

13C

NMR (75

MHz, CDCl3) δ 52.20, 55.91, 55.98, 56.07, 57.17, 76.73, 78.23, 102.71, 105.84, 106.87, 109.66,
122.71, 124.15, 125.32, 125.33, 130.33, 137.73, 137.86, 137.99, 148.97, 149.18, 149.37, 149.39,
168.31. HRDARTMS: Calcd for C22H20O6 m/z 380.12599; [M + H]+ m/z 381.13126 (calcd
381.13381).
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(2,6,7-Trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2)
To a suspension of lithium aluminum hydride (1.44 g, 37.9 mmol) in 50 mL of THF at 0
°C under a nitrogen atmosphere, was added dropwise, a solution of methyl 2,6,7trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1, 6.10 g, 16.04 mmol) in
235 mL of dry THF. The solution was stirred at room temperature for an additional 1 h,
then brought back to 0 °C, at which point 50 mL of EtOAc was added dropwise,
followed by careful addition of sodium sulfate decahydrate (10.00 g, 31.04 mmol). After
stirring for 5 h, the solution was filtered, and the solvent was removed by rotary
evaporation.

The product was purified by column chromatography (0.2:2 hexane–

EtOAc) to give (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2,
5.09 g, 14.43 mmol, 90% yield). 1H NMR (300 MHz, CDCl3) δ 7.89 (s, 1H), 7.71 (s, 1H),
7.42 (s, 1H), 7.41 (s, 1H), 7.03 (s, 1H), 5.00 (s, 3H), 4.91 (d, J = 2.3, 2H), 4.06 (s, 3H), 3.98 (s,
3H), 3.89 (s, 3H), 2.59 (t, J = 2.3, 1H).

13C

NMR (75 MHz, CDCl3) δ 55.94, 56.06, 57.36,

64.69, 76.45, 78.58, 103.24, 104.81, 106.55, 108.76, 123.76, 124.34, 126.79, 132.72, 135.68,
147.01, 148.80, 149.13, 149.22. HRDARTMS: Calcd for C21H20O5 m/z 352.13107; [M + H]+
m/z 353.13911 (calcd 353.13890).

242

9-(Bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3)
A stirred solution of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol
(3-2, 3.20 g, 9.08 mmol) in 270 mL of freshly distilled CHCl3 was cooled to 0 °C. After
stirring for 15 min, a solution of phosphorous tribromide (2.70 g, 9.99 mmol) in 38 mL of
CHCl3 was added dropwise. The reaction mixture was then stirred for an additional 2 h
at room temperature, then poured over ice, and the two layers separated. The organic
phase was dried over MgSO4, filtered and rotary evaporated to give 9-(bromomethyl)2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3, 3.51 g, 8.45 mmol, 93% yield) as
a yellow solid that was then placed under vacuum for 1 h and used without further
purification. 1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.81 (s, 1H), 7.62 (s, 1H), 7.48 (s,
1H), 7.17 (s, 1H), 4.97 (d, J = 2.3, 2H), 4.94 (s, 2H), 4.10 (s, 3H), 4.07 (s, 3H), 3.99 (s, 3H),
2.59 (t, J = 2.3, 1H).

13C

NMR (75 MHz, CDCl3) δ 33.81, 56.12, 56.17, 56.20, 57.40, 76.58,

78.44, 103.53, 105.08, 106.70, 108.92, 124.15, 125.18, 125.53, 126.67, 129.54, 137.51, 138.02,
147.70, 148.94, 149.56, 149.59. HRDARTMS: Calcd for C21H19BrO4 m/z 414.04667; [M +
H]+ m/z 415.02252 (calcd 415.05450).
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(S)-Dimethyl 2-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9 yl)methylamino)
pentanedioate (3-4).
To

a

stirred

solution

of

9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-

ynyloxy)phenanthrene (4.90 g, 11.8 mmol) in 420 mL DMF was added K2CO3 (8.48 g,
61.3 mmol) and stirring continued for 15 min. 1-42b (13.0 g, 61.3 mmol) was then
added, and the reaction mixture allowed to stir at 70 °C overnight. The solution was
then rotary evaporated, and the resulting crude product was partitioned between
CHCl3 and H2O. The organic layer was then dried over MgSO4 and concentrated in
vacuo to afford the crude of 3-4 as a dark-yellow oil that was used without further
purification. HRDARTMS: Calcd for C28H31NO8 m/z 509.20497; [M + H]+ m/z 510.21248
(calcd 510.21279).
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(S)-Methyl

5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-

yl)methyl)pyrrolidine-2-carboxylate (3-5)
The crude diester, (S)-dimethyl 2-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9
yl)methylamino)pentanedioate (3-4, 5.10 g, 10.0 mmol), was dissolved in 70 mL of
MeOH and 35 mL of HOAc and stirred for 3 h at 45 °C. The mixture was then cooled to
room temperature, concentrated in vacuo, and the residue was chromatographed over
silica gel (0.2:2 hexanes–EtOAc) to afford (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop2-ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (3-5, 3.97 g, 8.31 mmol,
83% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H), 7.80 (s, 1H), 7.59
(s, 1H), 7.38 (s, 1H), 7.17 (s, 1H), 5.50 (d, J = 14.5, 1H), 4.97 (d, J = 2.3, 2H), 4.37 (d, J =
14.6, 1H), 4.09 (s, 3H), 4.01 (s, 3H), 4.00 (s, 3H), 3.82 (dd, J = 9.1, 3.2, 1H), 3.57 (d, J = 1.7,
3H), 2.64–2.51 (m, 2H), 2.37 (ddd, J = 16.9, 9.4, 3.9, 1H), 2.17–2.04 (m, 1H), 2.04–1.91 (m,
1H).

13C

NMR (75 MHz, CDCl3) δ 22.95, 30.00, 44.94, 52.49, 56.11, 56.14, 56.56, 58.68,

76.53, 78.51, 103.27, 105.42, 106.75, 108.75, 124.77, 124.90, 125.17, 126.62, 126.96, 127.87,
147.39, 149.29, 149.45, 149.52, 172.46, 174.82. HRDARTMS: Calcd for C27H27NO7 m/z
477.17875; [M + H]+ m/z 478.18873 (calcd 478.18658).
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(S)-5-Oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9yl)methyl)pyrrolidine-2-carboxylic acid (3-6).
To the alkylated pyroglutamate ester, (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (3-5, 2.60 g, 5.44 mmol) in
dioxane (60 mL) was added 2 N KOH (30 mL) and MeOH (48 mL). After vigorous
stirring for 12 h, the solution was cooled (4 °C), acidified to pH 3 with 2 N HCl and
chilled overnight. The resulting solid was then filtered, and the filter cake was rinsed
with 10 mL of ice-cold water to afford (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylic acid (3-6, 2.45 g, 5.28 mmol,
97% yield as a white solid. 1H NMR (300 MHz, pyridine) δ 8.59 (s, 1H), 8.32 (s, 1H), 8.18
(s, 1H), 7.85 (s, 1H), 7.39 (s, 1H), 6.05 (d, J = 14.4, 1H), 5.24 (d, J = 2.3, 2H), 4.83 (d, J =
13.6, 1H), 4.29 (dd, J = 8.0, 4.4, 1H), 4.13 (s, 3H), 3.96 (s, 3H), 3.83 (s, 3H), 3.67 (t, J = 2.3,
1H), 2.83–2.67 (m, 1H), 2.49 (ddd, J = 16.4, 8.4, 4.7, 1H), 2.27–2.13 (m, 2H).

13C

NMR (75

MHz, pyridine) δ 23.76, 30.65, 45.28, 56.06, 56.23, 56.55, 57.98, 59.71, 78.11, 86.13, 105.08,
106.70, 108.00, 109.89, 125.69, 126.26, 127.48, 127.68, 129.41, 148.58, 175.32, 175.51.
HRDARTMS: Calcd for C26H25NO7 m/z 463.16310; [M+H]+ m/z 464.17009 (calcd
464.17093).
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(S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2b]isoquinoline-11,14(9H,12H)-dione (3-7).
Method A: Trifluoromethanesulfonic anhydride (0.350 mL, 2.071 mmol) was added to
a

well

stirred

suspension

of

(S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-

ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylic acid (3-6, 0.80 g, 1.73 mmol)
in CH2Cl2 (80 mL) at -30 °C.

The reaction mixture was allowed to reach room

temperature slowly and stirred 48 h. The solvent was then evaporated and the resulting
residue was passed through a plug of silica gel. The crude product was then
concentrated and added to a stirred mixture of CH2Cl2 (55 mL) and 2 g K2CO3 in water
(35 mL) for 4 h. The organic phase was then evaporated affording a dark oil that was
then chromatographed over silica (0.1:2 MeOH–CHCl3) to give (S)-2,6,7-trimethoxy-3(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)dione (3-7, 0.415 g, 0.932 mmol, 54% yield).
Method B: Trifluoroacetic anhydride (1.320 mL, 9.49 mmol) was added to a well-stirred
suspension

of

(S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-

yl)methyl)pyrrolidine-2-carboxylic acid (3-6, 1.10 g, 2.37 mmol) in CH2Cl2 (130 mL). The
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mixture was stirred at room temperature for 15 min, and boron trifluoride diethyl
etherate (0.584 mL, 4.75 mmol) was added. The mixture was stirred at room
temperature for 24 h, after which time the solvents were evaporated. To the resulting
residue was added a mixture of CH2Cl2 (100 mL) and 4 g of K2CO3 in water (50 mL) for
4 h. The organic phase was dried, then evaporated, affording (S)-2,6,7-trimethoxy-3(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)dione (3-7, 0.65 g, 1.45 mmol, 61% yield). 1H NMR (300 MHz, CDCl3) δ 9.09 (s, 1H), 8.05
(s, 1H), 7.78 (s, 1H), 7.26 (s, 1H), 5.71 (d, J = 18.1, 1H), 4.98 (d, J = 2.4, 2H), 4.67 (d, J =
18.1, 1H), 4.39 (s, 1H), 4.13 (s, 3H), 4.06 (s, 9H), 2.60 (d, J = 2.3, 1H), 2.58–2.52 (m, 4H).
13C

NMR (75 MHz, CDCl3) δ 20.95, 30.25, 40.89, 56.05, 56.13, 56.32, 61.17, 76.68, 78.48,

103.10, 104.20, 106.36, 108.20, 121.66, 121.84, 124.40, 128.21, 137.68, 138.04, 146.83, 149.42,
150.38, 152.08, 174.17, 195.73. HRDARTMS: Calcd for C26H23NO6 m/z 445.15254; [M +
H]+ m/z 446.16409 (calcd 446.16036).
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(13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8).
To

a

solution

of

(S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-

dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione

(3-7, 0.30 g, 0.67

mmol) in THF (25 mL) was added lithium tri-sec-butylborohydride (0.808 mL, 0.808
mmol) in THF at -78 °C under N2. After stirring at -78 °C for 3.5 h, a mixture of i-PrOH
(3 mL) and H2O (3 mL) was added, followed by silica gel (200 mg). The mixture was
then brought to 0 °C and stirred for 30 min. After stirring, the mixture was filtered
through a Celite pad, and the filtrate was evaporated in vacuo. The residue was purified
by flash column chromatography (0.1:2 MeOH–CHCl3) to afford (13aS,14S)-14-hydroxy2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2b]isoquinolin-11(9H)-one (3-8, 0.244 g, 0.545 mmol, 81% yield).

1H

NMR (300 MHz,

CDCl3) δ 8.00 (s, 1H), 7.67 (s, 1H), 7.61 (s, 1H), 6.71 (s, 1H), 5.07–5.00 (m, 1H), 4.98 (d, J =
2.3, 2H), 4.30 (d, J = 17.5, 1H), 4.05 (t, J = 7.7, 6H), 3.86 (d, J = 8.9, 1H), 3.79 (s, 1H), 3.71 (s,
3H), 3.06 (s, 1H), 2.70 (dd, J = 13.9, 8.0, 1H), 2.63 (t, J = 2.3, 1H), 2.60–2.44 (m, 3H), 2.25
(dt, J = 14.8, 9.6, 1H).

13C

NMR (75 MHz, CDCl3) δ 14.32, 19.25, 22.83, 30.93, 31.76, 40.99,

47.85, 55.84, 55.97, 56.18, 57.37, 65.78, 76.58, 78.55, 93.62, 101.36, 102.11, 102.93, 105.02,
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106.97, 122.26, 123.69, 124.09, 124.32, 129.88, 136.30, 137.50, 138.15, 138.38, 146.66, 146.73,
148.72, 148.72, 148.77, 149.37, 149.64, 175.44, 175.47. HRDARTMS: Calcd for C26H25NO6
m/z 447.16819; [M + H]+ m/z 448.17798 (calcd 448.17601).

(13aS,14S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (3-9)
A suspension of lithium aluminum hydride (0.153 g, 4.02 mmol) in 50 mL of THF was
added, over 10 min, dropwise to a solution of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy3-(prop-2-ynyloxy)-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)one (3-8, 0.2 g, 0.447 mmol) in 80 mL of dry THF at -10 °C under a nitrogen atmosphere.
After addition, the reaction mixture was stirred for an additional 4 h at 0 ºC, at which
point 10 mL of EtOAc was added dropwise, followed by careful addition of 2 g of
sodium sulfate decahydrate. After stirring for an additional 5 h, the solution was
filtered, and the solvent was removed by rotary evaporation. The product was purified
by column chromatography (0.1:2 MeOH–CHCl3) to give (13aS,14S)-2,6,7-trimethoxy-3-
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(prop-2-ynyloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14ol (3-9, 0.138 g, 0.317 mmol, 71% yield).

HRDARTMS: Calcd for C26H27NO5 m/z

344.12599; [M + H]+ m/z 434.19722 (calcd 434.19675).

Preparation of 1-Azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11)
To 40 mL of dry THF under N2 was added tetraethylene glycol (5 g, 25.7 mmol) (dried
by addition and rotary evaporation of 15 mL of toluene). Methanesulfonyl chloride
(4.01 mL, 51.5 mmol) was then added by syringe, and the solution was stirred in an ice
bath as TEA (7.24 mL, 51.5 mmol) in 10 mL of THF was added dropwise over 27 min.
The ice bath was removed after 1 h of stirring, and the mixture stirred for an additional
3.5 h with occasional swirling. The yellow-white precipitate was dissolved by addition
of H2O (24.4 mL), and the resulting two phases were chilled on a cold water bath.
NaHCO3 (2.5 g, to pH 8) was added followed by NaN3 (3.35 g, 51.5 mmol), and stirring
was commenced.

Then, THF was removed by distillation, and the solution was

refluxed for 24 h at a temperature of 80 °C. The aqueous layer was extracted five times
with 20 mL aliquots of Et2O, with each layer of Et2O back-extracted with the same 20mL aliquot of satd NaCl. The organic layers were then combined, dried over MgSO4
and filtered. Concentration of the organic layers by rotary evaporation yielded 5.38 g
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(83%) of 3-11 as an oil. 1H NMR (300 MHz, CDCl3) δ 3.63 – 3.59 (m, 12H), 3.32 (t, J = 5.0,
4H).

13C

NMR (75 MHz, CDCl3) δ 42.12, 49.74, 61.33, 69.62, 69.90, 70.98, 71.91. The

NMR data matched those reported in the literature.211

HRDARTMS: Calcd for

C8H16N6O3 m/z 244.12839; [M+H]+ m/z 245.13518 (calcd 245.13621).

2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12)
Aqueous H3PO4 (40 mL of 0.65 M) was added to the diazide 3-11 (3.75 g, 15.4 mmol) and
the solution was brought to stirring while PPh3 (3.99 g, 15.2 mmol) in 30 mL of Et2O was
added dropwise over 45 min. The addition funnel was rinsed with 4 mL of ether, and
the solution was placed under N2 and stirred for 24 h. The aqueous layer was separated
and washed with 3 x 10 mL of Et2O, and 3.2 g of KOH was added. The mixture was
cooled to 4 °C after removal of traces of ether by evaporation. After 16 h, the PPh3 was
removed by filtration followed by the addition of 9.2 g of KOH (to 4 M). The aqueous
solution was then extracted 16 times with 7.5-mL aliquots of CH2Cl2, which were then
dried over MgSO4, filtered and concentrated in vacuo to furnish 2.55 g (76%) of 3-12 as
an amber oil. 1H NMR (300 MHz, CDCl3) δ 3.55 – 3.51 (m, 8H), 3.43–3.33 (m, 2H), 3.30–
3.22 (m, 2H), 2.73 (t, J = 4.7, 2H), 1.95 (s, 2H).
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13C

NMR (75 MHz, CDCl3) δ 41.36, 42.52,

60.85, 69.72, 69.95, 70.02, 70.30, 70.34, 71.00, 72.55, 72.89. The NMR data matched those
reported in the literature.211 HRDARTMS: Calcd for C8H18N4O3 m/z 218.13789; [M+H]+
m/z 219.14449 (calcd 219.14572).

Preparation

of

N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-

oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14)
Method A : TEA (0.102 mL, 0.724 mmol) was added to a solution of 3-12 (0.123 g, 0.561
mmol) in DMF (4 mL). After the solution was stirred for 30 min under N2, a solution of
N-hydroxsuccinimidobiotin (3-13, 0.23 g, 0.67 mmol) was added. The reaction mixture
was stirred for 12 h at room temperature and then concentrated in vacuo to give a
yellowish residue. Purification by silica gel column chromatography using 4:1 acetone–
hexane afforded 0.17 g (67%) of 3-14.
Method B: A mixture of D-(+)-biotin (0.2 g, 0.819 mmol), and 3-12 (0.36 g, 1.64 mmol),
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (622 mg,
0.82 mmol), and N,N-diisopropylethylamine (0.143 mL, 0.819 mmol) in DMF (10 mL)
was stirred at room temperature for 2 h. The reaction mixture was concentrated in
vacuo, and the residue was purified by flash column chromatography (10:1 CHCl3–
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MeOH) to give the amide 3-14 (0.306 g, 84%). 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J =
8.0, 1H), 7.60 (d, J = 8.2, 1H), 7.38 – 7.25 (m, 1H), 6.82 (t, J = 5.4, 1H), 6.59 (s, 1H), 4.46
(dd, J = 7.5, 4.8, 1H), 4.30–4.20 (m, 1H), 3.59 (dd, J = 9.8, 3.0, 14H), 3.49 (d, J = 5.0, 2H),
3.36 (dd, J = 10.8, 5.0, 5H), 3.08 (d, J = 4.6, 1H), 2.87–2.80 (m, 1H), 2.17 (t, J = 7.4, 2H),
1.71–1.51 (m, 5H), 1.37 (dd, J = 14.7, 7.4, 3H).

13C

NMR (75 MHz, CDCl3) δ 25.82, 28.15,

28.31, 35.99, 39.51, 45.09, 50.82, 55.69, 60.63, 62.12, 69.38, 69.77, 70.04, 70.11, 70.28, 70.58,
100.22, 100.35, 100.52, 111.15, 117.69, 126.30, 126.93, 127.61, 162.52, 164.48, 169.70, 174.41.
The NMR data matched those reported in the literature.156 HRDARTMS: Calcd for
C18H32N6O5S m/z 444.21549; [M+H]+ m/z 445.23002 (calcd 445.22331).

Methyl 2,6,7-trimethoxy-3-((1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4yl)methoxy)phenanthrene-9-carboxylate (3-1e)
In a 25-mL round-bottomed flask under an N2 atmosphere was added methyl 2,6,7trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1, 0.10 g, 0.26 mmol) , N(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-
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thieno[3,4-d]imidazol-4-yl)pentanamide

(3-14,

0.117

g,

0.263

mmol),

N,N-

diisopropylethylamine (0.184 mL, 1.05 mmol) and 2,6-lutidine (0.122 mL, 1.052 mmol)
in CH3CN (5 mL).

The reaction mixture was stirred for 5 min, after which time

copper(I) iodide (5.01 mg, 0.026 mmol) was added, and stirring was continued for an
additional 12 h.

The reaction mixture was then evaporated in vacuo and

chromatographed over silica gel (0.2:2 MeOH–CH2Cl2) to afford methyl 2,6,7trimethoxy-3-((1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenanthrene-9carboxylate (3-1e) as a yellowish solid. MALDI-TOFMS: Calcd for C40H52N6O11S m/z
824.3415; [M + Na]+ m/z 847.3280 (calcd 847.3313).

N-(2-(2-(2-(2-(4-(((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)methyl)-1H-1,2,3-triazol-1yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)pentanamide (3-17)
In a 25-mL round-bottomed flask under an N2 atmosphere, was added (13aS,14S)-2,6,7-
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trimethoxy-3-(prop-2-ynyloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2b]isoquinolin-14-ol (3-9, 0.08 g, 0.19 mmol), N-(2-(2-(2-(2azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)pentanamide (3-14, 0.082 g, 0.185 mmol), N,N-diisopropylethylamine
(0.129 mL, 0.738 mmol) and 2,6-lutidine (0.086 mL, 0.738 mmol) in CH3CN (5 mL). The
reaction mixture was stirred for 5 min. after which time copper(I) iodide (3.51 mg, 0.018
mmol) was added, and stirring was continued for an additional 12 h. The reaction
mixture was then evaporated in vacuo and chromatographed over silica gel (0.2:2
MeOH–CH2Cl2) to afford N-(2-(2-(2-(2-(4-(((13aS,14S)-14-hydroxy-2,6,7-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)methyl)-1H1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1Hthieno[3,4-d]imidazol-4-yl)pentanamide (3-17) as a yellowish solid. MALDI-TOFMS:
Calcd for C191H212O36 m/z 877.4044; [M + Na]+ m/z 900.4102 (calcd 900.3942).

Preparation of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10)
To a solution of tetraethylene glycol (6.0 g, 31 mmol) in 60 mL of THF was added
sodium hydride (60% in mineral oil, 0.781 g, 34.0 mmol) at 0 °C with frequent venting.
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After stirring for 15 min, 1.1 equiv of propargyl bromide (4.04 g, 34.0 mmol, 5.04 mL)
was added slowly, and the mixture was stirred at 0 °C for 2 h and then at 23 °C for an
additional 2 h. The reaction mixture was passed through a silica gel column and eluted
with EtOAc to give the purified product, 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10, 4.66
g, 20.08 mmol, 65% yield) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 4.07–4.02 (m, 2H),
3.55–3.49 (m, 15H), 3.45–3.40 (m, 2H), 3.03 (s, 1H), 2.36 (t, J = 2.4, 1H).

13C

NMR (75

MHz, CDCl3) δ 58.13, 61.34, 68.84, 70.14, 70.28, 72.38, 74.59, 79.46. The NMR data
matched those reported in the literature.156

HRDARTMS: Calcd for C11H20O5 m/z

232.13107; [M+H]+ m/z 233.14011 (calcd 233.13890).

1-Bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12)
3,6,9,12-Tetraoxapentadec-14-yn-1-ol (4-10, 1.3 g, 5.60 mmol) was dissolved in 40 mL of
freshly distilled CHCl3 and the reaction mixture cooled to -30 °C. After stirring for 15
min, a solution of PBr3 (1.818 g, 6.72 mmol) in 50 mL CHCl3 was added dropwise. The
reaction mixture was then stirred for an additional 4 h at 0 °C and then poured over ice,
and the two layers separated. The organic phase was dried over MgSO4, filtered and
rotary evaporated to give 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12, 1.32 g, 4.48
mmol, 80% yield). 1H NMR (300 MHz, CDCl3) δ 4.07 (s, 2H), 3.59 (s, 2H), 3.56–3.52 (m,
12H), 2.35 (dt, J = 8.3, 4.5, 1H).

13C

NMR (75 MHz, CDCl3) δ 29.48, 30.32, 58.17, 68.87,
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69.44, 70.38, 74.59, 79.49, 117.38, 117.53, 129.29, 137.55.

HRDARTMS: Calcd for

C8H16Br2O3 m/z 294.04667; [M + H]+ m/z 295.06781 (calcd 295.05450).

Methyl

3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-

carboxylate (4-1)
Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5, 2.1 g, 6.13 mmol)
was dissolved in 300 mL of acetone and heated to reflux. Then, to the stirred solution
was added 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12, 1.992 g, 6.75 mmol) and
stirring continued overnight. The reaction mixture was then filtered and the filtrate
evaporated in vacuo to give an oily residue. The yellowish-brown crude product was
then purified by flash column chromatography (2:0.2 EtOAc–hexanes) to afford methyl
3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate
(4-1, 2.63 g, 4.72 mmol, 77% yield) as an amber oil.

13C

NMR (75 MHz, CDCl3) δ 16.62,

16.69, 25.08, 25.14, 47.57, 52.14, 55.95, 62.92, 68.72, 74.70, 100.28, 100.31, 100.45, 106.88,
109.60, 122.32, 124.90, 127.15, 130.45, 137.28, 144.08, 146.53, 149.13, 149.32, 150.66, 168.36.
HRDARTMS: Calcd for C30H36O10 m/z 556.23085; [M] m/z 556.23236 (calcd 556.23085).
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(3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9yl)methanol (4-2)
To a suspension of lithium aluminium hydride (0.232 g, 6.11 mmol) in 50 mL of THF at
0 ºC under a nitrogen atmosphere, was added dropwise a solution of methyl 3-(3,6,9,12tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (4-1, 1.70 g,
3.05 mmol) in 150 mL of dry THF. The solution was stirred at room temperature for an
additional 4 h, then brought back to 0 ºC, at which point 50 mL of EtOAc was added
dropwise, followed by the careful addition of sodium sulfate decahydrate (10 g, 31.04
mmol). After stirring for 5 h, the solution was filtered, and the solvent was removed by
rotary evaporation. The product was purified by column chromatography (0.2:2
hexane–EtOAc) to give (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methanol (4-2, 1.356 g, 2.57 mmol, 84% yield). 1H NMR
(300 MHz, pyridine) δ 8.42 (s, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 7.98 (s, 1H), 7.49 (s, 1H), 5.55
(s, 2H), 4.49 – 4.44 (m, 2H), 4.29 (d, J = 2.4, 2H), 4.05 (s, 3H), 3.94 (d, J = 7.3, 6H), 3.88 (s,
3H), 3.72 (dt, J = 4.1, 3.2, 4H), 3.67 – 3.61 (m, 8H), 3.39 (t, J = 2.4, 1H). 13C NMR (75 MHz,
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CDCl3) δ 55.80, 56.00, 56.12, 58.48, 69.17, 74.72, 79.75, 100.14, 100.44, 103.20, 104.85,
105.27, 108.61, 123.80, 124.45, 124.58, 126.27, 132.29, 137.64, 137.81, 148.47, 148.66, 148.99,
149.14. HRDARTMS: Calcd for C29H36O9 m/z 528.23593; [M] m/z 528.23555 (calcd
528.23593).

1-(9-(Bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12-tetraoxapentadec14-yne (4-3)
A stirred solution of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methanol (4-2, 1.45 g, 2.74 mmol) and 2,6-di-tertbutylpyridine (0.131 g, 0.686 mmol) in 180 mL of freshly distilled CHCl3 was cooled to 0
°C. After stirring for 15 min, a solution of PBr3 (0.89 g, 3.29 mmol) in 30 mL CHCl3 was
added dropwise. The reaction mixture was then stirred for an additional 2 h at room
temperature, and then poured over ice and the two layers separated. The organic phase
was dried over MgSO4, filtered and rotary evaporated to give 1-(9-(bromomethyl)-2,6,7trimethoxyphenanthren-3-yloxy)-3,6,9,12-tetraoxapentadec-14-yne (4-3, 1.51 g, 2.55
mmol, 93% yield) as a yellow solid which was then placed under vacuum for 1 h and
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used without further purification. 1H NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 7.77 (s,
1H), 7.61 (s, 1H), 7.47 (s, 1H), 7.13 (s, 1H), 4.94 (s, 2H), 4.39 (t, J = 5.1, 2H), 4.15 (d, J = 2.3,
1H), 4.13 – 4.11 (m, 1H), 4.09 (s, 3H), 4.08 (d, J = 1.4, 1H), 4.06 (s, 3H), 3.71 – 3.67 (m, 2H),
3.64 – 3.57 (m, 9H), 2.39 (t, J = 2.4, 1H). 13C NMR (75 MHz, CDCl3) δ 34.00, 56.12, 56.21,
56.36, 58.61, 68.97, 71.14, 74.78, 75.33, 100.51, 103.59, 105.11, 105.62, 108.89, 117.76, 124.15,
125.44, 125.53, 126.52, 137.44, 137.55, 147.65, 148.90, 149.39, 149.53, 149.67. HRDARTMS:
Calcd for C29H35BrO8 m/z 590.15153; [M] m/z 591.15454 (calcd 591.15936).

(S)-dimethyl

2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-

trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4).
To a stirred solution of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)3,6,9,12-tetraoxapentadec-14-yne (4-3, 0.90 g, 1.52 mmol) in 420 mL of DMF was added
K2CO3 (8.48 g, 61.3 mmol) and stirring was continued for 15 min. (S)-1,5-dimethoxy1,5-dioxopentan-2-aminium chloride (1-42b, 1.28 g, 6.09 mmol) was then added, and
the reaction mixture was allowed to stir at 70 °C overnight. The solution was then
rotary evaporated, and the resulting crude product was partitioned between CHCl3 and
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H2O. The organic layer was then dried over MgSO4 and concentrated in vacuo to afford
the crude of (S)-dimethyl 2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4, 0.939 g, 1.369 mmol, 90%
yield) as a dark-yellow oil that was used without further purification. HRDARTMS:
Calcd for C36H47NO12 m/z 685.30983; [M] m/z 686.24476 (calcd 686.31765).

(S)-Methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5)
The crude diester, (S)-dimethyl 2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4, 2.2 g, 3.2 mmol), was
dissolved in 70 mL of MeOH and 35 mL of AcOH and stirred for 3 h at 45 °C. The
mixture was then cooled to room temperature, concentrated in vacuo, and the residue
chromatographed over silica gel (0.1:2 hexanes-EtOAc) to afford (S)-methyl 1-((3(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5oxopyrrolidine-2-carboxylate (4-5, 1.72 g, 2.63 mmol, 82% yield) as a yellowish-white
solid. 1H NMR (300 MHz, CDCl3) δ 7.81 (s, 1H), 7.73 (s, 1H), 7.53 (s, 1H), 7.33 (s, 1H),
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7.11 (s, 1H), 5.43 (d, J = 14.5, 1H), 4.38 (d, J = 3.6, 1H), 4.36 (d, J = 4.7, 2H), 4.31 (s, 1H),
4.19 (dd, J = 8.3, 4.9, 1H), 4.13 – 4.11 (m, 2H), 4.06 (s, 3H), 3.97 (s, 6H), 3.95 (s, 3H), 3.80
(dd, J = 9.1, 3.1, 2H), 3.76 – 3.71 (m, 3H), 3.69 (d, J = 5.0, 3H), 3.68 – 3.64 (m, 3H), 3.61 (d, J
= 7.1, 13H), 3.53 (s, 3H), 2.61 – 2.45 (m, 2H), 2.35 – 2.27 (m, 2H), 2.19 – 2.03 (m, 2H), 1.98
– 1.90 (m, 1H).

13C

NMR (75 MHz, CDCl3) δ 22.95, 30.00, 44.94, 52.49, 56.11, 56.14, 56.56,

58.68, 76.53, 78.51, 79.85, 103.27, 105.42, 106.75, 108.75, 124.77, 124.90, 125.17, 126.62,
126.96, 127.87, 147.39, 149.29, 149.45, 149.52, 172.46, 174.82. HRDARTMS: Calcd for
C35H43NO11 m/z 653.28361; [M] m/z 654.28097 (calcd 654.29144).

(S)-1-((3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6)
To the alkylated pyroglutamate ester, (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (45, 1.1 g, 1.683 mmol) in dioxane (40 mL) was added 2 N KOH (24 mL) and MeOH (28
mL). After vigorous stirring for 12 h, the solution was cooled (4 °C), acidified to pH 3
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with 2 N HCl and chilled overnight. The resulting solid was then filtered, and the filter
cake was rinsed with 10 mL of ice-cold water to afford (S)-1-((3-(3,6,9,12tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5oxopyrrolidine-2-carboxylic acid (4-6, 1.023 g, 1.599 mmol, 95% yield) as a white solid.
HRDARTMS: Calcd for C34H41NO11 m/z 639.26796; [M+H]+ m/z 640.27554 (calcd
640.27579).

(S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-7).
Method A: Trifluoromethanesulfonic anhydride (0.211 mL, 1.251 mmol) was added to
a well stirred suspension of (S)-1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6, 0.8 g,
1.251 mmol) in CH2Cl2 (60 mL) at -30 °C. The reaction mixture was allowed to reach
room temperature slowly, and it was stirred for 48 h. The solvent was then evaporated,
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and the resulting residue passed through a plug of silica gel. The crude product was
then concentrated and added to a stirred mixture of CH2Cl2 (45 mL) and 1.5 g of K2CO3
in water (25 mL) for 4 h. The organic phase was then evaporated affording a dark oil,
which was then chromatographed over silica (0.1:2 MeOH–CHCl3) to give (S)-3(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-7, 0.350 g, 0.563
mmol, 45% yield).
Method B: Trifluoroacetic anhydride (0.21 mL, 1.50 mmol) was added to a well stirred
suspension

of

(S)-1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-

trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6, 0.8 g,
1.251 mmol) in CH2Cl2 (60 mL). The mixture was stirred at room temperature for 15
min and BF3Et2O (0.154 mL, 1.251 mmol) was added. The mixture was stirred at room
temperature for 24 h, after which time the solvents were evaporated. To the resulting
residue was added a mixture of CH2Cl2 (50 mL) and 2 g of K2CO3 in water (40 mL) for 4
h.

The organic phase was dried then evaporated to afford (S)-3-(3,6,9,12-

tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2b]isoquinoline-11,14(9H,12H)-dione (4-7, 0.350 g, 0.563 mmol, 45% yield). HRDARTMS:
Calcd for C34H39NO10 m/z 621.25740; [M+H]+ m/z 622.25343 (calcd 622.26522).
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(13aS,14S)-3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8).
To a solution of (S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-8, 0.40 g, 0.64
mmol) in THF (25 mL) was added lithium tri-sec-butylborohydride (0.165 mL, 0.772
mmol) in THF at -78 °C under N2. After stirring at -78 °C for 3.5 h, a mixture of i-PrOH
(3 mL) and H2O (3 mL) was added followed by silica gel (200 mg). The mixture was
then brought to 0 °C and stirred for 30 min. After stirring, the mixture was filtered
through a Celite pad, and the filtrate was evaporated in vacuo. The residue was purified
by flash column chromatography (0.1:2 MeOH–CHCl3) to afford (13aS,14S)-3-(3,6,9,12tetraoxapentadec-14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8, 0.273 g, 0.438 mmol,
68% yield). MALDI-TOFMS: Calcd for C34H41NO10 m/z 623.2731; [M + H]+ m/z 624.2837
(calcd 624.2809).
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(13aS,14S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-9).
A suspension of lithium aluminium hydride (0.012 g, 0.321 mmol) in 25 mL of THF was
added, over 10 min, dropwise to a solution of (13aS,14S)-3-(3,6,9,12-tetraoxapentadec14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8, 0.1 g, 0.160 mmol) in
20 mL of dry THF at -10 °C under a nitrogen atmosphere. After addition, the reaction
mixture was stirred for an additional 4 h at 0 ºC, at which point 8 mL of EtOAc was
added dropwise, followed by careful addition of 1 g of Na2SO410H2O. After stirring
for an additional 5 h, the solution was filtered and the solvent was removed by rotary
evaporation.

The product was purified by column chromatography (0.1:2 MeOH-

CHCl3) to give (13aS,14S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-9, 0.064 g,
0.104 mmol, 65% yield). MALDI-TOFMS: Calcd for C34H43NO9 m/z 609.29378; [M-H]m/z 608.3265 (calcd 608.28596).
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Methyl

2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-

thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)2,5,8,11-tetraoxatridecan-13-yloxy)phenanthrene-9-carboxylate (4-1a)
In a 25-mL round-bottomed flask under an N2 atmosphere, was added methyl 3(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (41, 0.10 g, 0.18 mmol), N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14, 0.080 g, 0.180 mmol),
2,6-lutidine (0.084 mL, 0.719 mmol) and N,N-diisopropylethylamine (0.126 mL, 0.719
mmol) in CH3CN (5 mL). The reaction mixture was stirred for 5 min. after which
copper(I) iodide (3.42 mg, 0.018 mmol) was added and stirring continued for an
additional 12 h.

The reaction mixture was then evaporated in vacuo and

chromatographed over silica gel (0.2:2 MeOH–CH2Cl2) to afford methyl 2,6,7trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13yloxy)phenanthrene-9-carboxylate (4-1a) as a yellowish solid. MALDI-TOFMS: Calcd
for C48H68N6O15S m/z 1000.4463; [M + Na]+ m/z 1023.4335 (calcd 1023.4361).
268

(S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)2,5,8,11-tetraoxatridecan-13-yloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate
(4-5a).
In a 25 mL round-bottomed flask under an N2 atmosphere, was added (S)-methyl 1-((3(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5oxopyrrolidine-2-carboxylate

(4-5,

0.11

g,

0.18

mmol),

N-(2-(2-(2-(2-

azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)pentanamide (3-14, 0.080 g, 0.180 mmol), N,N-diisopropylethylamine
(0.126 mL, 0.722 mmol) and 2,6-lutidine (0.084 mL, 0.722 mmol) in CH3CN (3.5 mL).
The reaction mixture was stirred for 5 min. after which copper(I) iodide (3.44 mg, 0.018
mmol) was added, and stirring continued for an additional 12 h. The reaction mixture
was then evaporated in vacuo and chromatographed over silica gel (0.2:2 MeOH–
CH2Cl2) to afford (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yloxy)phenanthren-9-yl)methyl)pyrrolidine-2-
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carboxylate (4-5a) as a yellowish solid.

MALDI-TOFMS: Calcd for C191H212O36 m/z

1097.4991; [M + Na]+ m/z 1120.4710 (calcd 1120.4889).

N-(2-(2-(2-(2-(4-(13-((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)-2,5,8,11-tetraoxatridecyl)1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1Hthieno[3,4-d]imidazol-4-yl)pentanamide (4-14)
In a 25-mL round-bottomed flask under an N2 atmosphere, was added (13aS,14S)-3(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-19, 0.09 g, 0.15 mmol), N-(2-(2(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)pentanamide (3-14, 0.07 g, 0.15 mmol), N,N-diisopropylethylamine
(0.103 mL, 0.590 mmol) and 2,6-lutidine (0.07 mL, 0.6 mmol) in CH3CN (3.5 mL). The
reaction mixture was stirred for 5 min after which time copper(I) iodide (2.81 mg, 0.02
mmol) was added, and stirring was continued for an additional 12 h. The reaction
mixture was then evaporated in vacuo and chromatographed over silica gel (0.2:2
MeOH–CH2Cl2) to afford N-(2-(2-(2-(2-(4-(13-((13aS,14S)-14-hydroxy-2,6,7-trimethoxy270

9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)-2,5,8,11tetraoxatridecyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (4-1a) as a yellowish solid.
MALDI-TOFMS: Calcd for C52H75N7O14S m/z 1053.5093; [M-H]- m/z 1052.5172 (calcd
1052.5015).
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2. Appendix

APPENDIX
1H and 13C NMR for selected compounds

283

1H

NMR spectrum (300 MHz, CDCl3) of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47)
284

13C

NMR (75 MHz, CDCl3) spectrum of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47).
285

1H

NMR spectrum (300 MHz, CDCl3) of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52).
286

13C

NMR (75 MHz, CDCl3) spectrum of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52)
287

1H

NMR spectrum (300 MHz, CDCl3) of (2,3,6,7-tetramethoxyphenanthren-9-yl)methanol (1-53)
288

13C

NMR (75 MHz, CDCl3) spectrum of (2,3,6,7-tetramethoxyphenanthren-9-yl)methanol (1-53)
289

1H

NMR spectrum (300 MHz, CDCl3) of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63)
290

13C

NMR (75 MHz, CDCl3) spectrum of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63)
291

1H

NMR spectrum (300 MHz, C5D5N) of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b)
292

13C

NMR (75 MHz, C5D5N) spectrum of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b)
293

1H

NMR spectrum (300 MHz, CDCl3) of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9yl)methyl)pyrrolidine-2-carboxylate (1-65)
294

13C

NMR (75 MHz, C5D5N) spectrum of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9yl)methyl)pyrrolidine-2-carboxylate (1-65).
295

1H

NMR spectrum (300 MHz, C5D5N) of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine2-carboxylic acid (1-50).
296

13C

NMR (75 MHz, C5D5N) of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-2carboxylic acid (1-50)
297

1H

NMR spectrum (300 MHz, CDCl3) of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2b]isoquinoline-11,14(9H,12H)-dione (1-45).
298

13C

NMR (75 MHz, CDCl3) of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline11,14(9H,12H)-dione (1-45).
299

1H

NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66)
300

13C

NMR (75 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66)
301

1H

NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (1-62b)
302

13C

NMR (75 MHz, CDCl3) of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2b]isoquinolin-14-ol (1-62b)
303

1H

NMR spectrum (300 MHz, CDCl3) of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1)
304

13C

NMR (75 MHz, CDCl3) spectrum of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1)
305

1H

NMR spectrum (300 MHz, CDCl3) of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate
(2-2)
306

13C

NMR (75 MHz, CDCl3) spectrum of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate
(2-2)
307

OCH3
O

O

OCH3
O

H3CO
OCH3

2-3

1H

NMR spectrum (300 MHz, CDCl3) of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate
(2-3)
308

13C

NMR (75 MHz, CDCl3) spectrum of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate
(2-3)
309

OCH3
O

O

OCH3
O

H3CO
OCH3
2-4

1H

NMR spectrum (300 MHz, CDCl3) of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4)
310

OCH3
O

O

OCH3
O

H3CO
OCH3
2-4

13C

NMR (75 MHz, CDCl3) spectrum of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4)
311

1H

NMR spectrum (300 MHz, CDCl3) of methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5).
312

13C

NMR (75 MHz, CDCl3) spectrum of methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5)

313

1H

NMR spectrum (300 MHz, CDCl3) of methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1)
314

13C

NMR (75 MHz, CDCl3) spectrum of methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1)
315

1H

NMR spectrum (300 MHz, CDCl3) of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2)
316

13C

NMR (75 MHz, CDCl3) spectrum of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2)
317

1H

NMR spectrum (300 MHz, CDCl3) of 9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3)
318

13C

NMR (75 MHz, CDCl3) spectrum of 9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3)
319

1H

NMR spectrum (300 MHz, CDCl3) of (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9yl)methyl)pyrrolidine-2-carboxylate (3-5).
320

13C

NMR (75 MHz, CDCl3) spectrum of (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9yl)methyl)pyrrolidine-2-carboxylate (3-5).
321

1H

NMR spectrum (300 MHz, C5D5N) of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9yl)methyl)pyrrolidine-2-carboxylic acid (3-6).
322

13C

NMR (75 MHz, C5D5N) of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methyl)pyrrolidine2-carboxylic acid (3-6)
323

1H

NMR spectrum (300 MHz, CDCl3) of (S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (3-7)
324

13C

NMR (75 MHz, CDCl3) spectrum of (S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (3-7)
325

1H

NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8)
326

13C

NMR (75 MHz, CDCl3) spectrum of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8)
327

1H

NMR spectrum (300 MHz, CDCl3) of 1-azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11)

328

13C

NMR (75 MHz, CDCl3) spectrum of 1-azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11)

329

1H

NMR spectrum (300 MHz, CDCl3) of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12)
330

13C

NMR (75 MHz, CDCl3) spectrum of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12)

331

1H

NMR spectrum (300 MHz, CDCl3) of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14).
332

13C

NMR (75 MHz, CDCl3) spectrum of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14)
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1H

NMR spectrum (300 MHz, CDCl3) of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10)
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13C

NMR (75 MHz, CDCl3) spectrum of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10)
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1H

NMR spectrum (300 MHz, CDCl3) of 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12)
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13C

NMR (75 MHz, CDCl3) spectrum of 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12)
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4-1

1H

NMR spectrum (300 MHz, CDCl3) of methyl 3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthrene-9-carboxylate (4-1)
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13C

NMR (75 MHz, CDCl3) spectrum of methyl 3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthrene-9-carboxylate (4-1)
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1H

NMR spectrum (300 MHz, C5D5N) of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9yl)methanol (4-2)
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13C

NMR (75 MHz, CDCl3) spectrum of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9yl)methanol (4-2)
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1H

NMR spectrum (300 MHz, CDCl3) of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12tetraoxapentadec-14-yne (4-3)
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13C

NMR (75 MHz, CDCl3) spectrum of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12tetraoxapentadec-14-yne (4-3)
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1H

NMR spectrum (300 MHz, CDCl3) of (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5)
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13C

NMR (75 MHz, CDCl3) spectrum of (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5)
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VITA

2. VITA
Samson Francis was born in Mbala, Zambia where he attended Chila elementary school.
His family relocated to the copper-rich town of Ndola, Zambia. There he attended
Simba School and completed his O-levels. After graduating with a distinction, he
accepted the opportunity to attend the University of Tennessee at Knoxville, where he
earned degrees in Chemistry and Biochemistry. He then joined the laboratory of Dr.
David C. Baker, who transformed him into a synthetic chemist. It remains to be seen
whether his upbringing in a Cu-rich environment and his love for the Cu(I)-catalyzed
1,3-dipolar Huisgen cycloaddition are interconnected. He subsequently “clicked”
himself “free” in 2009.
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